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ABSTRACT 
 
During the past few years, researchers working in tissue engineering (TE) have realized that 
drug delivery is a fundamental part of the TE strategy. Therefore, a large number of 
technologies have been optimized to guide the potential of drug delivery in those applications. 
Drug delivery systems (DDS) can be designed to provide controlled release of bioactive 
molecules to the site of action with minimal side-effects by reducing the exposure of the drug 
to other tissues. Microparticulate DDS are claimed to have several advantages, such as 
enhanced bioavailability, possibility for targeting delivery and minimally invasive 
administration, together with greater efficacy/safety.  
This PhD work describes attempts to develop particulate systems with potential application in  
TE strategies. Microparticles based on natural origin polymers (starch and chitosan and blends 
thereof) were used. In addition, a synthetic polymer (poly-ε-caprolactone, PCL) was used alone 
or combined with starch. For the preparation of these particulate systems, emulsion 
procedures, based on evaporation of solvents or use of crosslinking agents, were optimized. 
The developed systems were characterized in terms of morphology, physicochemical 
properties, particle size and size distribution. Their potential as DDS either for antibiotics 
(gentamicin sulphate, GTM), steroids (Dexamethasone, DEX) or growth factors (bone 
morphogenetic protein 2, BMP-2) was evaluated with encapsulation efficiencies of 93% for 
DEX, 67% for GTM and 24% for BMP-2. The release profiles were evaluated in environments 
mimicking physiological conditions and were characterized by three main phases typical of 
drug release from biodegradable carriers: i) burst release, ii) period of minimal release, and iii) 
the release of the remaining active agent while the polymeric matrix is degraded. 
The in vitro biocompatibility of the developed system was investigated using different cell lines 
where aspects such as cytotoxicity, cell proliferation and morphology were evaluated. 
Moreover, the maintenance of the activity/function of all entrapped molecules was 
investigated. The antibacterial activity of released GTM was assessed by an in vitro disc 
diffusion susceptibility test using Gram positive bacteria (Staphylococcus aureus) whereas the 
bioactivity of DEX and BMP-2 was analyzed by determining their ability to induce osteogenic 
differentiation of precursor cells. For the tested conditions, all developed microparticles were 
non-cytotoxic, highly biodegradable and suitable as carriers for sustained delivery purposes. 
The ability to isolate living cells is an essential aspect of TE research. Magnetic cell separation 
methods are among the most efficient methods for cell separation. Therefore, an additional 
objective of this work was to develop magnetic functionalized particles for cell isolation (e.g. 
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stem cell subpopulations). Towards this goal, surface functionalized magnetic poly-ε-
caprolactone microparticles (m-PCL) were fabricated. 13% of magnetite nanoparticles (core) 
were effectively entrapped within a poly-ε-caprolactone (shell). Amino and epoxy groups were 
introduced on the surface of the m-PCL. The m-PCL were characterized for morphology, 
particle size and size distribution, physicochemical and magnetic properties. Their 
effectiveness for covalent coupling of protein-like molecules was evaluated by using bovine 
serum albumin, resulting in coupling efficiency higher than 47% for epoxy and 71% for amino 
functionalized m-PCL. Additionally, cell viability, proliferation and morphology upon contact 
with developed microparticles were evaluated. The m-PCL were shown to be non-cytotoxic 
and their surface functionalization did not show any detrimental influence on cell viability and 
proliferation.  
Overall, the developed microparticulate systems are versatile and very promising to be used in 
TE strategies.  
v 
RESUMO 
 
Durante os últimos anos, tem havido um crescente interesse no desenvolvimento de sistemas 
de libertação controlada para aplicação em estratégias de engenharia de tecidos (ET) 
humanos. Os sistemas de libertação controlada podem ser utilizados com a finalidade de 
melhorar o índice terapêutico de fármacos por alteração da sua distribuição e, 
consequentemente, aumentar a sua eficácia terapêutica e/ou reduzir a sua toxicidade. 
Diversas tecnologias têm sido desenvolvidas e optimizadas a fim de direccionar o potencial da 
libertação controlada em aplicações de ET. Sistemas na forma de micropartículas para 
libertação de agentes bioactivos apresentam diversas vantagens tais como controlo da sua 
biodisponibilidade, possiblidade de direccionar a terapia e administração não invasiva. 
O presente trabalho de doutoramento pretende avaliar e explorar a potencial de sistemas de 
micropartículas para libertação controlada de agentes bioactivos em estratégias de ET de osso. 
Para tal, foram desenvolvidas micropartículas à base de polímeros naturais, nomeadamente 
misturas de amido e quitosano. Foi também usado o polímero sintético policaprolactona (PCL) 
isolado ou combinado com amido. As partículas foram produzidas recorrendo a técnicas de 
emulsão utilizando diferentes agentes reticuladores ou por evaporação de solventes. As 
propiedades físico-químicas assim como a morfologia e o tamanho das partículas foram 
avaliados de forma a caracterizar os sistemas desenvolvidos. Como agentes bioactivos foram 
usados o antibiótico gentamicina (GTM), o corticóide dexametasona (DEX) e o factor de 
crescimento proteína morfogenética do osso (BMP-2), tendo estes sido incorporados nos 
sistemas desenvolvidos com eficiências de encapsulamento de 67%, 93% e 24%, 
respectivamente. 
Os perfis de libertação foram estudados de forma a mimetizar condições fisiológicas, tendo-se 
observado três fases distintas: i) uma fase inicial em que ocorre libertação súbita do agente 
incorporado, ii) período de libertação mínima e iii) libertação do agente activo remanescente 
que ocorre com a degradação da matriz polimérica. 
A biocompatibilidade dos sistemas desenvolvidos foi testada in vitro usando linhas celulares, 
sendo avaliados parâmetros como a citotoxicidade, morfologia e proliferação celular. A 
actividade dos agentes incorporados foi analisada por diferentes métodos. A actividade 
antibacteriana da gentamicina libertada foi avaliadada pelo método da difusão em agar, que se 
baseia na determinação dos halos de inibição do crescimento de um dado microorganismo 
(bactéria Gram positiva Staphylococcus aureus). A actividade osteogénica dos agentes 
encapsulados DEX e BMP-2 foi analisada através de estudos in vitro com células precursoras, 
vi 
tendo-se avaliado a sua morfologia, proliferação e viabilidade, bem como a expressão de 
marcadores da linhagem osteogénica (e.g. ALP, osteocalcina). 
Todas as partículas desenvolvidas mostraram ser biodegradáveis e não citotóxicas nas 
condições testadas. Além disso, apresentam uma libertação controlada do agente incorporado 
sem comprometer a sua acção, o que as torna adequadas para aplicações em estratégias de 
ET.  
É conhecido que algumas nanopartículas magnéticas apresentam um enorme potencial para 
diversas aplicações biotecnológicas, nomeadadamente no isolamento de subpopulações de 
células estaminais/precursoras. Estas partículas podem ser revestidas com um material 
biocompatível e funcionalizadas com anticorpos específicos para determinado tipo de células. 
De facto, este trabalho envolveu também o desenvolvimento de partículas magnéticas 
funcionalizadas para o isolamento de células. Nanopartículas de magnetite foram revestidas 
com uma solução polimérica de PCL de forma a obter partículas do tipo core-shell. As 
partículas foram caracterizadas em termos de morfologia, tamanho e distribuição, sendo 
também avaliadas as suas propriedades fisico-quimicas e magnéticas. Posteriormente foram 
funcionalizadas com grupos epóxi e amino para ligação de proteínas na superfície. A sua 
biocompatabilidade foi avaliada em estudos in vitro. As micropartículas magnéticas não 
apresentaram citoxicidade nem afectaram a viabilidade e proliferação celulares, podendo ser 
usadas para isolamento de células. 
Em geral, pode afirmar-se que os sistemas de micropartículas desenvolvidas neste trabalho são 
versáteis e apresentam grande potencial para serem aplicadas em estratégias de engenharia 
de tecidos. 
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Chapter 1 - Introduction 
Drug delivery systems: Limitations, current research and future challenges 
 
1.1 ABSTRACT 
During the last few decades, a fair amount of scientific investigations focused on the 
developing of novel and efficient drug delivery techniques. According to different clinical 
needs, several specific biopharmaceutical carriers have been proposed. Micro- and 
nanoparticulated systems, membranes and films, gels and even microelectronic chips have 
been successfully applied in order to deliver biopharmaceuticals via different anatomical 
routes. The ultimate goal is to deliver the potential drug to its specific target, where it is 
needed. Thereby, the bioactive molecule should be protected against environmental 
degradation and delivery should be achieved in a dose and timely correct manner. Drug 
delivery systems (DDS) have several advantages, among others they are able to improve the 
stability, adsorption and therapeutic concentration of the molecules in combination with a 
long-term and controlled release of the drug. Moreover, the adverse effects related with some 
drugs can be reduced and thereby patient’s compliance could be improved. Currently, an 
increase on the research efforts and on the generation of novel results regarding DDS is 
observed. However, most of the developments remain in an investigational state without 
being successfully transferred to clinical applications. Even though, current research indicates 
that DDS may have potential advantages in comparison to traditional administration routes in 
many different applications. In this review, the constraints for successful accreditation of the 
available DDS in conjunction with their applications in preclinical and clinical investigations will 
be discussed. Moreover, it is our intention to highlight up-to-date findings in the field of drug 
delivery research and to envision future developments. 
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*This chapter is based on the following publication: 
Balmayor, E. R.; Azevedo, H. S.; Reis, R. L. Drug delivery systems: Limitations, current research 
and future challenges. 2009. Submitted. 
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Many different drug delivery systems (DDS) are being developed in distinct institutions. 
However, and despite significant progress accomplished on pharmaceutical research, the 
majority of DDS remains on the research stage. This raises the question what are the barriers 
to bring them from the laboratory bench to approved applied medications? These are two 
important questions among many that encouraged us to summarize the current limitations, 
present research and future challenges on the development of DDS.  
 
1.2 DDS: the start 
When a drug is administrated to the human body using traditional medication routes, 
a complex cascade of events is occurring. Depending on the anatomical route, the bioactive 
molecules are passing through several tissues and organs before reaching the site to perform 
their therapeutic action. In those organs, drugs can be biodegraded and inactivated due to the 
highly aggressive environment being either of chemical or biological nature. For instance per 
os medication encounters digestive enzymes in the upper digestive tract before being exposed 
to the highly acidic gastric juice [1]. In order to obtain relevant therapeutic levels, high initial 
concentrations of certain drugs need to be administered. 
Nowadays, different and more sophisticated molecules for therapeutic purposes are 
being developed. In some of those, the traditional administration routes may be problematic. 
Main typical difficulties encountered are short half-lives within the human body, severe 
adverse effects, and uncontrollable dosages. DDS can overcome these limitations by means of 
providing alternative mechanisms to introduce therapeutic agents into the body. The main 
goals behind the rationale of drug delivery research are represented in Figure 1.1. In addition, 
some of the well established advantages that offer the use of DDS compared to traditional 
administration methods of medications are summarized in text box 1.1. 
The main goal of DDS at the beginning of development was to raise the level of 
bioactive drugs in the blood. The pioneers’ investigations proposed the creation of a matrix or 
carrier that could control and guide the release of drug molecules. Additionally, this matrix 
may act as a rate-controlling device to deliver the bioactive drug in a pre-determined pattern, 
well localized place, and during a desired time period [2]. Therefore, polymers were selected 
as the most suitable materials. Features like biocompatibility and non-toxicity, hydrophilicity 
and biodegradability are some of the attractive properties of these materials that allow their 
selection as carriers for drug delivery [2].  
Hydrophilicity and biodegradability are two important properties defining the release 
mechanism of the contained drug. Hydrophilic matrices release the contained drug by 
diffusion phenomena due to the swelling of the polymer upon contact with fluids. Similarly for 
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biodegradable matrices, the rate of degradation in the physiological environment will control 
the release of the drug. Lately, natural occurring and biodegradable polymers are preferred 
when selected materials as carriers to conform DDS. They have the important advantages of 
rapid clearance from the body, being non-toxic, producing degradation products that can 
easily be metabolized and the absence of surgeries to remove medical devices from the body.  
 
Text box 1.1 Advantages of DDS compared with traditional medication* 
• Preservation of the stability and bioactivity of the drugs. Specifically in the case of sensitive 
drugs with short in vivo half-life, the bioactive molecule can be protected from 
biodegradation and inactivation due to the action of enzymes or environmental conditions 
(e.g. acidic gastric juice). E.g. proteins and peptides based drugs commonly destroyed after 
oral intake.  
• Improvement of the adsorption and therapeutic concentrations of the medications within 
the target tissue, organ or diseased part of the body. Hence, allows maintaining bioactive 
drugs at therapeutically desired range. 
• Allows reproducible, controlled and long term administration of the drugs. 
• Allows the possibility of deliver drugs at desired place of the body, i.e. site specific 
treatments and local administration. 
• The frequency of drug administration is reduced. 
• Harmful/adverse side effects related to systemic administration and over-dosages are 
eliminated or may be reduced by delivering continuous small amounts of drugs instead of 
large doses. 
• Drug administration may be improved and facilitated in deprived areas where medical 
supervision may be needed and is not available. 
• Improvement of patient compliance and comfort. Patients’ negligence in the treatments is 
avoided since they do not need to remember taking daily doses of long medications routines. 
Uncomfortable injections and pills can be avoided. 
• From an economic perspective, DDS may result in less expensive products, great variability 
on the market and less waste of drugs. Well established and classical drugs, with expiring 
patents, can be reformulated with novel administration mechanisms improving their 
therapeutic action. 
*Critically compiled from Refs. [1-4] 
 
The first generation of devices developed as DDS were mainly based on polymeric 
implants [2, 5, 6]. These implants were extensively used in the field of orthopedics and trauma 
(mainly bone). However, relative toxicity and inflammation related to these devices, together 
with the need for repeated surgical interventions for device tests and final removal became 
were strong disadvantages associated with these implants. Moreover, implants were painful 
for the patients. Implants used as drug containers bear the difficulty of controling or even stop 
the drug release without removing the device.  
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Figure 1.1 Goals in drug delivery (Adapted from Langer and Peppas [7]) 
 
Thus, novel devices are being proposed, such as those, where pharmaceutical agents 
are encapsulated within smart polymers or attached to them [1, 2, 8]. The highest complexity 
is, however, to move from research to product development, clinical applications, and finally 
commercial exploitation. This is due to the lack of technological feasibility, reproducibility, 
control and marketability that characterize most of the proposed DDS at the research level. 
The idea is to find “the effective formulation” by an optimal combination of a “good” drug and 
“good” polymeric matrix. This “effective DDS” should have reliable and consistent 
performance. 
Indeed, several new delivery technologies arise each year as result of frontier research. 
Every part of the body has been studied as potential route of administration. Consequently, 
transdermal patches [9-12], oral capsules and pills [13-15], injectable gels [16] and drug carrier 
suspensions [17-19] and novel inhalation systems [19, 20] are among the DDS available to-date 
with satisfactory results on medical uses. Reviewing their current clinical applications including 
their advantages and limitations is the objective of this manuscript. In addition, we include our 
findings and insights on the future challenges that face the development of DDS. 
 
1.3 Transdermal drug delivery 
Delivering drugs through the skin is regarded as an alternative to oral delivery or 
hypodermic injections [9, 10, 12]. The main advantages and drawbacks of transdermal drug 
Chapter 1 – Introduction 
6 
delivery systems are listed in Table 1.1. The fact that by simply removing an external patch 
applied to the patient’s skin immediately stops the administration of the drug highlights the 
security of this DDS. This advantage, together with their simplicity in use, makes such patches 
the most available and used DDS nowadays (Table 1.2). 
Presently available transdermal patches can be classified into two main categories: 
reservoir-and-matrix or drug-in-adhesive type [12]. A reservoir system holds the drug in a 
solution or gel, from which the delivery can be controlled by a rate-controlling film located 
between the drug reservoir and the skin. By contrast, drug-in-adhesive type combines the 
drug, adhesive and mechanical backbone of the patch into a simple design. The latter does not 
involve rate-controlling films or membranes. The skin permeability will control the rate of the 
drug delivery. 
However, the skin normally functions as a barrier to the exterior. This is mainly 
achieved by the stratum corneum, the outermost layer of the epidermis [9, 11, 12]. 
Nevertheless, possibilities exist to overcome this barrier. Low molecular weight drugs in the 
range of 100-500 Daltons are one approach to overcome the main limitation of transdermal 
DDS [9, 12]. However, to limit them only to low molecular weight substances as active 
compounds, is a drawback for extensive clinical application. 
 
Table 1.1 Advantages and limitations of transdermal DDS* 
Advantages Limitations 
• Low dose frequency leading to improved patient safety. 
• Simple and fast interruption and elimination from the body: 
By removing the topic patch, the drug delivery can be 
immediately stopped. 
• Easy accessibility of skin which aids in high patient 
compliance. 
• Easy to administer by the patient him/herself. 
• Induces steady state drug levels in the blood. 
• Avoids gastrointestinal irritation. 
• Avoids first pass effect by liver detoxification step. 
• Ability to achieve sustained release. 
• Thermal drug instability. 
• Chemical reactions of the 
drug with polymers and 
excipients. 
• Difficult to pass the skin 
natural barrier: stratum 
corneum 
*Critically compiled from Refs. [9-12] 
 
In order to be able to administer higher molecular weight drugs, other ways of 
circumventing the skin barrier were investigated, e.g. molecular absorption enhancers. These 
are substances that promote the passage of drugs through the different skin layers [11, 12, 21, 
22]. For example, terpene-derived compounds and phenol derivatives seem to improve 
transdermal absorption [12]. Clinical trials have been performed using this type of substances 
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such as linalool, alpha terpineneol and carvacrol in order to enhance the absorption of 
haloperidol [12, 23]. Linalool showed the most satisfactory results by inducing therapeutic 
levels of haloperidol. 
Another possibility of increasing the transport of drugs through the skin is by applying 
different energy forms [10-12], e.g. an electric field, ultrasound etc. These “active” methods of 
skin permeation include iontophoresis, which induces a potential difference across the skin 
[10-12]. Hence, it promotes the transfer of charged ionic drugs or high molecular weight 
compounds. Current clinical applications include the administration of lidocaine and 
iontocaine (Phoresor®), local anesthetics [1, 12] and dexamethasone, as well as local anti-
inflammatory agents [12]. Besides applying an electric gradient, sonophoresis and 
electroporation are alternative methods. However, these have been less studied. One final 
application is the use of low frequency ultrasound that enhanced absorption of mannitol [24]. 
 
Table 1.2 Transdermal DDS: current applications and available marketable products* 
Applications (Active drug)/Commonly used products 
• Menopause symptoms (estradiol)/Esclim®, Vivelle®, Vivelle-Dot®, Climara® 
• Smoker’s addiction (Nicotine)/Nicoderm CQ®, Nicotrol® 
• Chest pain due to heart disease (Nitro-glycerine)/Nitro-Dur®, Nitrodisc® 
• Low levels of male sex hormone (Testosterone)/Androderm® 
• continuous analgesia (Fentanyl)/Duragesic®, Transdermal System® 
• Motion sickness (scopolamine)/Transderm-Scop® 
• Contraceptive (ethinyl estradiol-norelgestromin)/Ortho-Evra® 
*Critically compiled from Refs. [9-12], and from www.drugs.com 
 
1.3.1 Microfabrication for transdermal drug delivery: microneedles 
In addition to the above mentioned chemical and physicochemical procedures, 
physically disrupting the stratum corneum has been used for improving transdermal drug 
delivery [2, 9-11, 25]. This technique uses microneedles to create “micro-holes” that allow for 
transdermal passage of drug molecules [2, 9, 25, 26]. Needles have been fabricated out of 
silicon, metals and polymeric materials. Moreover, these micro-devices have been coated with 
different compounds like proteins, DNA or virus particles [2, 10]. Sizes are usually 
characterized by ranges from sub-micron to millimeter scale [25, 26]. Recently, micron size 
needles have been used for transdermal drug delivery. These microneedles support delivery of 
drugs in combination with passive patches through the skin layers (Text box 1.2). 
In vitro experiments have shown a remarkable increase in skin permeability for both 
small (even nanoparticles) and large drug molecules [26, 27]. Animal experiments showed 
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major increases in transdermal delivery capacity of vaccines, oligonucleotides, insulin, 
desmopressin and human growth hormone [26, 28-30]. 
 
Text box 1.2 Microneedles as transdermal DDS* 
Fabrication of small needles in the micron scale offers persuasive possibilities to improve 
transdermal administration of drugs: 
• The outmost layer of the skin can be selectively “pierced” with small needles. The size 
should be large enough to allow the drug molecules to enter, but small enough to avoid 
reaching nerve terminations, causing pain or significant damage. 
• The permeability of the skin is increased (micron-scale pathways can be created into the 
skin). 
• Targeted effect to the stratum corneum layer of the skin. 
• Drugs can be delivered into the skin in a minimal invasive and controlled manner. 
• Greater device reproducibility and uniformity due to batch-processing techniques. 
• Possibilities of incorporation of different components for pulsatile release of drugs in 
response to physiological requirements. 
• Appears to be safe, well tolerated by patients and allow rapid skin recovery post-
administration. 
*Critically compiled from Refs. [1, 2, 8-11] 
 
Subsequent human trials proved that microneedles are painless, effective and reliable 
in delivering drugs [31, 32]. Naltrexone, for instance, was transdermally administered to 
healthy volunteers by using them [33]. Moreover, therapeutic serum concentrations were 
achieved. Additional transdermal drug delivery systems, based on microneedle technology, in 
clinical development are the influenza vaccine [34] and osteoporosis treatment [9, 10]. The 
influenza vaccine has successfully completed a phase III clinical trial. It has currently been 
submitted for registration in Europe by a collaborative effort of Becton Dickinson and Sanofi-
Pasteur [34]. A clinical phase II for the delivery of parathyroid hormone to treat osteoporosis is 
currently conducted by the company Zosano Pharmaceuticals [9, 10]. During these clinical 
trials no severe adverse effects have been reported. Furthermore, no infections or bleedings 
have been diagnosed. Only mild and temporary skin irritations could be observed. 
 
1.4 Oral drug delivery 
In addition to the parenteral, transdermal delivery route, the oral route is another 
preferred method [2, 35-37]. It is non-invasive and constitutes a convenient administration 
procedure with a good patient compliance. However, there are some limitations related with 
oral intake of drugs molecules. As eluded above, the destruction or inactivation of drugs, 
especially proteins and peptides, due to enzymatic degradation and acidity of the 
Chapter 1 – Introduction 
9 
gastrointestinal tract are detrimental for this administration route. Furthermore, the intestinal 
epithelium may form a barrier, inhibiting the uptake of large molecules [2]. Therefore, DDS 
may be a solution. Various approaches based on the use of protective coatings, targeted 
delivery, permeation enhancers, protease inhibitors and bioadhesive agents have been 
extensively investigated in recent years [2, 38-40]. These methods have shown to increase oral 
bioavailability of drug molecules.  
Nano- and microparticle DDS have been developed for oral administration of agents. 
Microfabricated devices can be designed with different shapes, sizes and surface morphologies 
by using a variety of materials [2, 41], maximizing the contact area with the intestinal 
epithelium. Several additives, like permeation enhancers and enzyme inhibitors, can be added 
to improve drug uptake and protect them from biodegradation. 
Unfortunately, these DDS display side effects, associated with the release kinetics 
(peaks) of the drugs. Therefore, strategies to improve drug delivery profiles are investigated 
[3]. Controlled release osmotic delivery systems, or push-pull systems, were successfully used 
to reformulate nifedipine based products [42, 43]. Extended bioavailability leading to an 
optimized blood pressure control with concomitant reduced side effects was observed. 
Similarly, oxybutynin chloride and methylphenidate were successfully reformulated [44]. 
Moreover, this technology allows for the delivery of hydrophobic and low permeability drugs. 
In addition to osmotic technology, multilayer matrices [45, 46] have been developed 
with different rates of swelling and biodegradation. This ensures controlling the rate of drug 
release through dissolution, diffusion and degradation of the matrix. The core of the multilayer 
matrix contains the drug(s). The additional layers regulate the diffusion of the drug(s) out of 
the device. This multilayer technology has been used to reformulate several immediate release 
formulations, such as diltiazem, paroxetine and diclofenac sodium [3]. 
 
1.5 Inhalation drug delivery 
Inhalative drugs utilize the huge surface area of the lungs to improve absorption. 
Inhalation represents a comfortable means for drug administration. Devices with dose counter 
and functional status indicator are already available in the market, especially for the treatment 
of asthma [4]. However, the efficacy of the traditional oral inhalers could be improved by using 
chitosan microspheres as nasal DDS for salbutamol administration [47]. Mainly, the controlled 
release of the drug was prolonged. 
Unfortunately, nasal mucosa presents a physical and metabolic barrier for drug 
permeation. Polar drug molecules and additive compounds have a poor absorption when using 
the nasal route [2]. To eliminate this limitation, the use of cyclodextrins as molecular carriers 
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seems to be promising. Chemically defined as cyclic oligosaccharides, cyclodextrins have the 
possibility of forming highly stable molecular inclusion complexes with a wide range of drug 
molecules both in solution or solid state [2, 48, 49]. The molecule of interest occupies the 
cyclodextrin hydrophobic cavity. The hydrophilic exterior allows dissolution in water. Thus, the 
drug molecules are protected from the environment and the hydrophilicity of the entire 
system is enhanced (Text box 1.3). Further absorption enhancers such as poly-L-arginine and 
lipids are also under investigation [1, 49]. Besides salbutamol administration, clinical trials have 
been conducted for testosterone, insulin, morphine and interferon among others [50-53]. 
 
Text box 1.3 Cyclodextrins as molecular carrier for traditional drugs formulations and DDS* 
The utilization of cyclodextrins in drug formulations design is based on I) enhanced solubility 
in water of poorly soluble drugs, II) stabilization of labile agents against biodegradation, III) 
taste modification by covering with flavors and IV) masking unpleasant odors. Particularly for 
DDS, cyclodextrins can control the release of encapsulated drugs. For example, in inhalation 
drug delivery formulations, cyclodextrins are able to reduce or minimize the enzymatic activity 
of nasal mucosa. Also, they can largely improve the permeation of various lipophilic drugs, 
and the fraction that is not absorbed is easily removed by the nasal mucociliary clearance 
system. These facts allow their selection to-date as a worldwide used preservation agent for 
nasal DDS. 
*Critically compiled from Refs. [1, 2, 48, 49, 54] 
 
1.6 Injectable drug delivery 
Modern technology tries to avoid the use of injections for drug administration. Usually 
as a result of pain and fear, patients are typically reluctant to use frequent injections. 
Additionally, drug toxicity related to transiently high plasma concentrations when 
administrated intravenously, needs to be avoided especially during chronic treatments. For 
example, some chemotherapeutics, steroids or antibiotics are potent drugs that may evoke 
severe adverse effects. The toxicity of these drugs limits their dosing and hence their drug 
efficacy. Therefore, it is desirable to develop systems that have a high efficiency, an 
accelerated onset in action and being minimally invasive or reduce the number of repeated 
injections. Injection systems are sometimes inevitable. 
The combination of a DDS with a therapeutic implant by means of using an injectable 
formulation has become increasingly attractive. The possibility of using biodegradable 
materials (avoid the need of surgical removal after therapeutic function) that can be injected 
(minimal invasive administration) and composed by drug delivery vehicles (local administration 
of therapeutic drugs) is a novel means in medical care. Hydrogels comprise an important 
matrix system for their application in such DDS [54, 55]. Their benefits and limitations while 
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being components of DDS are summarized in Table 1.3. At the same time, nano- or 
microcapsules can be added to the injectable implant to provide suitable mechanical 
properties and control release of antibiotics or anti-inflammatory drugs [54]. 
 
Table 1.3 Hydrogels: Benefits and limitations for their application in drug delivery* 
Hydrogels: three dimensional, cross-linked networks of water soluble polymers, with particular 
interest as DDS due to their unique physical properties: highly porous and hydrophilic structure. 
Benefits Limitations 
• Optimal pharmacokinetics: drugs can elute slowly maintaining 
high local concentration in the surrounding tissues for an 
extended period. 
• Highly biocompatible, promoted by high water content and 
their physicochemical similarity to native extracellular matrix.  
• Biodegradability and/or matrix dissolution via enzymatic, 
hydrolytic and environmental means. 
• Smart matrices responding to physiological stimuli. 
•  Relatively deformable, adjusting to the shape of the surface to 
which they are applied. 
• Can be designed with muco/bioadhesive properties. 
• Low tensile strength. 
• Limited quantity and 
homogeneity of the 
drug loaded. 
• Rapid drug release 
(High water content 
and porosity). 
• Some hydrogels may 
need surgical 
implantation and are 
not injectable. 
*Critically compiled from Refs. [54-56] 
 
1.7 Nanoparticles suspension as DDS 
Currently, nanoparticle suspensions are used as DDS for a variety of administration 
routes as it has partially been outlined above. A common advantage is their small size and 
particulated shapes, which increases the surface area and thereby enhances the dissolution 
rate and bioavailability [57]. 
When used as components of oral formulations, nanosuspensions can overcome the 
main limitation of bioavailability described for the oral administration route. By means of 
decreasing size and increasing the surface area leads to enhancement of the concentration of 
the released drug. Furthermore, mucosa-adhesion is also improved, which can accelerate the 
gastrointestinal transit [57-59]. As a result, bioavailability of the medication is improved. 
Animal studies indicated that an improved pharmacokinetic profile (optimal drug 
concentration in plasma for a prolonged time period) and bioavailability was obtained by the 
nanoparticulated formulation of danazol suspension [59]. Additionally, nanoparticulated 
systems can reduce the gastric irritation associated with oral intake. Experiments in rats 
showed that by reducing naproxen particle size from micro- to nanometers scale resulted in 
faster absorption, decreased gastric residence time and produced local high and prolonged 
concentrations of the drug [60]. 
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Injectable nano-formulations provide the possibility of administering hydrophobic 
drugs without using solvents, additives or other additional compounds. Generally, the use of 
nanosuspensions as injectable solutions can reduce the toxicity and adverse effects usually 
related with the high concentration of drugs administrated by this route [57]. 
As the main component of inhalation DDS, nanoparticles not only improve 
bioavailability and drug adsorption, but are also beneficial with respect to homogeneity. 
Moreover, a significant higher fraction can be administrated in each dose, lowering the need 
for systemic uptake. Clinical trials with budesonide nanoparticulated suspension indicated a 
two-fold drug concentration in plasma for longer periods of time and increased drug 
absorption, compared with the traditional inhalation product [61]. 
Nanosuspensions were initially developed to solve limitations related with poor drug 
solubility. To-date, they have been proven to be very efficient to optimize pharamacokinetics, 
drug bioavailability, safety and efficacy in all types of DDS and for different administration 
routes [57, 59]. Additionally, the protection of sensitive drugs molecules can be achieved by 
the combination of this technology and specific materials, resulting in the fabrication of 
nanosized devices for drug encapsulation [1, 2, 8]. Thus, this technology may be beneficial for 
the delivery of proteins, growth factors and peptides [3, 55, 62]. Moreover, this technology 
may be used in the future for cell encapsulation or targeting and gene delivery [1]. 
 
1.8 Novel findings and challenges facing DDS 
Nowadays, numerous medical equipments, rehabilitation techniques, drugs and 
minimal invasive chirurgical procedures have been constantly improved for the most diverse 
injuries. However, due to the limited capacity of some tissues to regenerate, the treatment of 
complicated and comminuted injuries is difficult and may fail. To generate new possibilities for 
tissue repair and regeneration, DDS can assist new emerging technologies (e.g. tissue 
engineering [55, 63]) based on the delivery of therapeutic proteins and peptides. Additionally, 
highly complex and sensitive proteins, like growth factors display a specific therapeutic action 
within narrow borders. This creates the need for DDS to provide more sophisticated and 
efficient devices. The efficient delivery of those therapeutic molecules to the injured site is 
necessary. Thereby, a high bioavailability and controlled release is of eminent importance. 
 
1.8.1 Growth factor delivery 
Nowadays, numerous growth factors have been identified and produced using 
recombinant technology [64]. Growth factors are naturally occurring proteins capable of 
stimulating cellular proliferation, migration and/or differentiation into a specialized phenotype 
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(e.g. osteoblast for bone or chondrocytes for cartilage regeneration). Thus, being involved in 
the regulation of several cellular functions, they can enhance the healing and regeneration 
process of diverse tissues [62, 65]. 
Traditional delivery strategies of growth factors have clear limitations. Therefore, only 
a limited number of those proteins have been approved and commercialized for therapeutic 
purposes. The lack of protection against biodegradation and the subsequent low local 
bioavailability are some of the disadvantages related with the delivery of growth factors by the 
traditional means. To overcome these limitations, several technologies have been explored for 
the better control of growth factors release. These technologies vary in their use of nano- and 
microfabricated systems in the form of fibers, capsules and particles, three dimensional porous 
scaffolds and injectable gels. All of them based on the use of biomaterials as the main 
component of their matrices. Fibrin hydrogel releasing IGF-I, for example, has been 
investigated to repair articular cartilage defects in an animal model [66]. Similarly, an alginate 
hydrogel carrying VEGF has been applied for treating ischemic disease in mice [67]. Moreover, 
in the same model, a mixture of VEGF and PDGF loaded in a polymeric scaffold was 
investigated [68]. Nano- and microparticles made of poly(glycolic) and poly(lactic) acid [69], silk 
fibroin [70], and gelatin [71, 72] have also been extensively investigated for the loading and 
release of growth factors in different applications. 
Polymers as DDS for growth factors achieve a localized and controlled release to yield 
a desirable concentration over a period of time. The release profile can be optimized to the 
desired clinical application by tailoring either the properties of the polymeric matrix or the 
features of the developed device during their processing (e.g. vehicle size, porosity and pore 
size and distribution, crosslinking, and degradation rate) [73]. 
Biomaterials have proven to be highly useful in delivering growth factors in a 
controllable manner and by providing protection against non-friendly environments 
maintaining the bioactivity of those molecules. In the past few years, novel and sophisticated 
technologies have been developed besides the use of polymeric matrices creating new 
possibilities for the delivery of growth factors. Cell and gene therapy are further examples of 
application of these technologies. These investigations will lead to a future development 
where growth factors will be delivered/expressed/produced at the site of interest and only at 
the levels and time at which they are required. 
 
1.8.2 Cell encapsulation 
As stated above, there are still limitations to currently available DDS. Moreover, it is 
difficult to deliver peptides and proteins such as growth factors. Therefore, the need exist to 
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find alternative approaches for drug delivery. Cells can be considered as “biological factories”. 
They can continuously produce and release therapeutic agents. Delivery can be performed by 
cell encapsulation or immobilization within a semipermeable membrane [74]. This ensures 
protection against the immune system and diminishes mechanical stress. The membrane 
should allow diffusion of nutrients and oxygen towards the cells and waste products as well as 
the therapeutic agent in the opposite direction (Figure 1.2). 
 
Nutrients + O2
Waste,
therapeutic products,
Secreted or expressed proteins
Host immune system
 
Figure 1.2 Function of the semipermeable membrane in cell encapsulation technology (Adapted from 
Orive, G. et al. [74]) 
 
Advantages of cell encapsulation technology as DDS are [74-77]: I) no need for 
immunosuppression, II) fully biocompatible materials are used for the capsules that do not 
interfere with cellular function or exert toxicity. The capsules can be tailored to obtain the 
optimal properties for cell encapsulation such as permeability of the membrane, III) 
therapeutic products can be released in a sustained and controlled way for continuously long 
time periods, IV) bioactivity of the therapeutic agent is guaranteed since they are produced by 
the cells, V) cells can easily be genetically modified to express any desired protein for therapy, 
VI) safety. When the capsule degrades, the foreign cells will be eliminated immediately by the 
immune system. VII) Finally, the common toxicity due to the high drug concentrations is not 
present. 
Capsules have small sizes and can therefore be easily administrated into the blood 
circulation. Furthermore, the ratio between capsule surface and volume is improved in 
comparison to other devices geometries allowing transfer of oxygen and nutrients into the 
capsules ensuring high cell viability [78]. Capsules can be easily produced due to established 
processing methods (e.g. emulsions, ionic complexations, spray drying, etc). Additionally, so 
called core-shell capsules entrap cells inside a free empty core surrounded by a 
semipermeable shell. Usually, the diffusion is controlled by size-exclusion phenomena and 
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diffusion rate. Therefore, the material that composes this semipermeable shell is of eminent 
importance. The optimum size for these devices is 100-500 µm [77]. 
Several biomaterials can be used for cell encapsulation. They are biocompatible and do 
not interfere with cellular function. Alginate seems to be the most studied for cell 
encapsulation. It shows biocompatibility and biodegradability, although some immune 
reactions may occur. Alginate creates three dimensional structures by the formation of 
interchain bridges upon reaction with multivalent ions. Thereby, it forms a gel-like structure. 
A wide range of cell types and sources have been used for encapsulation such as 
genetically modified cells expressing desired proteins, therapeutic stem cells or disease specific 
cell types (table 1.4). For the latter, pancreatic islets cells have been encapsulated to treat 
diabetes in both animal studies [79, 80] and pilot clinical trials [81, 82].  
 
Table 1.4 Cells encapsulation systems recently employed* 
Factors to consider for a suitable cells: I) allogenic vs. xenogenic source, II) controlled proliferation once 
encapsulated, III) possibility for genetic modification. 
Developed systems  Application 
Alginate-Kidney cells 
-Parathyroid cells 
-chondrocytes 
-Leydig cells 
-Adrenal chromatin cells 
-Stem cells 
-Myeloma cells 
Alginate/HEMA-MMA-Fibroblast 
  -Myoblast 
  -Ovary cells 
  -Hepatocytes 
 
  -PC12 pheochromocytoma cells 
 
Alginate/Chitosan-Tumor cells 
Chitosan-Fibroblast 
-Chondrocytes 
Collagen-Myoblast 
Hyaluronic acid-Chondrocytes 
Dextran/RGD-Human embryonic stem cells 
 
Agarose-Murine embryonic stem cells and kidney cells 
Agarose/Gelatin-Feline kidney cells 
Hemophilia, neurotrophic factors 
Artificial organs 
Bone-cartilage regeneration 
Hormone replacement 
e.g. Parkinson´s disease 
e.g. bone regeneration 
Hepatic growth factor release 
Epilepsy, metabolic deficiencies 
Cancer, metabolic deficiencies 
Fabry disease 
Liver related diseases and 
transplantation 
Neurotrophic and neurotransmitters 
factors 
Cancer vaccine, interleukins 
In vitro study: tissue engineering 
 
In vitro study 
In vitro study: cartilage formation 
In vitro study: vascular 
differentiation 
In vitro study: tissue engineering 
In vitro study: Increase in metabolic 
activity 
*Critically compiled from Refs. [74-77, 83-89] 
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Another example are choroid plexus cells, that encapsulated in an alginate based 
system released neurotrophic factors to the brain in a primate model to prevent degeneration 
of neurons in Huntington´s disease [90]. Entrapped bone marrow stromal cells in poly lactic 
glycolic acid capsules enhanced bone regeneration in an animal model [91]. 
 
1.8.3 Gene therapy 
Gene therapy is another example of a new emerging technology that facilitates the 
delivery of growth factors, as high and sustained levels of growth factors at the site of injured 
cannot be achieved by administration as a protein. The most suitable approach to accomplish 
satisfactory results is to combine this novel and emerging technology with the well established 
achievements from the drug delivery and tissue engineering field. 
The gene encoding the desired growth factor can be transferred into a cell by the use 
of viral or non-viral vectors (figure 1.3). The transfected cell subsequently secretes the desired 
protein (Figure 1.3 A). In addition, the transfected cell can differentiate into a desired 
phenotype (osteoblast for bone or chondrocyte for cartilage regeneration) (Figure 1.3 B). 
Local gene delivery can be achieved by either in vivo or ex vivo approaches [92-95]. 
Basically, the in vivo approach [93] simply directly administers the vector into the injured 
tissue. However, serious safety concerns exist for this approach due to lack of control of the 
virus. On the other hand, the ex vivo strategy [92] provides more control over each step. This 
strategy is based on the in vitro genetic modification of cells, where the growth and 
transfection can be carefully controlled. Of note, the cells can be harvested in an autologous 
way. Finally, the modified cells can be re-injected or transplanted into site of injury. Numerous 
advantages are claimed [92-95] for the ex vivo strategy: I) the patient’s cells can be 
cryopreserved at any stage of the process to be used in subsequent therapies, II) the 
concentration of the expressed protein can be controlled by controlling the amount of vector 
during transfection, thereby diminishing systemic adverse effects or toxicity. 
Several studies on the use of gene therapy have been reported recently. Studies on 
gene therapy of urological dysfunction [92], bone and cartilage injuries [93-97] and 
cardiovascular dysfunction [98] have been reported (Huard et al.). An adenovirus expressing 
BMP-2 has been used to induce bone formation [99]. A polyhedron promoter of baculovirus 
encoding BMP-2 loaded onto collagen sponges induced ectopic bone formation in rats after 4 
weeks (Hosseinkhani et al.) [100]. Inducible nitric oxide synthase adenovirus transduced cells 
were more effective to treat erectile dysfunction when injected to the corpus cavernosum of 
adult rats in comparison with plasmid or adenoviral solutions [101]. 
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Figure 1.3 Representation of an autologous ex vivo gene therapy. The cells are isolated, grown and 
transfected in vitro in a controllable fashion before re-administration into the injured site. Two examples 
are represented, the transfected cells can sustained release therapeutic entities A) and can be induced 
to differentiated into different phenotypes for tissue regeneration B) 
 
Despite the fact that a significant portion of gene-therapy research is conducted for 
bone and cartilage regeneration, only few have been tested in clinical trials for human joint 
diseases. Viruses such as retrovirus, adenovirus and lentivirus, are still the preferred vectors 
due to their potential efficiency [93, 95, 102]. However, they have safety concerns related to 
their intrinsic cytotoxicity, immunogenicity and possible mutagenesis that prevent them from 
being transferred to clinical applications Therefore, numerous efforts are still required in order 
to increase the transfection efficiency of non-viral vectors. 
 
1.9 CONCLUDING REMARKS: envisioning the future of DDS 
As stated before, the main aim of DDS at the beginning was to raise the serum level of 
therapeutic agents. This evolved to locally deliver cells, anticancer drugs, growth factors and 
therapeutic genes. DDS has become, therefore, a powerful tool in health care. 
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Transdermal DDS are currently the most employed products. Drug delivery devices for 
the transdermal route have passed successfully through in vitro, in vivo and human studies. 
They show a combination of safety and efficacy in use. Indeed, the skin seems to remain an 
excellent route for DDS. These DDS are even under constant improvement today, as it can be 
observed by developed microneedles. DDS for oral, inhalation, injection will need additional 
efforts to increase reproducibility, control of drug concentrations and release profiles. The 
possibility of overcoming their limitations and successfully enter human clinical trials seems to 
be close to reality. 
New challenges for the future, besides the improvement of known DDS, are the 
delivery of therapeutic entities using “biological devices”. E.g. cells are recognized as a source 
for potential delivery of therapeutics. Cell and gene therapy concepts are already introduced 
into the clinical arena. Although they are not yet established as approved therapeutic 
techniques, remarkable results have been obtained, mainly in the field of bone and cartilage 
regeneration. At the experimental level many studies have been reported with success to 
prove the feasibility of these therapies for tissue healing. A fair amount of research is still 
needed to successfully transfer cell and gene based technologies to the medical practice. The 
unavailability of safe vectors carrying therapeutic genes appears to be the main obstacle in 
these technologies. Therefore, in our opinion, the optimization of the use of non-viral vectors 
is of major importance in the future of cell and gene related therapies. 
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Chapter 2 – Materials and Methods 
 
2.1 Hypotheses and experimental approach 
This PhD work attempts to shed light on several key factors regarding the development 
and characterization of novel microparticle systems for molecular delivery in bone 
regeneration strategies. The specific aims for this work include: 
- Develop and characterize particulate systems based on different materials and 
exhibiting diverse properties; 
- Evaluate the carrier potential of the developed systems for the controlled release of 
biologically relevant molecules; 
- Evaluate in vitro the biocompatibility of the developed carrier systems and their 
ability to foster osteogenesis. 
- Develop an optimize methods to prepare magnetic particles with uniform and 
adequate size and functionalized surfaces for cell isolation applications. 
 
The hypotheses used in this work include: 
- Non-toxic and biodegradable microparticles with adequate properties can be used for 
the incorporation and release of a wide group of bioactive agents, including antibiotics, 
steroids and growth factors. 
- Selected bioactive agents can be encapsulated within the microparticle systems by 
adequate methods, and incorporated molecules remain active after encapsulation and release.  
- Microparticles based on starch combinations provide sustained release for 
incorporated bioactive agents. 
- Loaded microparticles are biocompatible and promote desired biological responses 
(e.g. cell differentiation). 
- Functionalized magnetic-poly-ɛ-caprolactone microparticles can be used to covalently 
bind protein-like molecules (e.g. antibodies) and separated by the application of an external 
magnetic field. 
 
The work described in this dissertation can be divided into three main parts. The first 
two sections include the development of particulate delivery systems for the controlled 
release of bioactive agents relevant in bone repair strategies: i) antibiotics (gentamicin 
sulphate) to combat bone infection and ii) osteoinductive agents (bone morphogenetic protein 
2 and dexamethasone) for enhancing bone regeneration. The final research topic addressed in 
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this thesis, presented in chapter 8, is entirely dedicated to the development of particulate 
materials for cell isolation purposes, to be further applied in cell research and therapy. The 
overall experimental approach was to create microparticulate materials for the efficient and 
controlled delivery of bioactive molecules. The materials were characterized from a materials 
science perspective and tested in vitro to assess their potential as delivery carriers and 
biological performance. Each of these parts is related, yet scientifically independent. Several 
experiments were carried out to understand the fundamental aspects of their formulation on 
their resulting functionality and biocompatibility, which can be sub-divided as follows: 
i) Preparation of microparticulate systems with different properties using three different 
polymeric materials namely a blend of starch with poly-ɛ-caprolactone (SPCL), chitosan-
starch conjugate (CHT-ST), poly-ɛ-caprolactone (PCL); 
ii) Incorporation and in vitro release of bioactive molecules (gentamicin sulphate, bone 
morphogenetic protein-2, and dexamethasone) using the developed microparticle 
systems; 
iii) Characterization of the developed microparticles and drug loaded microparticles 
regarding morphology, size distribution and chemical structure. Surface characterization 
of the functionalized particles was performed for the poly-ɛ-caprolactone system; 
iv) In vitro enzymatic degradation studies of the microparticles, including evaluation of 
the release profile of the entrapped bioactive drugs in an enzymatic environment; 
v) Protein binding studies on surface functionalized particles (poly-ɛ-caprolactone 
system only); 
vi) Biocompatibility of the obtained microparticles (cell viability, proliferation and 
morphology as a result of the contact of the microparticles with different cell types).  
vii) Determination of the bioactivity of entrapped/in vitro released bioactive molecules: 
antibacterial activity of released gentamicin sulphate and biological activity of released 
bone morphogenetic protein-2 and dexamethasone towards osteogenesis.  
 
2.2 Materials 
The majority of the chemical reagents, unless otherwise noted, was purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and used as provided. Reagents and solvents for high-
performance liquid chromatography (HPLC) were of HPLC grade and obtained from LABSCAN 
(CITY, Ireland). Similarly, reagents for spectroscopic analysis (e.g. potassium bromide (KBr) for 
FTIR and deuterated solvents for 1H-NMR) were obtained with the adequate requirements for 
each technique. Details are presented for each chemical or material when used for the first 
time in this chapter.  
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Further details are provided in this chapter for the materials used in the cell culture 
studies (e.g. cell lines and primary cells, culture medium components and cell culture supplies). 
All the chemicals were stored and manipulated following the manufacturer’s 
instructions and safety practices. 
 
2.2.1 Corn starch-poly-ɛ-caprolactone blend 
A polymeric blend of corn starch with poly-ε-caprolactone (SPCL, 30-70 wt %) was used 
for the production of the starch-based microparticles (Chapters 5, 6 and 7). This blended 
material was supplied by Novamont (Italy) in granular form and processed by conventional 
injection moulding under optimized conditions [1] in a Klockner-Ferromatik Desma FM20 
machine to produce compact discs (Ø=1 cm). More details about the thermal properties of this 
polymeric blend have been described elsewhere [2]. 
SPCL is both biodegradable and biocompatible material and combines the properties 
of each polymer in a single composition. The hydrophilic and biodegradability nature of starch, 
associated with a synthetic hydrophobic polymer (PCL) suggested the potential of this material 
to develop microparticle systems for drug delivery applications.  
SPCL discs were used without further treatment. Before the preparation of the 
microparticles, the discs were manually cut in small pieces and subsequently dissolved in 
methylene chloride under vigorous stirring to form the microparticles.  
 
2.2.2 Poly-ɛ-caprolactone 
Poly-ε-caprolactone (TONETM PCL-787) was obtained from Union Carbide Chemicals 
and Plastics Division (USA). The average molecular weight, reported by the manufacturer, was 
125 kDa.  
The PCL was obtained in a granular form and used as received for the core-shell 
microparticles preparation (Chapter 8). In detail, this polymer was used for the entrapment of 
magnetite content into a polymeric shell for the development of the magnetic particulate 
system. PCL was selected for this study due to its well known biocompatibility and its 
semicrystalline nature that makes this polymer very easy to process by a variety of techniques. 
Furthermore, its surface can be easily functionalized.  
 
2.2.3 Chitosan 
Chitosan (from crab shells, medium molecular weight) was purchased from Sigma-
Aldrich (USA). Molecular weight and degree of N-deacetylation were determined prior use. 
The determination of chitosan molecular weight (MW) was conducted by a viscosimetric 
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method [3], using 0.3 M acetic acid/ 0.2 M sodium acetate as a solvent mixture. The viscosity 
average molecular weight (MW) was calculated based on the Mark-Houwink equation [4, 5]. 
The MW of the chitosan was found to be 385 kDa. The degree of N-deacetylation of the 
chitosan was determined by 1H-NMR sprectroscopy method [6], and was found to be 81.25%. 
Chitosan was used, without further treatment, to obtain a conjugation complex with 
oxidized starch. Subsequently, a microparticulated system was developed by the use of the 
chitosan-starch complex (Chapter 3 and 4). 
 
2.2.4 Soluble potato starch 
Starch from potato origin was supplied as powder by ATO (The Netherlands). This 
polysaccharide was modified to make it water soluble (designated as Paselli 2 by the 
manufacturer). Before using this polymer, an oxidation treatment was performed.  
 
2.3 Preparation of different microparticulated systems 
A variety of methods have been reported for the preparation of both nano- and 
microparticulated systems. The most widely used techniques are methods based on emulsions 
(e.g. suspension polymerization, water-in-oil single and double emulsions), solvent 
evaporation, organic phase separation or coacervation, and spray-drying methods [7-13]. In 
the presented studies, we have selected water-in-oil emulsions and solvent evaporation as the 
more suitable methods to employ in the preparation of the microparticles, mainly based on 
the physicochemical properties of the materials used.  
 
2.3.1 Microparticles for the controlled delivery of bioactive agents 
2.3.1.1 Corn starch-poly-ε-caprolactone blend microparticles (SPCL): Dexamethasone and bone 
morphogenetic protein-2 loading 
The selected method to produce the SPCL microparticles was based on an emulsion 
solvent extraction/evaporation technique [14]. Once SPCL has been dissolved in methylene 
chloride, this solution was dropped into a 200 mL polyvinyl alcohol (PVA) solution and 
emulsified for 4 h under constant mechanical stirring in order to evaporate the organic solvent 
providing structural integrity to the microparticles. Different experimental conditions were 
evaluated, namely different polymeric concentrations (SPCL, 5-20%), stirring rates 
(400-20000-rpm), PVA concentrations and molecular weights (0.5-5%, 30 000-100 000 g/mol). 
The resulting microparticles where then collected by filtration, thoroughly washed with 
distilled water and vacuum dried in a desiccators and/or freeze-dried. For the microparticles 
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loaded with the growth factor (BMP-2) a lyophilization process was performed due to the 
sensitivity of those molecules to high temperatures. 
After selection of the proper condition, dexamethasone (DEX) (97%, cell culture tested, 
Sigma-Aldrich, USA) was loaded by mixing the SPCL solution in methylene chloride with the 
steroid at different percentages (5, 10 and 15% (w/w), relatively to polymer weight). The same 
procedure was performed as described for unloaded microparticles. The reaction medium was 
stored at 4 oC for later quantification of unloaded DEX.  
For the microparticles to be loaded with bone morphogenetic protein-2 (BMP-2) 
(Recombinant human BMP-2, > 95%, R&D systems, USA), a co-encapsulation process was 
performed using bovine serum albumin (BSA) (≥96%, Sigma-Aldrich, USA). BSA protects 
bioactive molecules from inactivation in presence of harsh organic solvents. 200 mg of BSA and 
10 µg of BMP-2 were mixed and added to the SPCL solution before the addition to the stirring 
PVA emulsification medium. After formation of the microparticles, the reaction medium was 
collected and stored at 4 oC for quantification of unloaded proteins (please see section 2.6.2). 
All experiments using DEX and BMP-2 loaded microparticles were carried out in 
triplicate. 
 
2.3.1.2 Starch-conjugated chitosan microparticles (CHT-ST): Gentamicin sulfate loading 
Hydrated polymers, like chitosan, usually need crosslinking to provide them with 
structural stability. Conjugation of chitosan with oxidized starch can lead to a more stable 
complex. The most common crosslinker agents for chitosan are glutaldehyde [15] and 
formaldehyde [16]. They are capable of forming highly stable products. However, their toxicity 
and the possibility of impairing the biocompatibility of their crosslinked products are 
considered major drawbacks [15, 17]. Moreover, natural origin polysaccharides with free 
aldehyde groups like starch or cellulose have been investigated for possible conjugation with 
chitosan [18-20]. As a result, a polysaccharide complex is obtained with the needed structural 
integrity together with an enhancement of biocompatibility, biodegradability and 
hydrophilicity of the resulting systems. 
Sodium periodate oxidation of soluble starch. Starch was oxidized to generate a 
polyaldehyde able to react with the primary amino groups of chitosan by means of imine 
conjugation (highly unstable conjugate) [21]. Subsequently, a reduction process is needed to 
stabilize the final conjugate. Briefly, soluble starch was dissolved in distilled water (0.02 g/mL) 
in a light protected glass vessel. Subsequently, sodium iodate (10 mg/mL) was added dropwise 
into the starch solution, allowing the reaction to proceed for 30 minutes at room temperature 
under slow magnetic stirring. Finally, in order to quench the reaction, glycerin (0.1 mL/mL 
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solution) was added and stirred for additional 10 minutes. The resulting solution was dialyzed 
(Dialysis tubing cellulose membrane, MWCO 12 kDa, Sigma-Aldrich, USA) against distilled 
water for two days with several daily changes. The oxidized starch solution was concentrated 
by using an ultra-concentrator Amicon® stirred cell 8010 (Millipore, USA) and stored at 4 oC in 
a light protected glass vessel until further use.  
Starch-conjugated chitosan complex formation. Chitosan solution was prepared by 
dissolving the polymer in 1% acetic acid solution. The same volume (e.g. 10 mL) of chitosan 
(1.5% (w/v)) and oxidized starch (2% (w/v)) solutions were mixed thoroughly and the pH 
adjusted to 5.5. The gel-like solution formed was further used for the formation of the starch-
conjugated chitosan microparticles (CHT-ST). 
Starch-conjugated chitosan microparticles. CHT-ST microparticles were prepared by 
water-in-oil emulsification methods using reductive alkylation crosslinking procedure [22]. In 
this case, both chitosan and oxidized starch are soluble in water and non-soluble in oil. 
Therefore, an emulsion of the aqueous solution of these polymers is easily formed using oil as 
the non-soluble phase. Additionally, any further modification to the technique like crosslinking 
or drug loading is feasible whenever they are soluble in the polymeric solution (aqueous 
phase).  
The previously formed CHT-ST polymeric solution (gel-like, pH=5.5) was added 
dropwise into a glass reactor containing mineral oil (1% of Tween 80). The oleic phase was 
continuously emulsified with a mechanical stirrer at 600 rpm for 30 minutes to allow the 
formation of a stable emulsion. Subsequently, a suitable volume of cold acetone was slowly 
added and allowed to proceed for two hours. The microparticles were removed from the 
reaction medium by filtration and washed with distilled water/acetone mixture (1:1) to 
remove the oil adhering to their surface. After drying at room temperature, the microparticles 
were incubated for three hours with 0.5 M sodium carbonate buffer solution (pH 8.5) to allow 
the conjugation between reactive aldehyde groups (Starch) and primary amino groups 
(Chitosan). After repeatedly washing with distilled water, the microparticles were incubated in 
sodium borohydride solution (0.05%, w/v) for one hour to reduce excess of reactive aldehyde 
groups, and to confer stabilization to the imine conjugation (CHT-ST) into covalent bonds. 
Finally, the resulting microparticles were washed with distilled water and allowed to dry at 
room temperature. 
Three variations were subsequently introduced to the standard procedure described 
above (starch-conjugated chitosan microparticles without using external crosslinking agents): i) 
two different crosslinking agents were employed: sodium tripolyphosphate (TPP) and 
glutaraldehyde (GA), at concentrations in the range 0.5-2%. Crosslinking was achieved by 
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immersing the obtained samples for 3 hours into the crosslinker agent solution, ii) the amount 
of starch in the composition of the CHT-ST conjugate polymer solution used for the 
microparticles preparation was varied (1-4%), iii) the stirring rate employed to form the 
emulsion was increased from 400 to 800 rpm aiming at producing smaller sizes microparticles.  
For the microparticles to be loaded with gentamicin (GTM) (puriss. p.a., Fluka-Bio 
Chem. Co., Switzerland) the drug was directly added to the starch-conjugated chitosan 
polymeric solution and carefully dissolved (GTM initial concentrations: 5, 10, and 15 mg/mL of 
polymer solution). The subsequent procedure used for the formation of the CHT-ST 
microparticles loaded with GTM was the standard procedure described above without any of 
the described modifications. However, the effect of external ionic crosslinking on the drug 
loading and in vitro release was investigated by the use of TPP. Hence, the GTM loaded 
microparticles were immersed into three different concentrations of sodium tripolyphosphate 
(TPP) solution (0.5, 1, and 2% w/v) for 30 minutes. The initial concentration of GTM used for 
this study was 15 mg/mL. The reaction medium and washing solutions were stored at 4 oC until 
further quantification for unloaded GTM. All the encapsulation procedures described for GTM 
were performed in triplicate. 
 
2.3.2 Magnetic microparticles for the immunomagnetic separation of cells 
2.3.2.1 Magnetic poly-ε-caprolactone microparticles (m-PCL). Entrapment of magnetite core 
within a polymeric shell 
Magnetite nanoparticles. The magnetite nanoparticles were synthesized by a 
co-precipitation method [23-26]. For that purpose, two different chloride salts were used as 
iron source (Fe3+/Fe2+) and a concentrated solution of ammonium hydroxide to cause 
co-precipitation. Briefly, FeCl3.6H2O (1.80 M) and FeCl2.4H2O (1.20 M) were dissolved in 
distilled water (previously degassed by N2 bubbling). Under a N2 atmosphere and vigorous 
mechanical stirring, the mixture was heated to 80 oC. Subsequently, 40 mL of ammonium 
hydroxide solution (25% in water) were rapidly added, maintaining the reaction conditions for 
the following 30 minutes. Temperatures in the range of 70-80 oC and the constant N2 
atmosphere used reduce the oxygen content of the precipitation medium. This minimizes the 
oxidation of the formed magnetite (Fe3O4) to ferromagnetic oxides (Fe2O3). After the formation 
of the magnetite particles, oleic acid was added and the mixture was heated to 80 oC for 30 
minutes. At this time, the mixture changed to a deep black lump indicating the formation of 
the magnetite particles. The precipitate was separated by the use of an external magnetic field 
and then extensively washed using a mixture of distilled water and acetone (1:1). The particles 
are attracted towards the external magnet within a few minutes allowing discarding the 
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supernatants. At the end of this procedure, a fine black precipitate with superparamagnetic 
behavior was obtained and dried using a vacuum desiccator at room temperature. 
Magnetite nanoparticles entrapment into PCL shell. Core-shell magnetic 
poly-ε-caprolactone microparticles (m-PCL) have been prepared by emulsion solvent 
extraction/evaporation method [14]. The synthesized magnetite nanoparticles were included 
inside the polymeric shell. In brief, PCL was completely dissolved in methylene chloride under 
vigorous stirring with the subsequent addition of the magnetite nanoparticles. The mixture 
was sonicated for 10 minutes using an ultrasonic bath, to ensure a good dispersion of the 
magnetite nanoparticles in the polymeric solution. Subsequently, the suspension was dropped 
into a continuously stirred PVA medium (100 mL), and emulsified for 4 hours. Different 
experimental conditions, such us magnetite to polymer ratio (0.005-0.15%), PVA concentration 
(0.5-2%) and stirring rate (11000-24000 rpm) were tested. The m-PCL microparticles were then 
collected by magnetic decantation, washed with distilled water and lyophilized to obtain a fine 
brownish powder. 
 
2.3.2.2 Surface functionalization of the m-PCL core-shell microparticles 
Amino groups. The functionalization of the surface of the m-PCL microparticles with 
amino groups (-NH2) was achieved by an aminolysis process [27]. For that purpose, dried 
m-PCL microparticles were immersed in a mixture of 1,6-hexanediamine/2-propanol using 
different experimental conditions. The microparticles were chemically functionalized in 
1,6-hexanediamine at concentrations in the range of 2-20% and at two different temperatures 
(25 and 37 oC) for a time period varying from 30 to 90 minutes. The reaction vessel was 
maintained under constant agitation placed inside a shaking bath (100 rpm). At the end of 
each treatment period, the amino functionalized m-PCL (NH2-m-PCL) microparticles were 
collected by magnetic decantation, and extensively dialyzed (Dialysis tubing cellulose 
membrane, MWCO 12 kDa, Sigma-Aldrich, USA) using deionized distilled water to remove the 
free 1,6-hexanediamine. Subsequently, the particles were dried in a vacuum desiccator at 
room temperature. 
Epoxy groups. Epoxy groups were introduced on the surface of the m-PCL 
microparticles by adapting a previously reported method [28]. The procedure is based on the 
use of a plasma activation step followed by a chemical reaction. Both plasma activation and 
chemical functionalization were carried out in a radio frequency plasma reactor “PlasmaPrep5” 
(Gala Instruments, Germany). Before the experiments, the plasma chamber was thoroughly 
purged with a continuous flow of the gas (O2) used during the treatment to reduce trace 
amounts of air and moisture. The m-PCL microparticles were exposed to oxygen plasma to 
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activate the surface by peroxy and hydroxyl functional groups. The gas flow (O2) was adjusted 
in order to keep a constant pressure of 0.18 mbar inside the chamber. A power of 90 W was 
applied. The duration of the surface activation was 2 min. Subsequently, vapors of 
epichlorohydrin (ECH) were introduced inside the chamber (vapor pressure 13.8 mmHg at 
21.1-oC) and allowed to react with the particles for 30 minutes. 
Both, amino and epoxy functionalized m-PCL microparticles were then stored under 
controlled dry conditions, using a vacuum desiccator to preserve their surface activity for 
further characterization and use.  
 
2.3.2.3 Protein binding studies 
Immunomagnetic cell isolation usually involves specific interactions between antigens 
or antibodies bound onto the surface of the particles, and the counterparts in or on the 
surface of the cells. Hence, antigens and antibodies determine the efficacy of the isolation 
process. Aiming to demonstrate the potential of the developed magnetic microparticles for 
covalent binding of protein molecules, we have selected bovine serum albumin (BSA) as a 
model protein to study the binding ability of the functionalized m-PCL microparticles. 
NH2-m-PCL microparticles. A typical carbodiimide (N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC) (commercial grade, Sigma-Aldrich, USA) activation-
adsorption experiment was carried out [21]. Briefly, 10 mg of dried NH2-m-PCL microparticles 
were resuspended in 0.05 M MES buffer followed by the addition of a freshly prepared EDC 
solution (40 mg/mL). The suspension was carefully mixed at room temperature. Subsequently, 
the BSA (≥96%, Sigma-Aldrich, USA) was dissolved in MES buffer and added to the 
microparticle suspension. The suspension was mixed on an orbital shaker for two different 
time periods (5 hours and overnight), and at two different temperatures (25 and 37 oC). 
Subsequently, the supernatants were collected and filtered (Low protein binding Durapore® 
(PVDF) syringe filter unit, 0.22 µm pore size, Millipore, USA). BSA concentration was 
determined by UV spectrophotometry at 280 nm. The microparticles were washed and 
resuspended in MES buffer and stored at 4 oC for further analysis. 
Epoxy-m-PCL microparticles. These particles were used without previous activation of 
the surface of the microparticles. The dried particles were washed in MES buffer and 
subsequently mixed with BSA. The experimental procedure was identical to the previously 
described for NH2-m-PCL microparticles. 
The effect of several experimental parameters on the covalent binding of BSA was 
studied, i.e. pH (3.5-7, MES buffer, 0.05 M) and ionic strength (concentrations of NaCl: 0.1, 0.5 
and 1.5 M). In addition, the efficiency of the covalent BSA binding to the surface groups of the 
Chapter 2 – Materials and Methods 
32 
m-PCL functionalized microparticles was investigated. Thus, the BSA-microparticles complexes 
were immersed in buffer medium containing 1% Tween 20, which removes only the physically 
adsorbed protein [29, 30]. After elution, the released BSA was measured at 280 nm. 
Aiming to visualize the BSA covalently bound to the surface of functionalized 
microparticles, confocal laser scanning microscopy (CLSM) (Olympus IX81, Japan) was 
performed. BSA was labeled with fluorescein isothiocyanate (FITC) prior the binding 
experiments [31]. Briefly, FITC dissolved in DMSO (10 mg/mL) was slowly added to a 10 mg/mL 
BSA solution in 0.1 M carbonate buffer (pH 9), under moderate and continuous agitation at 
room temperature. The mixture was allowed to react overnight at 4 oC in a light protected 
vessel. The labelled protein solution was then extensively dialysed (Dialysis tubing cellulose 
membrane, MWCO 12 kDa, Sigma-Aldrich, USA) against PBS buffer (0.01 M, pH 7.4) at 4 oC and 
stored as lyophilized powder in a light protected container for further use.  
The subsequent binding experiments were carried out following the procedure 
described above, but using the labeled FITC-BSA as protein. After elution of the physically 
adsorbed FITC-BSA, the labeled protein-microparticles complexes were washed with distilled 
water, mounted using “Vectashield” mounting medium (Vector Laboratories, USA) and 
visualized by CLSM. 
 
2.4 Physicochemical characterization of the developed microparticles.  
The characterization of the developed microparticles was divided into three major 
categories: morphological analysis, particle size and size distribution, and structural 
characterization. 
 
2.4.1 Morphological analysis 
Optical microscopy (OM/OLT). Examination of the shape and stability of the 
suspensions of the different particles produced was accomplished by mounting a sample 
suspension (5 mg of micro/nanoparticles per mL in distilled water) onto a glass slide. The 
samples were observed by an optical microscope with a polarized light source (Olympus BH2, 
Japan). The samples were photographed using a high-resolution Leica camera for image 
acquisition (Leica Microsystems GmbH, Germany). This observation was particularly relevant 
to assess the stability of the magnetite nanoparticles suspensions.  
Scanning electron microscopy (SEM). To analyze the obtained microparticles for their 
shape and surface morphology, together with their morphology after drug loading and in vitro 
release, all employed samples were analyzed by scanning electron microscopy (SEM). 
Additionally, this technique was applied to study changes in the morphology of the 
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microparticles after being subjected to in vitro enzymatic degradation (please see section 2.7). 
A portion of dried microparticles was mounted onto aluminium stubs with a carbon tape and 
gold sputter-coated (Fisons Instruments, Sputter Coater SC502, UK). All images were collected 
with a Leica Cambridge S-360 model (UK) scanning electron microscope.  
Micro-computed tomography (μ-CT). A representative sample of the porous SPCL 
microparticles was scanned by micro-computed tomography (μ-CT) using a μ-CT 20 equipment 
(SCANCO Medicals, Switzerland). The energy of the scanner used was 100 kV/ 98 μA intensity. 
A threshold range of values of 141-255 was used to estimate the porosity of the samples. 
Approximately 40 slices of the sample were obtained. Mimics (Materialise, Belgium), CT 
Analyser and CT Vol Realistic 3D Visualization (SkyScan, Belgium) software were used for image 
processing and to create and visualize the three-dimensional structure.  
 
2.4.2 Size distribution: Sieves meshes and dynamic light scattering (DLS) 
To determine the size distribution of the different microparticles obtained, the 
samples were separated through a series of standard sieves (20, 60, 100, 125, 150, 250, 450, 
500, 650, 900 and 1000 μm; Linker Industrie-Technik, Germany). The microparticle fraction 
that passed through a sieve and was retained on the sieve with a certain pore size was 
collected and weighed, and finally correlated with the total mass of the microparticles sample 
analyzed. These series of standard sieves were also used to separate the particles by size and 
to obtain microparticle samples with uniform size to be used in further experiments. 
In the case of the produced magnetite nanoparticles, the Nano ZS ZEN3600 equipment 
(dynamic light scattering) (Malvern Instruments, UK) was used to determine the particle size 
and size distribution. For sample preparation, 1 mg of dried magnetite nanoparticles was 
resuspended in a mixture of glycerol and ultrapure distilled water (1:1). 
 
2.4.3 Fourier transformed infrared spectroscopy (FTIR) 
The chemical structure of the microparticles was analyzed by fourier transformed 
infrared spectroscopy (FTIR) (IRPrestige-21 FRIT-8400S, Shimadzu, Japan) in transmission 
mode. Unloaded microparticles, after drug loading and release, and during in vitro degradation 
process were analyzed by FTIR. Weighed samples (1-mg) were mixed with spectroscopic KBr 
(40 mg) and then formed into a disc in a manual press (161-1100 hand press, PIKE 
Technologies, USA). Transmission spectra were recorded using at least 32 scans with 4 cm-1 
resolution, in the spectral range of 4000-500 cm-1. 
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2.4.4 Nuclear magnetic resonance spectroscopy (
1
H-NMR) 
In the particular case of CHT-ST microparticles, when FTIR spectroscopy could not be 
used, due to the similarity of the spectra of both polysaccharides, nuclear magnetic resonance 
spectroscopy (1H-NMR) was selected. 1H-NMR spectra were acquired on a Varian Unit Plus 300 
MHz spectrometer (USA). For all samples, the following experimental parameters were used: 
256 scans recorded, 5200 Hz filter width, 90o pulse corresponding to a pulse width of 11 μs, 4 s 
relaxation delay, and a temperature of 60 oC. For quantification purposes, the peak area 
method was used after the start and end points of the integration of each peak had been 
manually selected. For sample preparation, 10 mg of each sample were put into an NMR tube 
(φ=0.3 mm) and 1 mL of deuterated solvent was added. Chitosan is soluble in moderately acid 
conditions. Hence, chitosan and CHT-ST microparticles were dissolved in 0.98 mL of D2O and 
0.02 mL of DCL, waiting for complete dissolution. On the other hand, starch and GTM were 
dissolved in D2O. The samples were briefly sonicated at room temperature to ensure complete 
dissolution and homogenization of the sample. 
 
2.4.5 X-ray diffraction (XRD) 
In order to confirm the encapsulation into and the in vitro release of DEX from the 
SPCL microparticles, as well as to determine the physical state of the entrapped molecule, 
X-ray diffraction patterns of DEX loaded SPCL microparticles were obtained in a X-ray 
diffractometer (X’Pert MPD, Philips, The Netherlands). In addition, during the preparation of 
the magnetic PCL microparticles, the formation of magnetite (Fe3O4) and their presence into 
the m-PCL microparticles was similarly confirmed. The data collection was performed with a Cu 
anode and monochromator used at a voltage of 40 kV. The samples were analyzed over the 
angle range (2θ) of 2o-60o. 
 
2.4.6 Thermogravimetric analysis (TGA) 
For the magnetic particulated system, m-PCL, different magnetite contents were 
encapsulated within the polymeric shell by the use of different magnetite to polymer ratios. 
Hence, to determine the magnetite content entrapped inside the polymeric shell a 
thermogravimetric analyzer (Q500, TA Instruments, USA) was used. Dried samples were 
analyzed in closed alumina cups at a temperature range of 30-700 oC. The used heating rate 
was 10 oC/minute. All the experiments were carried out under nitrogen atmosphere. PCL 
microparticles without iron content were used as controls. 
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2.4.7 Vibrational magnetometry (VSM) 
Aiming to study the magnetic properties of both magnetite nanoparticles and m-PCL 
microparticles, a vibrating sample magnetometer (VSM, LakeShore, USA) was used. Two 
different temperatures were used for sample analysis (5 and 300 K). The applied magnetic field 
was varied from 60-000 to - 60 000 Oe. Values of saturation magnetization (Ms) and 
remanence magnetization (Mr) as well as coercive field (Hc) and saturation field (Hs) were 
determined. 
 
2.5 Surface characterization of the functionalized m-PCL microparticles 
To confirm and quantify the presence of both amino and epoxy groups on the surface 
of the m-PCL microparticles as a result of the functionalization treatments, two different 
analyses were performed.  
 
2.5.1 Amino groups: ninhydrin colorimetric assay 
2,2-Dihydroxyindane-1,3-dione, commonly known as ninhydrin, is a chemical used to 
detect ammonia or primary and secondary amines. The principle behind the use of ninhydrin 
as main component of a quantitative colorimetric assay relies in the formation of a deep blue 
or purple color product (Ruhemann's purple) when reacting with free amines. This colored 
product is characterized by a strong absorbance at a wavelength of 570 nm in the ultraviolet 
spectrum. Therefore, the ninhydrin reaction product can be by quantified by UV spectroscopy 
[32]. Among the several applications of this method, ninhydrin can also be used to monitor 
solid phase peptide synthesis and in amino acid analysis of proteins [32].  
In our study, in which amino groups are being introduced to functionalize a polymeric 
surface, this assay is particularly useful for their detection and quantification. Ninhydrin binds 
to amino groups present on the surface of the polymer producing a purple pigment that can be 
detected using a spectrophotometer (570 nm) [33-35]. Based on that principle, the -NH2 
surface functionalized microparticles (10 mg) were immersed in 1.0 M ninhydrin solution 
prepared in ethanol for at least 1 minute. The container vessel was then heated to 80 oC to 
accelerate the reaction of the ninhydrin with the amino groups present on the surface of the 
microparticles. After discarding the supernatant and allowing the complete evaporation of the 
ethanol, 5 mL of 1,4-dioxane was added to dissolve the ninhydrin-treated microparticles. After 
complete dissolution of the samples, 5 mL of isopropanol were added to stabilize the formed 
blue compound. The sample was filtered to remove any insoluble material, and the 
absorbance of the final solution was measured (570 nm). For quantification purposes, a 
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calibration curve was prepared using solutions of known concentration of 1,6-hexanediamine 
in a mixture of 1,4-dioxane/ isopropanol (1:1). 
The ninhydrin assay is sensitive to the presence of free amino groups from any source. 
Therefore, solvents or chemicals with amino groups should not be used in order to avoid the 
interferences.  
 
2.5.2 Epoxy groups: X-ray photoelectron spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) is a quantitative spectroscopic technique that 
measures the surface elemental composition. In this thesis, XPS was used to confirm the 
success of the surface functionalization after the different treatments.  
The analyses were performed (ESCALAB 250iXL” spectroscope, VG Scientific, UK) with 
PISCES software for data acquisition and analysis. XPS measurements were carried out using 
monochromatic Al (Kα) radiation (1486.92 eV). Photoelectrons were collected from a take-off 
angle of 90o relative to the sample surface. The measurement was performed in constant 
analyzer energy mode (CAE) with 100 eV for survey spectra and 20 eV for high-resolution 
spectra. Charge referencing was carried out by setting the lower binding energy C 1s 
photopeak at 285.0 eV. The identity of the chemical functional groups was determined from 
the high-resolution peak analysis of carbon-1s (C1s) and oxygen-1s (O1s). For sample 
preparation, a suspension of dried microparticles was prepared in ethanol and dripped onto a 
silicon wafer surface. After the complete ethanol evaporation, the sample was introduced in 
the XPS pre-chamber for the measurements. 
 
2.6 In vitro experiments to study the release of bioactive molecules 
Microparticles loaded with the different bioactive molecules selected in this thesis 
were employed to determine the percentages of drug loading and encapsulation efficiencies, 
together with the studies of the profiles of the in vitro release of the respective encapsulated 
molecules. As described before, the microparticles used for these studies are the following: 
DEX loaded SPCL, BMP-2 loaded SPCL and GTM loaded CHT-ST microparticles. 
For each of these systems, pre-weighed microparticles were suspended in phosphate 
buffered saline (PBS) solution (pH 7.4, 0.01 M) at a concentration of 2.5 mg/mL, except for the 
BMP-2 loaded SPCL microparticles that were used at 30 mg/mL in PBS. The microparticles were 
maintained at 37 oC under constant agitation (50 or 100 rpm) in a shaking water bath. The 
incubation time for DEX and GTM loaded microparticles was 30 days, whereas for BMP-2 
loaded microparticles was 10 days. At predetermined time points, 1 mL aliquots of the 
supernatants were collected and replaced with the same volume of fresh PBS solution. The 
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supernatants were then stored at -80 oC for drug quantification. All the release experiments 
were carried out in triplicate. Results are reported as average + standard deviation. 
 
2.6.1 Quantification of DEX by reverse-phase high-performance liquid chromatography (RP-
HPLC) 
The collected samples during the preparation of the DEX loaded particles (reaction 
medium) and from the in vitro release study were prepared for high-performance liquid 
chromatography (HPLC) quantification. Samples from the reaction medium were extracted 
three times with a 1:1 mixture of hexane and ethyl acetate solvents. The final extract was 
collected and the solvent mixture allowed evaporating under nitrogen flow. The dry extract 
was reconstituted in a mixture of acetonitrile/water in the same proportions (mobile phase) 
prior to the analysis. On the other hand, the aliquots from the release medium (PBS solution 
containing released DEX) were directly analyzed. 
DEX was quantified by reverse-phase (RP) HPLC. HPLC was performed on a Jasco PU-
2080 Plus system using a RP-18 column (LiChrospher, 5 μm, Merck, Germany) with 
acetonitrile/water (50:50 v/v) as mobile phase at a flow rate of 0.5 mL/min. Absorbance was 
monitored at 254 nm (UV detector Jasco 870-UV). The column was eluted under isocratic 
conditions during 20 min. Data acquisition and peak areas were determined with Shimadzu C-
R6A Chromatopac software (Figure 2.1). The concentration of DEX was calculated by using a 
calibration curve (y = 8697.18 + (1.65 X 107)x, R2= 0.9995). Triamcinolone was used as an 
internal standard (Figure 2.1). 
 
2.6.2 Quantification of BMP-2 by an enzyme-linked immunosorbent assay (ELISA) 
BMP-2 present in the reaction medium in which the BMP-2 loaded microparticles were 
obtained and in the aliquots from the in vitro release study were quantified using an enzyme-
linked immunosorbent assay (ELISA) (Human BMP-2 Quantikine® ELISA Kit, R&D Systems, USA) 
according to the manufacturer’s instructions. The samples stored at -80 oC were thawed at 
room temperature without any further heating before analysis. Several samples were included 
as controls, including plain PBS, unloaded SPCL microparticles and BSA loaded SPCL 
microparticles. BMP-2 was quantified using a calibration curve of recombinant BMP-2 from 
human origin included in the original kit. 
All the quantification analyses were performed in duplicate assays by the use of 
triplicate samples. 
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Figure 2.1 Illustrative chromatogram and calibration curve obtained as a result of the quantitative 
analysis of the aliquots from the in vitro release study of DEX from SPCL microparticles in PBS medium 
 
2.6.3 Quantification of GTM by indirect spectrophotometric methodology 
A wide variety of methods can be used to quantify aminoglycoside antibiotics (e.g. 
gentamicin), namely fluorescence polarization immunoassay, enzyme-linked immunosorbent 
assay (ELISA), microbiologic assay, chromatographic and spectrophotometric methods [36]. 
Among all of them, spectrophotometric methods are preferable. They are usually rapid, very 
sensitive and relatively cheap when compared with the ones mentioned above. The main 
requirement for this method is the absorbance of light in the UV-visible spectrum region by 
the analyzed compounds. Since GTM does not absorb ultraviolet nor visible light, an indirect 
method is required for its spectrophotometric assay. Similarly to already mentioned ninhydrin 
(please see section 2.5.1) several derivatizing agents are reported to react with primary and 
secondary amines present in the GTM molecule to yield chromophoric products [36]. In this 
previously reported study, where a comparative quantitative analysis was performed, the best 
results were obtained when o-phtaldialdehyde was used [36].  
Therefore, in this thesis an indirect spectrophotometric method was used for the 
quantification of GTM, using o-phtaldialdehyde as derivatizing agent. Briefly, the 
o-phtaldialdehyde reagent was formulated by dissolving 0.25 g of o-phtaldialdehyde in a 
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mixture of methanol (6.25 mL) and 2-mercaptoethanol (0.3 mL). Subsequently this solution 
was added to 56 mL of sodium borate (0.04 M, pH 8) buffer solution to formulate derivatizing 
reagent. The reagent was maintained in a brown bottle protected from the light for at least 
24-h before use. For the colorimetric measurement, GTM solution, o-phtaldialdehyde reagent 
and isopropanol were mixed in an equal volume ratio, and incubated for 30 minutes at room 
temperature. The absorbance was subsequently measured at 332 nm. The concentration of 
GTM was calculated using a calibration curve (y = 0.02 + 9.55 x, R2= 0.9996) (Figure 2.2). 
 
300 400 500 600 700
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Gentamicin sulfate: UV Spetrum
3 2
1
λ
2
=296.00 nm, A=0.2035
λ
3
=283.00 nm, A=0.2083
λ
1
=332.50 nm, A=0.7313
A
bs
o
rb
an
ce
Wavelength (nm)
0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
A
bs
o
rb
an
ce
Concentration (mg/mL)
(a) (b)
 
Figure 2.2 Absorption spectra of gentamicin sulphate sample (a). Calibration curve for absorbance 
versus concentration obtained by the use of a gentamicin solution of known concentration (b) 
 
2.6.4 Drug loading and Encapsulation efficiency percentages 
The drug loading and encapsulation efficiency are two important parameters to be 
determined during the encapsulation of bioactive molecules. Usually those two parameters 
are used indistinctly, and several research studies tend to confuse their meaning. The drug 
loading is the relation between the weight of the drug partition loaded into the microparticles 
and the total weight of the loaded microparticles. The encapsulation efficiency is defined as 
the relation between the difference of the total weight of the drug to be loaded or added and 
the remaining drug partition in the reaction medium after encapsulation process; and the total 
weight of the drug to be loaded or added. In order to clarify, both parameters establish a 
relation of the weight of the drug partition loaded into the microparticles and: i) drug loading 
with the total weight of the microparticles and ii) encapsulation efficiency with the total 
weight to be loaded or initially added.  
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In all experiments, knowing the initial concentration of drugs added (DEX, BMP-2 and 
GTM), and the concentration of unloaded drug (remaining in the reaction medium where 
loaded microparticles were produced) quantified by the different techniques described above, 
it was possible to determine both parameters according to known equations [37]. 
 
[ ] 100/% 21 ×= WWDL        (2.1) 
 
( )[ ] 100/% 343 ×−= WWWEE       (2.2) 
 
Where DL = drug loaded, EE = encapsulation efficiency, W1 is the weight of drug in the 
microparticles, W2 is the total weight of microparticles, W3 is the total weight of drug added, 
and W4 is the weight of drug that remained in the reaction medium after encapsulation. 
 
2.7 In vitro enzymatic degradation studies 
Two of the developed systems in this thesis aimed to be used as carriers of important 
bioactive molecules as part of drug delivery systems: SPCL microparticles for DEX and BMP-2 
and CHT-ST microparticles for GTM. One important and desired property is biodegradation 
when designing drug delivery systems. Biodegradable polymers are able to release the 
entrapped drug as their degradation take places. Thus, by controlling the degradation rate of 
polymeric materials the drug release can be identically monitored. 
The enzymatic degradation of the developed carrier systems was investigated by 
incubating the microparticles in PBS (0.01 M, pH 7.4) and PBS containing selected enzymes. In 
the case that SPCL microparticles, α-amylase (150.5 U/L), lipase (102 U/L) and their mixture 
were used to mimicking an enzymatic environment. For CHT-ST microparticles, only α-amylase 
(150.5 U/L) was used. The microparticles were incubated in a ratio of 1:10 with the selected 
degradation solution at 37 oC under constant shaking (50-60-rpm). The incubation period 
amounts up to 8 weeks for the CHT-ST microparticles and up to 12 weeks for the SPCL 
microparticles. The PBS solutions containing the enzymes were changed weekly to maintain 
the desired level of enzyme activity throughout the experiment. Meanwhile, sodium azide 
(0.02%) was added to the degradation solution to avoid possible microbial growth. At the end 
of the pre-selected degradation times, the supernatants were removed and stored at -80 oC 
until further analysis. The microparticles were then thoroughly washed with distilled water. 
The excess of solution was carefully removed with filter paper and the samples were carefully 
weighed for the determination of water uptake [38]. Subsequently, the samples were allowed 
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to dry at room temperature until constant weight. The final weight of the samples was used 
for the calculation of the weight loss [38]. The supernatant solutions were used to determine 
the concentration of released DEX or GTM (when loaded microparticles were used) as well as 
the concentration of reducing sugars released into the solution as a result of starch 
degradation. The amount of reducing sugars was estimated by the dinitrosalicylic acid (DNS) 
method [39].  
Experiments were performed in triplicate for all the conditions: triplicates were 
performed for each sample at each time period and the results are shown as mean ± standard 
deviation. 
The weight loss and water uptake were calculated by the use of the equations 2.3 and 
2.4. 
 
( )[ ] 100/% ×−= iif WWWlossWeight       (2.3) 
 
( )[ ] 100/% ×−= iiw WWWuptakeWater      (2.4) 
 
Where Wi is the initial weight of the sample, Ww is the wet weight of the sample 
(water uptake) and Wf is the final weight of the dry sample (weight loss). 
Samples were analyzed for their morphology changes and eventual modifications in 
the chemical composition at each time point of analysis (by SEM, FTIR and 1H-NMR as 
described in section 2.4.1, 2.4.3 and 2.4.4 respectively). 
 
2.8 Biological evaluation of the obtained microparticles 
In order to evaluate the effect of the produced microparticles (SPCL, CHT-ST and 
m-PCL) on cells, three different types of cells where used: human osteoblast-like cell line 
(SaOs-2) (ECACC, UK), mouse skeletal myoblast cell line (C2C12) obtained from the German 
Collection of Microorganisms and Cell Cultures DSMZ-ACC565 (Germany) and human adipose-
derived stem cells (ASC) from the Blood Bank of the upper Austrian Red Cross (Austria).  
The microparticles used for the studies in contact with the cells were sterilized by 
ethylene oxide (EtO) using pre-optimized conditions [40]. For that purpose, pre-weighed 
microparticles were put into 1 mL vials with pierced caps allowing the gas to enter into the 
closed container. Subsequently, the in vitro experiments were performed to investigate the 
effects on cell viability, proliferation and morphology. 
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2.8.1 Cytotoxicity 
Polymeric materials to be used in medical applications should be characterized by two 
relevant features: biofunctionality and biocompatibility. Cytotoxicity, as initial phase in testing 
biocompatibility, detects cell death or other negative effect of materials on cellular functions. 
Several methodologies for cytotoxicity assay are described nowadays as standardized 
procedures. Assessing cell membrane integrity is one of the most common procedure to 
measure cell viability and cytotoxic effects and can be performed by the use of vital dyes, such 
as trypan blue or propidium iodide. Alternatively, the passage of substances (e.g. lactate 
dehydrogenase (LDH)) that are normally inside cells to the outside can be monitored. 
Cytotoxicity can also be monitored using the MTT or MTS assay. This assay measures the 
reducing potential of the cell using a colorimetric reaction. Viable cells will reduce both, MTT 
and MTS reagent to a colored formazan product that can be quantified spectrophotometrically 
at 490 nm [41]. 
In order to test the possible cytotoxicity of the developed microparticles, the effect of: 
i) the different processing conditions employed to produce the samples, ii) the earlier 
degradation of the samples with subsequent release of degradation products and iii) direct 
contact over the cells, was evaluated by performing a standard MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay [42, 43]. 
Different experiments, based on the use of different samples, were performed to 
assess the cell viability by using SaOs-2 and C2C12 cells. Initially, the microparticles were 
incubated in Dulbecco’s Modified Eagle’s Medium without phenol red (DMEM, Sigma-Aldrich, 
USA) (0.5 mg/mL) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Biochrom 
AG, Germany) and 1% of antibiotic/antimycotic (Gibco, USA), for 24, 48, and 72 hours at 37 oC 
and 60 rpm. The microparticles may release potential toxic leachables (from the microparticles 
processing) and early degradation products to the medium. In another experiment, the 
microparticles from the different production conditions were incubated in direct contact with 
the cells or indirectly placed in transwell inserts (12 mm, 0.4 µm pore size). This allowed us to 
evaluate any differences on cell behavior as a result of direct or indirect contact of the samples 
to the cells. 
To perform the MTS assay, SaOs-2 and C2C12 cells in DMEM medium without phenol 
red (supplemented as described above) were plated at appropriated cell number depending 
on the type of sample used. The plates were then incubated at 37 oC in a humidified 
atmosphere containing 5% CO2 for 24 hours to achieve approximately 80% confluence. After 
this seeding period, the culture medium was replaced by DMEM supplemented with the 
different samples (filtered material extracts (0.45 µm pore size), microparticles (1 mg/mL) and 
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transwells containing 1 mg microparticles). The plates were incubated for 24 hours in the case 
of the extract samples and from 1 to 7 days in the case of the particular samples (transwells or 
directly added). The MTS test was performed according to the CellTiter 96 One Solution 
Proliferation Assay Kit (Pormega, USA) manufacturer’s instructions and as described previously 
[43, 44]. The absorbance was determined in a microplate reader (EL 312e Biokinetics reader, 
Biotek Instruments, USA) at 490 nm. The results are expressed as the percentage (%) of cell 
viability in comparison with the 100% proliferation attributed to the positive control (fresh 
complete culture medium). Latex rubber extracts, produced by identical methodology as for 
the sample extracts, was used as negative control for the experiments where the extracts of 
the particles were analyzed. The samples were tested at least in triplicates per three 
independent experiments. 
 
2.8.2 Cell proliferation 
Cell morphology and proliferation changes as a result of the contact of the 
microparticles with the cells, were used to evaluate the biocompatibility and feasibility of the 
m-PCL microparticles. Two cell types were used in contact with the m-PCL particles, SaOs-2 
and ASC. ASC are used because of the potential impact of isolating this cell type by this method 
as it is frequently used in regenerative medicine applications. Hence, the evaluation of the 
ASCs response to the m-PCL microparticles was of importance for their future application. 
Cell proliferation is the measurement of the number of cells that are dividing in a 
culture over time. One way of measuring this parameter is by performing clonogenic assays, in 
which a defined number of cells are plated onto the appropriate matrix and the number of 
colonies that are formed after a period of growth are enumerated. In addition, some 
techniques also evaluating cell proliferation are based in the use of more indirect parameters, 
in which molecules that regulate the cell cycle are measured (e.g. CDK kinase assays). 
However, the measurement of DNA synthesis as a marker for proliferation is the most 
common used methodology. In this assay, labeled DNA precursors (e.g. 3H-thymidine or 
bromodeoxyuridine) are added to cells and their incorporation into DNA is quantified after 
incubation. The amount of labeled precursor incorporated into DNA is quantified either by 
measuring the total amount of labeled DNA in a population, or by detecting the labeled nuclei 
microscopically. Incorporation of the labeled precursor into DNA is directly proportional to the 
amount of cell division occurring in the culture [45]. During the course of this thesis, DNA 
based assay was selected to be use for cell proliferation studies.  
Following the culture conditions already described for cell viability, a SaOs-2 and ASC 
cells suspensions were plated in 12-well plates (1 X 105 cells/mL, 1.5 mL per well). Twenty-four 
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hours after cell seeding, the culture medium was replaced by a 1 mg/mL suspension of the 
m-PCL microparticles. After different incubation time (1, 3 and 7 days), supernatants were 
removed and further analyses performed. 
Cell proliferation was evaluated by quantifying the DNA content using PicoGreen 
(“dsDNA” quantification kit, Molecular Probes, USA) according to the manufacturer’s 
instructions. This assay is based in the use of a fluorescent dye, PicoGreen, sensitive and 
specific for double-stranded DNA (dsDNA). Briefly, the cell monolayer was carefully washed 
with PBS buffer (0.01M, pH 7.4). The cells were then lysed by osmotic and thermal shock. The 
obtained supernatant was subjected to the DNA analysis. Fluorescence was measured (485 nm 
excitation and 528 nm emission) in a microplate reader and the DNA amounts calculated 
according to a standard curve. The samples were tested in triplicate in three independent 
assays. 
 
2.8.3 Cell morphology 
Changes in cell morphology constitute a strong indication of the cell responses to, 
either the contact with biomaterials or the stimulus by bioactive molecules. During the course 
of a cell culture experiments, the cell morphology is being constantly evaluated by visual 
observation indicating the status of the cells. A variety of dyes like methylene blue, trypan blue 
and neutral red are frequently used to visualize specific cellular components.  
In this thesis, the morphology of ASCs was analyzed by microscopic observation after 
incubation with the m-PCL microparticles for 3 and 7 days. Prior observation, each well was 
washed with 0.1 M PBS and fixed with 2.5% glutaraldehyde solution in PBS (careful was taken 
to avoid the aspiration of the particles from the well). The cells were stained with 0.4% 
methylene blue and examined by light-microscopy (Axioplan imager Z1, Carl Zeiss, Germany). 
Methylene blue staining was used to better visualize the cells and to make the nuclei more 
visible. The analyzed samples were photographed using a high-resolution camera for image 
acquisition (Leica Microsystems GmbH, Germany). 
 
2.9 Determination of the bioactivity of the encapsulated and released bioactive molecules 
To evaluate the capability of developed carriers for the controlled release of 
biologically active agents, three different molecules were incorporated into microparticles: 
DEX and BMP-2 as osteogenic agents into SPCL microparticles; and GTM as an antibiotic into 
CHT-ST microparticles. Several parameters were evaluated to prove their feasibility as drug 
delivery systems as described earlier in this chapter (e.g. drug loading and encapsulation 
efficiency, release profile in different environment). Maintaining the activity of the bioactive 
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molecules upon the encapsulation process, during storage time, and during the in vitro release 
period is important. 
 
2.9.1 DEX and BMP-2 release from SPCL microparticles: in vitro evaluation of their biological 
activity towards osteogenesis 
Osteocalcin promotor activation assay. This experiment was performed to indirectly 
assess osteogenic differentiation. Cells were transfected using a vector expressing the 
osteocalcin (OCN) promoter coupled to a secretable metridia-luciferase. Activation of the OCN-
promotor as a result of the release of DEX or BMP-2 results in luminescence that is indicative 
for osteogenesis. 
In detail, 0.5 X 105 C2C12 cells/mL were plated in 24-well plates and incubated at 37 oC 
in a humidified environment containing 5% CO2 for 24 hours. Subsequently, cells were 
transfected by standard lipofectamine transient transfection, using a vector expressing the 
osteocalcin (OCN) promotor driving the luciferase reportergene. Briefly, 1 µg of reporter vector 
DNA was used together with 2 µg of lipofectamine (Invitrogen, Germany) per well. The DNA 
was mixed with the lipofectamine transfection agent under serum free conditions following 
the manufacturer´s instructions. The cells were incubated with the transfection solution (37 oC, 
5% of CO2 humidified atmosphere) by using DMEM containing 5% FCS for 4 hours. Following 
transfection, the culture medium was replaced with DMEM supplemented with 1% FCS, 50 µM 
ascorbic acid and 10 mM β-glycerophosphate (osteogenic differentiation medium=OM). The 
cells were cultivated for another 24 hours. Finally, the culture medium was exchanged with 
different samples for bioactivity testing: i) collected supernatants from BMP-2 and DEX in vitro 
release, ii) a suspension of BMP-2 and DEX loaded microparticles in DMEM (1% FCS, OM) and 
iii) transwell inserts containing BMP-2 and DEX loaded microparticles. The amounts of 
microparticles used vary in the range of 1-10 mg/mL culture medium. During the following five 
days’ observation period, the medium was not refreshed. At the end, both supernatants and 
cells were individually collected and stored at -80 oC for further analysis. The activation of the 
OCN-promotor was measured in the collected supernatants using luminescence imaging 
(Xenogen, USA) upon administration of luciferin (Figure 2.3). The amount of photons was 
measured and established a relative measure of OCN-promotor activity.  
Alkaline phosphatase assay (ALP). Alkaline phosphatase is an enzyme involved in the 
initial process of bone extracellular matrix mineralization. Thus, during the occurrence of 
osteogenesis, ALP is expressed by cells which are in a more osteoblast differentiated stage. 
Consequently, it is regarded as an indicator of an osteoblastic phenotype. In our studies, the 
effect of the released DEX and BMP-2 on ALP activity was evaluated in C2C12 cells after five 
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days of incubation by the use of a p-nitrophenol (pNP) assay [46, 47]. This assay is based on 
the occurrence of hydrolysis of p-nitrophenyl phosphate (colorless compound) in the presence 
of alkaline phosphatase enzymes to yield free p-nitrophenol product (yellow). This product can 
be spectrophotometrically measured at 405 nm [47]. Briefly, cells were lysed by osmotic 
(0.25% Triton-X-100 in PBS) and heat shock. Subsequently, 50 µL substrate solution was added 
per well (containing p-nitrophenyl phosphate disodium salt) for 30 minutes at room 
temperature. The optical density was determined at 405 nm in a microplate reader and the 
activity of ALP calculated according to a standard curve. The standard curve was constructed 
by the use of pNP solutions of known concentrations. 
In addition, the collected supernatants from the DEX release, as well as DEX loaded 
microparticles were tested in human ASCs for ALP activity to determine DEX bioactivity in 
primary stem cells. 
 
 
Figure 2.3 Representative luminescence image of analyzed samples 
 
Mineralization assay. Mineralized matrix and calcium deposits were simultaneously 
evaluated by the use of von Kossa and Alizarin red staining as an indication of late osteogenic 
differentiation. Staining with the von Kossa method is a qualitative assay for mineralization. A 
positive reaction is manifested by brown or black staining, which in general can be identified 
together with the presence of bone nodules formation [47]. On the other hand, Alizarin red is 
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used to determine qualitatively and quantitatively, the presence of calcific deposition by cells 
of an osteogenic lineage.  
C2C12 cells were seeded at a density of 0.5 X 104 cell/mL using OM supplemented with 
the DEX and BMP-2 loaded microparticles (1 mg/mL) up to 14 days. After 3, 7, 14 days of 
incubation, the cells were washed twice with PBS solution (without calcium and magnesium) 
and fixed with 4% formaldehyde solution in PBS. Von Kossa staining was performed to visualize 
the presence of mineralized deposits. The fixed cells were consecutively incubated with 5% 
silver nitrate solution in distilled water, 5% sodium carbonate solution in 25% formaldehyde 
and 5% sodium thiosulphate solution in distilled water. After washing the cells with distilled 
water, the staining was observed by phase contrast microscopy (Zeiss, Germany). 
Alizarin red staining for detection of calcium deposits was performed by incubating 
fixed cells for 5 minutes in a 0.05% Alizarin red solution in PBS at room temperature. The 
stained cells were washed with distilled water prior microscopic observation. 
 
2.9.2 GTM released from CHT-ST microparticles: in vitro evaluation of bioactivity 
Aminoglycosidic antibiotics (e.g. gentamicin) are often administered clinically, alone or 
combined with other antimicrobial agents, for the treatment of severe bacterial infections. 
Therefore, in our study, we selected Staphylococcus aureus, a gram-positive bacterium, to test 
the bactericidal activity of released GTM. The standard antibiotic disc diffusion method [48] in 
LB-Agar was employed. Following this method, it is possible to determine the inhibition zones 
of the bacteria as a result of the released GTM from impregnated paper discs placed in the 
growth plates. 
The strain used, S. aureus ATCC 25923, was obtained from the Biology Department, 
University of Minho, Braga, Portugal. Fresh isolates were cultured by plating a bacterial 
suspension (1.5 X 108 CFU/mL) on LB Agar in sterile Petri dishes for 24 hours at 37 oC 
(Luria-Bertani Agar, Lennox, Difco Laboratories, USA), immediately before each experiment. All 
collected samples from the GTM in vitro release experiments up to 30 days were diluted to 
0.25 mg/mL with sterile PBS buffer. Subsequently, 13 mm sterile absorption discs (BBLTM 
TaxoTM PM Discs, BD Co., USA) were placed on the agar plates and 20 μL of each sample was 
directly pipetted onto each disc. A PBS impregnated disc was used as a negative control 
sample. A standard solution of gentamicin sulphate 0.25 mg/mL was applied as positive 
control. All agar plates were incubated at 37 oC for 16-18 h. Each sample was tested in 
triplicate, using different plates. After incubation, the diameters of the inhibition zone were 
measured using a micrometer. 
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From the relation between the diameter of inhibition zones of the samples (released 
GTM) and a standard GTM solution (considered standard for the maximum inhibition zone), 
the relative activity (%) can be determined [49]. 
 
[ ] 100/IZ% s ×= mIZActivityelativeR      (2.5) 
 
Where IZs is the diameter of sample inhibition zone and IZm is the diameter of 
maximum inhibition correspondent to the standard GTM solution (0.25 mg/mL). 
The stability of the GTM loaded CHT-ST microparticles upon storage was tested in well 
closed containers at 4 oC and 25 oC for different periods of time (2-12 weeks). Subsequently, 
samples were resuspended in sterile PBS and the in vitro release of GTM was analyzed, as well 
as the antibacterial activity of the released antibiotic. 
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Chapter 3 
Highly biodegradable starch-conjugated chitosan microparticles as carrier for the 
controlled release of antibiotic drugs: Preparation, characterization and in vitro 
release study 
 
3.1 ABSTRACT 
Starch-conjugated chitosan microparticles (CHT-ST) were produced aimed to be used as a 
carrier for the long term sustained/controlled release of antibiotic drugs. The microparticles 
were prepared by a reductive alkylation crosslinking method, starting with the oxidation of 
soluble starch to produce the polyaldehyde, followed by a water-in-oil (w/o) emulsion 
crosslinking technique. The morphology of the microparticles was examined by light 
transmission microscopy (LM) and scanning electron microscopy (SEM). The obtained 
microparticles showed a spherical shape, with a slightly rough and porous surface, and a size 
range of 80-150 μm. Gentamicin (GTM), an aminoglycosidic antibiotic with a broad spectrum, 
was entrapped into the CHT-ST microparticles and its release profile was studied in vitro. 
1
H-NMR spectroscopic technique was performed to characterize the system and the possible 
changes in the microparticles chemical structure upon GTM encapsulation. Increasing 
concentrations of GTM (from 50 to 150 mg/mL), led to a decrease in the encapsulation 
efficiency (from 67 to 55%), while drug loading increased from 4 to 27%. A sustained release of 
GTM was observed over a period of 30 days. The release kinetics could be controlled using an 
ionic crosslinker agent. For instance, the drug release can be prolonged by increasing the ionic 
crosslinking density. In addition, a bacterial inhibition test on Staphylococcus aureus was 
conducted to determine the relative bactericidal activity of the released GTM. The diameter of 
the sample inhibition zone ranged from 12 to 17 mm, which is corresponding with 70 to 100% 
of relative activity. The released concentration of GTM was found to be well above the 
literature reported minimal inhibition concentration (MIC).  
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*This chapter is based on the following publication: 
Balmayor, E. R.; Baran, E. T.; Azevedo, H. S.; Reis, R. L. Highly biodegradable starch-conjugated 
chitosan microparticles as carrier for the controlled release of antibiotic drugs: Preparation, 
characterization and in vitro release study. 2009. Submitted. 
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3.2 INTRODUCTION 
Polysaccharides are very attractive materials for biomedical applications due to their 
unique properties. They are usually abundant in nature, being obtained from renewable 
sources, and have been shown to be non toxic and biocompatible [1, 2].  
Chitin and starch are among the most widespread polysaccharides in nature [3]. Chitin 
(poly β-(1-4) N-acetyl-D-glucosamine), is synthesized by a diverse number of living organisms 
from arthropods, crustaceans (crab and shrimp shells), to cell walls of fungi [4]. Chitosan is a 
product of partial chitin deacetylation and can be defined as a copolymer of D-glucosamine 
and N-Acetyl-D-glucosamine [5, 6]. It is one of the biomaterials most studied and proposed to 
be used in a broad range of biomedical applications [7, 8] because of its biocompatible, 
biodegradable and non toxic well demonstrated properties [8, 9]. Starch is cheap, abundant 
and edible polysaccharide, with interesting biodegradable properties [10-12]. It contains a 
mixture of two molecules: amylose and amylopectin. Depending on the starch source, the 
relative weight percentages of those molecules varies between 72-82% amylopectin, and 
18-33% amylose [13, 14]. Amylose is responsible for the film forming capability of starches 
[15]. The use of those natural macromolecules has been proposed for microencapsulation of 
bioactive materials [16] and as a carrier in drug delivery systems [17-19]. 
Blends of natural polysaccharides are promising systems for the production of films, 
sponges, hydrogels, micro- and nanoparticles for the encapsulation of drugs, enzymes or cells 
[20]. Furthermore, in most cases the presence of natural polysaccharides in blend 
compositions enhances biocompatibility and biodegradability, and confers hydrophilicity to the 
resulting systems. A highly desired property for a biomaterial proposed for biomedical and a 
drug delivery application is biodegradability within body fluids [21].  
The use of medical drugs in a safe manner for treating diseased parts of the human 
body requires the development of new carrier systems capable of improving their release 
profile, while maximizing its therapeutic effect. Aminoglycoside antibiotic drugs have shown 
low effectiveness when administered orally [22]. Typically the human body deals reasonably 
well with this type of drugs, allowing their rapid clearance from the body. They are absorbed 
from the small intestine and inactivated very fast in the liver [23]. Therefore, the route of their 
administration can only be done intravenously, intramuscularly or topically [22], with the 
inconvenience of fast elimination and the need for repetitive dosages. Consequently, the 
development of novel drug compositions for the sustained release of this type of drugs is thus 
of great interest.  
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One member of the group of aminoglycoside antibiotics is Gentamicin (GTM). Besides 
its wide antibacterial spectrum, GTM is one of the few heat stable antibiotics that remains 
active even after heating [24]. This fact makes GTM a very useful antibiotic for drug 
formulations that requires the use of high temperatures during the manufacturing/ 
encapsulation process. 
In the present study, a novel injectable long term drug delivery system with increased 
biodegradation has been developed based on the conjugation of starch with chitosan. In 
addition, the developed system was shown to be capable of releasing initially a large dose of 
antibiotic and then sustain its release, therefore providing an effective method to treat locally 
bacterial infections. 
 
3.3 EXPERIMENTAL 
3.3.1 Materials 
Chitosan (medium molecular weight), sodium tripolyphosphate (TPP) (technical grade, 
85%), mineral oil (puriss. p.a.), sodium periodate (ACS reagent, > 99.8%), deuterium oxide 
(D2O) (99.9% D) and deuterium chloride (DCL) (35 wt %, 99% D) were obtained from 
Sigma-Aldrich (USA). Soluble potato starch was supplied by ATO (The Netherlands). Gentamicin 
sulfate from Micromonospora purpurea (GTM, puriss. p.a.) was purchased from Fluka-Bio 
Chem. (Switzerland). All other chemicals were of analytical grade and used as received. 
The determination of chitosan molecular weight (MW) was conducted by viscosimetric 
method [15], using 0.3 M acetic acid/ 0.2 M sodium acetate as a solvent mixture. The viscosity 
average molecular weight (MW) was calculated based on the Mark-Houwink equation [25, 26]. 
The MW of the chitosan was found to be 385 kDa. The degree of N-deacetylation of the 
chitosan was determined by 
1
H-NMR sprectroscopy method [27], and was found to be 81.25%. 
 
3.3.2 Preparation of CHT-ST microparticles 
3.3.2.1 Sodium periodate oxidation of soluble starch 
The oxidation reaction of soluble starch was performed according to a procedure 
previously described [28]. Briefly, soluble starch was dissolved in distilled water (0.02 g/mL) in 
a light protected glass vessel. 0.125 mL of sodium iodate (10 mg/mL) was added per mL of 
starch solution, allowing the reaction to proceed for 30 minutes at room temperature under 
slow magnetic stirring. Finally, glycerin (0.1 mL/mL solution) was added and stirred for 
additional 10 minutes. The solution was transferred into a dialysis tube (Dialysis tubing 
cellulose membrane, MWCO 12 kDa, Sigma-Aldrich, USA) and dialyzed against distilled water 
for two days with several daily changes. The oxidized starch solution was concentrated by 
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Chitosan, 1.5% (w/v) Oxidized Starch, 2% (w/v) 
 
Magnetic stirring (300 rpm, 10 minutes) 
Adjust pH to 5.5 (NaOH 0.5M) 
CHT + ST weight ratio 1.5:2 (w/w) 
Gentamicin sulfate 
CHT-ST-GTM mixture 
Magnetic stirring (300 rpm, 30 minutes) 
Mineral Oil 
TWEEN 80 Top stirring 
(600 rpm, 10 minutes) 
dropwise Top stirring 
(600 rpm, 30 minutes) 
Acetone (4oC) 
Top stirring 
(600 rpm, 120 minutes) 
CHT-ST GTM loaded microspheres 
Washing with Acetone-Water 1:1 (v/v) 
Room temperature drying 
Alkaline treatment (pH 8.5) 
Reduction treatment (NaBH4) 
TPP crosslinking treatment (Optional) 
Washing with Water 
Room temperature drying 
using an ultra-concentrator Amicon® stirred cell 8010 (Millipore, USA) and stored at 4 
o
C in a 
light protected glass vessel until further use.  
 
3.3.2.2 CHT-ST microparticles preparation 
CHT-ST microparticles were prepared by water-in-oil emulsification methods, using 
reductive alkylation crosslinking procedure [29]. The preparation procedure is illustrated in 
Figure 3.1. Chitosan solution 1.5% (w/v) was prepared by dissolving the polymer in aqueous 
acetic acid solution (1%). Chitosan (1.5%, 10 mL) and oxidized starch (2% (w/v), 10 mL) 
solutions were mixed throughly using magnetic stirring, and the pH adjusted to 5.5 by using 
0.5-M NaOH. The polymer solution was put dropwise into a glass reactor containing mineral oil 
with 1% of Tween 80 and emulsified with a top stirrer at 600 rpm for 30 minutes. After 
emulsion formation, 30 mL of cold acetone was added slowly and allowed to proceed for two 
hours. The microparticles were removed from the reaction medium by filtration and washed 
with distilled water/acetone mixture (1:1 v/v). After drying at room temperature, the 
microparticles were transfered to a 0.5 M sodium carbonate buffer solution (pH 8.5) and 
incubated for three hours to allow the conjugation between reactive aldehyde groups (Starch) 
and primary amino groups (Chitosan). After repeatedly washing with distilled water, the 
microparticles were incubated in sodium borohydride solution (0.05% w/v) for one hour to 
reduce excess of reactive aldehyde groups, and to confer stabilization to the imine conjugation 
(ST-CHT) into covalent bonds.  
 
 
Figure 3.1 Schematic diagram showing the developed preparation procedure of chitosan-starch 
microparticles 
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3.3.3 Physicochemical characterization 
3.3.3.1 Light transmission (LM) and scanning electron microscopy (SEM) 
The morphology and size of the dried microparticles were analyzed by light 
transmission microscopy (LM) and scanning electron microscopy (SEM). A microparticles 
suspension (5 mg/mL) was photographed using an optical microscopy Olympus BH2 with 
polarized light source (Olympus, Japan), using a high-resolution Leica camera for image 
acquisition (Leica Microsystems GmbH, Germany). For SEM observation, the microparticles 
were mounted onto metal stubs with a carbon tape and gold sputter-coated (Sputter Coater 
SC502, Fisons Instruments, UK). The size, shape and surface morphology of the microparticles 
were analysed with SEM (Leica Cambridge S-360, UK). 
 
3.3.3.2 Size distribution 
In order to determine the size distribution of the microparticles obtained under the 
different experimental conditions, a dry sample was weighed and then separated through a 
series of standard sieves (20, 60, 100, 125, 150, 250, 450, 500, 650, 900 and 1000 μm, Linker 
Industrie-Technik, Germany). The microparticle fraction that has been retained on sieve with 
certain porous size was collected and weighed, and finally correlated with the total mass of the 
microparticles.  
 
3.3.3.3 Nuclear magnetic resonance spectroscopy (
1
H-NMR) 
1
H-NMR spectra were acquired on a Varian Unit Plus 300 MHz spectrometer (USA). For 
all the samples the following experimental parameters were used: 256 scans were recorded, 
5200 Hz filter width, 90
o
 pulse corresponding to a pulse width of 11 μs, 4 s relaxation delay. 
The experiments were run at 60 
o
C. For quantitative analysis, the peak area method was used 
and the start and end points of the integration of each peak were selected manually. For the 
sample preparation, 10 mg of each sample were exactly weighed into a NMR tube (φ=0.3 mm) 
and 1 mL of deuterated solvent was added. Chitosan and CHT-ST microparticles were dissolved 
in 0.98 mL of D2O and 0.02 mL of DCL, waiting for complete dissolution, and starch and GTM 
were dissolved in D2O. The sample was sonicated at room temperature for 30 min and used for 
1
H-NMR measurement. 
 
3.3.4 Gentamicin loading 
For drug encapsulation, GTM was directly added to the polymer solution using various 
initial concentrations of GTM (5, 10 and 15 mg/mL of polymer solution) to determine the 
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influence of drug concentration in the encapsulation efficiency (EE). The preparation of the 
GTM loaded microparticles was performed as described in section 3.3.2.2 (Figure 3.1). 
Furthermore, the effect of ionic crosslinking on the drug loading/release was investigated. In 
order to allow microparticles to be further ionic crosslinked, the GTM loaded microparticles 
were immersed into three different concentrations of sodium tripolyphosphate (TPP) solution 
(0.5, 1, 2% w/v) for 30 minutes. The microparticles were then removed by filtration and 
washed several times with distilled water and allowed to dry at room temperature. The 
reaction medium and washing solutions were stored at 4 
o
C until further quantification for 
unloaded GTM. The initial concentration of GTM used for the crosslinking studies was 
15-mg/mL. Encapsulation procedures for each employed GTM initial concentration were 
performed in triplicate. 
 
3.3.5 In vitro drug release studies 
Pre-weighed GTM loaded CHT-ST microparticles were suspended in 0.01 M PBS 
(pH-7.4) using a solid:liquid weight ratio of 2.5:1 (mg/mL). The microparticles were maintained 
at 37 
o
C under constant agitation (50 rpm) for 30 days in a shaking water bath. At 
predetermined time points, 1 mL aliquots were taken and replaced with same volume of fresh 
PBS solution. All the release experiments were carried out in triplicate, using unloaded CHT-ST 
microparticles as control. 
 
3.3.5.1 Quantitative analysis of the released GTM 
An indirect spectrophotometric method was used for the quantification of GTM, using 
o-phtaldialdehyde as derivatizing agent [24]. The procedure can be described as follows: 
o-phtaldialdehyde (0.25 g) was dissolved in a mixture of methanol (6.25 mL) and 
2-mercaptoethanol (0.3 mL). The resulting solution was mixed with 0.04 M sodium borate 
(56-mL, pH 8) buffer solution. For the colorimetric measurement, GTM solution, 
o-phtaldialdehyde reagent and isopropanol were mixed in an equal volume ratio, and 
incubated for 30 minutes at room temperature. The absorbance was then measured at 
332-nm. The concentration of GTM was calculated by using a calibration curve. 
For the determination of the encapsulation efficiency and GTM loading into the 
microparticles, the amount of the drug remaining in the reaction medium during the loading 
process was quantified according to known equations [30]. 
 
 
 
Chapter 3 – Starch-chitosan microparticles: carrier for the controlled release of antibiotic drugs 
58 
3.3.6 Microbiological determination of the activity of released GTM: in vitro evaluation 
The GTM released from the CHT-ST microparticles was tested for bactericidal activity 
using Staphylococcus aureus as a pathogenic microorganism. Standard strain of S. aureus ATCC 
25923 (American Type Culture Collection) was obtained from the Department of Biology, 
University of Minho, Braga, Portugal.  
Fresh isolates were cultured for 24 hours at 37 
o
C in LB-Agar (Luria-Bertani Agar, 
Lennox, Difco Laboratories, USA), immediately before each experiment.  
 
3.3.6.1 Susceptibility study: Determination of inhibition zones 
The standard antibiotic disc diffusion method [31] in LB-Agar was employed for the 
assessment of the in vitro activity of the released GTM against the selected bacteria, by 
determination of the inhibition zones. For this, a bacteria suspension with concentration in the 
range of 1.5 X 10
8
 UFC/mL was seeded in LB Agar sterile Petri dishes. All samples (released 
GTM solutions from the microparticles up to 30 days) were diluted to 0.25 mg/mL with sterile 
PBS buffer. Subsequently, 13 mm sterile absorption discs (BBL
TM
 Taxo
TM
 PM Discs, BD, USA) 
were placed on the agar plates and 20 μL of each sample was directly pipetted onto each disc. 
A disc impregnated with a solution of sterile PBS was used as control sample, and a standard 
solution of gentamicin sulfate 0.25 mg/mL was also tested. All agar plates were incubated at 
37 
o
C for 16-18 h. Each sample was tested in triplicate, using different plates. After incubation, 
the diameters of the inhibition zone were measured using a micrometer. 
From the relation between the samples diameter of inhibition zones (GTM released) 
and a standard GTM solution (considered standard for the maximum inhibition zone), the 
relative activity (%) can be determined [32]. 
 
3.3.6.2 Short term stability testing: encapsulated GTM activity 
For the stability tests, GTM loaded CHT-ST microparticles were stored in a well closed 
container at 4 
o
C and 25 
o
C for different periods of time (2, 4, 8 and 12 weeks). After each time 
point, samples were resuspended in sterile PBS and the in vitro release of GTM was analyzed, 
as well as the microbiological activity of the released antibiotic following the described 
techniques above.  
 
3.4 RESULTS AND DISCUSSION 
3.4.1 Preparation and characterization of CHT-ST GTM loaded microparticles 
In this study, CHT-ST microparticles were developed by means of combining two 
natural origin biodegradable polymers in order to enhance biodegradability of the carrier 
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50 μm 
200 μm 
system under physiological conditions. In addition, other important properties for their use as 
delivery vehicles for aminoglycoside antibiotics were investigated, namely adequate 
microparticle size and morphology (suitability to be used as injectable system), encapsulation 
efficiencies, controlled release and satisfactory activity of the released drug. 
The morphology, shape and size of unloaded and GTM loaded microparticles were 
analyzed by LM and SEM (Figure 3.2).  
 
 
 
Figure 3.2 Morphological characterization of the chitosan-starch microparticles. Polarized LM images of 
the obtained microparticles (a). SEM micrographs of gentamicin loaded microparticles: magnifications 
200X (b), 1000X (c), 3000X (d) 
 
The general features of the obtained CHT-ST microparticles can be observed in Figure 
3.2 (a). In this general view, it can be observed the spherical shape presented by the obtained 
microparticles, which was further confirmed by SEM analysis. In addition, at higher 
magnification is possible to observe in more detail a single microparticle with a diameter of 
about 100 µm (Figure 3.2 (c)) showing a slightly rough surface and the presence of small pores 
(around 1 μm size, Figure 3.2 (d)). No evident differences were observed between unloaded 
(a) (b) 
(c) (d) 
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and GTM loaded microparticles. GTM loaded microparticles maintained the initial spherical 
shape and morphological characteristics of unloaded microparticles. 
The particles have a narrow size distribution (Figure 3.3). Almost 60% of the 
microparticles are smaller than 100 μm, around 15% are in the range 100-150 μm, and less 
than 7% are smaller than 60 μm. Thus, a highly homogeneous microparticular system was 
obtained. 
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Figure 3.3 Chitosan-starch particle size distribution. The graph shows the results for the unloaded 
microparticle sample (CS, Table 3.1) 
 
3.4.2 Spectroscopic characterization of CHT-ST GTM loaded microparticles 
1
H-NMR spectroscopy was performed to confirm the presence of both polysaccharides 
in the obtained microparticles and analyze their chemical structure in the formulation. At the 
same time, the presence of GTM into the microparticles and possible chemical interactions 
between polymers and drug were also analyzed. 
GTM can be identified in the spectrum of loaded microparticles (Figure 3.4 (a) and (b)). 
GTM, as a complex mixture of several compounds [33, 34], gives a very complex 
1
H-NMR 
spectrum but exhibiting characteristic peaks (Figure 3.4 (b)) [35, 36]. From the obtained 
spectrum, it is possible to identify the main signals as a result of the presence of GTM in the 
developed microparticles. The presence of both polysaccharides (chitosan and starch) as 
components of the polymeric matrix was also identified in the microparticles spectrum. For 
chitosan (Figure 3.4 (c)) a typical doublet peak, as result of the presence of the deacetylated 
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unit at 5.04 ppm, and a peak (singlet) at 2.18 ppm from the acetylated residue, can be found in 
the resulting microparticles spectrum (Figure 3.4 (a)) [37, 38]. Finally, as result of the presence 
of the starch in the composition of the microparticles, an intense signal at 5.6 ppm can be 
assigned to the anomeric proton from the α(1→4) linkages of the amylose molecules in the 
starch structure [39-41]. 
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Figure 3.4 
1
H-NMR spectra of gentamicin loaded microspheres ↓ (a), Gentamicin sulfate ↔ (b), Chitosan 
 (c) and Starch  (d). Assigned to gentamicin sulfate the signals at 2.7 and 2.6 ppm, singlets resulting 
from the protons in the amino methyl groups present in the garosamine and purpurosamine 
components of gentamicin and a very intense peak at 1.2 ppm assigned to the methyl groups of 
garosamine molecules [32-36] 
 
Obviously, the chemical shifts do not match exactly with the shift of the GTM and 
starch in aqueous solution, due to the pH of the solvent used (D2O with 2% of DCL). There were 
no changes on the signals in the loaded microparticles spectra. Moreover, no new peaks have 
appeared in the spectra when comparing with the polymers used and drug to be loaded 
spectrum, indicating that no noticeable interaction between the drug encapsulated with the 
polymeric matrix had occurred. This may indicate that the drug loading and in vitro release is 
not expected to be affected by any possible chemical interaction between drug and polymer 
chemical groups. 
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3.4.3 GTM loading into microparticles 
3.4.3.1 Determination of drug loading and encapsulation efficiency of GTM. Effect of the initial 
drug concentration 
The drug loading and encapsulation efficiency (EE) are very important determinations 
to be made when developing systems for the controlled release of drugs [30]. Higher values of 
EE are desirable, from the economical point of view and also because lower amounts of 
microparticles will be necessary, minimizing the amount of foreign material introduced into 
the patients. In order to maximize EE, several approaches have been used, including different 
methods for drug loading [42, 43], the use of charged groups in the polymer [44], increasing 
drug solubility and its initial concentration [45, 46], among others. 
As expected, the drug loading increased significantly (from 4.8 to 27.1%) when GTM 
concentration increases from 5 to 15 mg/mL in the polymer solution, leading to a decrease in 
the EE (from 67.2 to 55%) (Table 3.1, Figure 3.5).  
 
Table 3.1 Experimental conditions for the preparation of gentamicin loaded chitosan-starch 
microparticles. Values of encapsulation efficiency (EE, %), drug loading (%) and kinetic parameters 
obtained for the developed microparticular system 
Sample 
GTM 
(mg/mL) 
TPP 
(%) 
Size 
(μm) 
GTM loading 
(%) 
EE 
(%) 
Diffusion exponent 
n (r) 
CS
a
 - - 096.1±12.4 - - - 
CSG
b
-1 15 - 119.4±8.3 n.d. n.d. 0.68 (0.9998) 
CSG-2 5 - 103.7±22.9 04.86±1.74 67.24±3.11 n.d. 
CSG-3 10 - 111.5±18.5 11.14±2.21 60.97±2.08 n.d. 
CSG-4 15 - 116.6±31.8 27.14±1.98 55.01±2.65 n.d. 
CSGT
c
-5 15 0.5 089.3±28.6 n.d. n.d. 0.60 (0.9980) 
CSGT-6 15 1 080.4±22.3 n.d. n.d. 0.59 (0.9812) 
CSGT-7 15 2 081.1±17.9 n.d. n.d. 0.54 (0.9971) 
Common experimental conditions for all experiments: 
CHT-ST: 1.5:2 (w/w). Volume of polymer solution: 10 mL 
Mineral Oil 70 mL (1% Tween 80, (v/v)) 
Stirring rate: 600 rpm 
a
CS-chitosan-starch microparticles 
b
CSG-gentamicin loaded chitosan-starch microparticles 
c
CSGT- gentamicin loaded chitosan-starch microparticles ionically crosslinked with TPP 
n.d.- not determined 
 
This is a predictable consequence of the increment of the initial amount of drug, which 
causes a gradual increment of the drug loading until a saturation level is achieved. Moreover, 
increasing the initial amount of the drug into the polymer solution, the partition of hydrophilic 
drug molecules solubilized in surrounding aqueous solution increases, which can explain the 
resulting decrease on the EE. Finally, it must be considered that during encapsulation 
processes, and when using polymeric microparticles, there is a saturation level for the drug to 
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be entrapped within the polymer droplets during the emulsion formation, and as a result the 
encapsulation becomes more difficult with the increments on the initial drug concentration. 
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Figure 3.5 Effect of initial gentamicin concentration on encapsulation efficiency and drug loading 
 
3.4.4 GTM release study 
3.4.4.1 Release profiles and TPP concentration effect 
Generally, three main stages are observed in a typical release pattern of bioactive 
compounds from biodegradable polymeric matrices [47]. The first stage is characterized by a 
burst release, due to the rapid diffusion of the bioactive agent located closer to the surface of 
the polymeric matrix and desorption of closely bound drug. The contact of the polymeric 
matrix with the release medium results in the swelling of the matrix (which strongly depends 
on the hydrophilic groups of polymer and crosslinking degree), allowing the drug encapsulated 
inside to start to diffuse through the polymer into the external environment (second stage). 
Finally, the polymer degradation starts to control the release process allowing the initial 
solubilization of the matrix and the release of the remaining bioactive agent occurs as the 
polymer is eroded. Consequently, two important properties of the system play a significant 
role in the release kinetics: the solubility of the bioactive agent into the surrounding medium, 
and the rate of polymer degradation. These release stages have been previously observed by 
other authors [48-50].  
In this case, GTM is highly soluble in aqueous solutions and, as a result, the entrapped 
GTM molecules diffused rapidly into the external aqueous solution (Figure 3.6 (b)). About 54% 
Chapter 3 – Starch-chitosan microparticles: carrier for the controlled release of antibiotic drugs 
64 
of the encapsulated drug is released in the first 24 hours. The burst release was observed to be 
followed by two sustained release stages. During the first nine days, 73% of the total 
entrapped GTM was released, being the remaining drug slowly released in the subsequent 
days. The second stage may be controlled by the swelling of the polymeric matrix (highly 
hydrophilic in this case) allowing aqueous solution to penetrate through the polymer, resulting 
in the diffusion of the GTM to the medium. Lastly, as result of the extended contact of the 
polymeric matrix with the surrounding medium, the polymer degradation (by hydrolysis 
mainly) starts to takes place, allowing the remaining drug to be released. After 30 days, 82% of 
drug was released (Figure 3.6 (b)). 
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Figure 3.6 Release profiles of gentamicin from chitosan-starch microparticles. Influence of 
tripolyphosphate crosslinking concentrations on the gentamicin release profiles (c), (d), (e). The first 24 
hours of release is enlarged for all the conditions (please see Table 3.1 for samples abbreviations 
description). 
 
Although the initial burst release is considered an undesirable behavior when 
developing sustained release systems, for delivering antibiotics a high dose is normally 
required at initial days to combat bacterial infections effectively and then slowly prolong the 
release for longer time periods to complete the treatment. Various chemical modifications of 
the polymeric matrix provide prolonged release times of entrapped antibiotics. In this study, 
we proposed the use of a non-toxic ionic crosslinker (sodium tripolyphosphate, TPP) to adjust 
the release of the GTM from CHT-ST microparticles by controlling the crosslinking density. 
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It is clear that the GTM release was significantly slowed down as the CHT-ST 
crosslinking density was increased. Moreover, increasing TPP concentrations, the initial burst 
release is retarded (Figure 3.6 (b), (c) and (d)). The microparticles produced using higher TPP 
concentrations were more rigid, decreased size (Table 3.1) and showing less swelling in PBS, 
thus resulting in a slower diffusion of the GTM molecules through the CHT-ST matrix into the 
PBS medium, with the consequent slowed down of the initial burst release. Under these 
conditions, the swelling and subsequent matrix degradation is also retarded, resulting in a 
smaller percentage of GTM released at the end of 30 days incubation. As a final result, a more 
sustained and slow release of GTM from the CHT-ST microparticles can be achieved for higher 
degree of crosslinking. Although the fastest release rate was observed from microparticles 
without ionic crosslinking, this system was still quite effective to ensure a sustained release of 
GTM after the initial burst stage. 
 
3.4.4.2 Analysis of drug release mechanism 
A number of mathematical models have been proposed to describe the mechanisms of 
drug release from polymeric devices. The Higuchi [51], Korsmeyer [52] and Peppas [53, 54] 
equations can be mentioned as the most widely used to date and are mainly based on the 
Fickian diffusion equation [55, 56]. In order to analyze the release mechanism of the GTM from 
CHT-ST microparticles, and the effect of the TPP crosslinking over the release behavior, the 
obtained data was processed using of the empirical expression proposed by Ritger-Peppas 
[53]. 
Table 3.1 summarizes the values obtained for the diffusion exponent (n) considering 
the CHT-ST microparticles with and without TPP crosslinking treatment. The results show that 
CHT-ST microparticles prepared with 2% TPP crosslinking exhibited a lower GTM diffusion 
exponent, n. Values of n were calculated and found to be 0.68 for microparticles without TPP, 
and 0.54 for the samples obtained with the highest TPP crosslinking density. The drug 
transport mechanism obtained for all experimental conditions was Non-Fickian diffusion or 
Anomalous (indication of the superposition of both extreme phenomena: drug diffusion and 
macromolecular chain relaxation) [53, 54]. This result indicates that neither absolute Fickian 
diffusion (as result of pure drug diffusion) nor Case II-zero order (because of polymer chain 
relaxation) was the predominant mechanism in this case, since an Anomalous drug transport 
was obtained. This can be understood as a close combination of contributions of polymer 
relaxation and drug diffusion factors that determine the drug release mechanism. In the case 
of various concentration of TPP (0.5, 1 and 2%) the GTM release was clearly slowed down by 
the increase of the TPP concentration. Analysing the values obtained for n the result shows in 
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all cases an anomalous drug transport mechanism (Table 3.1), from which it can be concluded 
that the crosslinking density does not show a significant influence in the drug transport 
mechanism (anomalous in all the cases), affecting solely the diffusion coefficient value.  
 
3.4.4.3 Activity of released GTM 
One very important factor when designing drug delivery systems is the maintenance of 
the activity or function of the bioactive molecules entrapped in the polymeric matrix. In the 
present study, the relative activity of the released GTM from the microparticles was screened 
in vitro against S. aureus (following standard procedures approved by NCCLS) [31].  
The obtained results, in values of relative activity (%) and inhibition zones diameters 
(mm), are shown in Figure 3.7.  
 
Figure 3.7 Inhibition zone of released gentamicin from chitosan-starch microparticles. The inserted 
picture represents a photographic observation of the antimicrobial activities against Staphylococus 
aureus. PBS solution without GTM (used as negative control) resulted in no inhibition zone around the 
impregnated disc (a). Disc impregnated with gentamicin released after 15 days, as shown in the line 
graph (360 hours) (b) 
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The diameters of inhibition zones vary from 17 mm for the standard GTM solution to 
12 mm for the GTM released after 30 days of incubation, and the corresponding relative 
activities change from 100% to 70% (Table 3.2). It can be seen that released GTM have 
inhibition zones values similar to the one obtained for the standard solution of this antibiotic. 
Moreover, the obtained results, in terms of diameter inhibition zone (mm) and relative 
antibactericidal activities (%) are in the same range to the ones reported in the literature for 
gentamicin sulfate against S. aureus [57, 58]. These results indicated that GTM was not affected 
in terms of stability and antibactericidal activities after the encapsulation process and 
microparticles processing, neither during the release experiments performed for 30 days in 
PBS at 37 
o
C. 
 
Table 3.2 Diameter of the inhibition zones and relative activities of the released gentamicin against 
Staphylococcus aureus 
Sample
a
/Release Day Diameter inhibition zone (mm) Relative Activity (%) 
GTM CTRL 17.0±1.9 100 
CSG-1/1 16.2±1.2 95.29 
CSG-1/2 17.0±0.7 100 
CSG-1/3 15.7±1.5 92.35 
CSG-1/4 15.5±1.3 91.18 
CSG-1/5 15.2±2.1 89.41 
CSG-1/7 14.5±0.7 85.29 
CSG-1/14 14.0±1.4 82.35 
CSG-1/30 12.0±0.9 70.59 
a
CSG: Chitosan-Starch GTM loaded sample/GTM release day (Related experimental conditions in Table 3.1) 
 
3.4.4.4 Effect of storage temperature and time on the release profile and activity of entrapped 
GTM 
A slightly faster initial burst release was observed during the first 12 hours, with the 
increasing storage time and temperature (Figure 3.8). The plateau obtained as result of a 
sustained release up of 4 days remains unchanged. This result was more pronounced for the 
samples stored at 25 
o
C. The released GTM remains active against S. aureus, but a decrease in 
the relative activity was found with increasing storage time. 
From the obtained results, the sustained release of GTM from the CHT-ST 
microparticles does not seem to be significantly impaired. The activity of the GTM remains up 
to 50% for all the samples tested after 30 days of release. It can be concluded that the 
developed system allows its storage in a controlled environment for at least 30 days. Samples 
stored for more than 4 weeks maintained a sustained release of GTM, and the released 
antibiotic remains active against S. aureus.  
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Figure 3.8 Release profiles of gentamicin from chitosan-starch microparticles after being stored for 
different conditions of time (4 and 12 weeks) and temperature (4 
o
C and 25 
o
C) 
 
3.5 CONCLUSION 
In this work, microparticles with spherical shape and uniform size distribution were 
produced using a water-in-oil emulsion crosslinking method. The emulsion method is a very 
simple and effective technique for the production of spherical microparticles for chitosan and 
similar hydrogel-like polymers, on which the microparticles properties can be tailored by 
adjusting the experimental conditions. A successful conjugation of chitosan to starch was 
achieved by means of a reductive alkylation procedure. This method provides several 
advantages namely the use of natural crosslinkers, avoiding the use of toxic crosslinkers agents 
like the extensively employed glutaraldehyde, and also an enhancement of the chitosan 
biodegradation by the presence of physiological enzymes such as α-amylase, due to the starch 
conjugation (a subsequent publication shows biodegradability results). The potential of the 
developed CHT-ST microparticles for the sustained release applications was evaluated by 
studying the loading and release of aminoglycosides, like Gentamicin sulphate. Important 
parameters, such as initial GTM concentration, showed a noticeable influence on the 
encapsulation efficiency and drug loading, resulting in an increase in the drug loading when 
the initial GTM concentration was increased. The encapsulation efficiencies decreased, 
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however, with increasing percentages of drug loading. The release studies of entrapped GTM 
in PBS medium showed a long term sustained release during 30 days following an anomalous 
drug transport mechanism. The release kinetics can be retarded by further ionic crosslinking 
the polymer conjugate with sodium tripolyphosphate, reducing the burst release. The bacterial 
inhibition test performed against Staphylococus aureus showed that biodegradable CHT-ST 
microparticles are able to release GTM with a high bactericidal activity, for a 30 days period, 
time necessary for effective treatment of infections by this bacteria. Studies on the stability of 
encapsulated GTM showed that samples stored under controlled conditions for periods up to 
12 weeks maintain a sustained release pattern of GTM, and the released antibiotic remains 
active against S. aureus. Biodegradable microparticles loaded with important antibiotics can 
provide effective treatments for persistent infections. 
Further studies will be focused on the enzymatic degradation behaviour of the 
developed microparticles, to demonstrate the initial hypothesis of enhanced biodegradability 
of the proposed system. 
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Chapter 4 
Highly biodegradable starch-conjugated chitosan microparticles as carrier for the 
controlled release of antibiotic drugs: In vitro enzymatic degradation and cytotoxicity 
evaluation 
 
4.1 ABSTRACT 
The effect of enzymatic degradation on the release behavior of gentamicin (GTM) from starch-
conjugated chitosan microparticles (CHT-ST) was investigated upon exposure to an α-amylase 
containing solution up to 8 weeks. The degradation of the microparticles was followed by 
gravimetric measurements, scanning electron microscopy (SEM) and spectroscopic techniques 
(FTIR/
1
H-NMR). SEM observations showed an increase in the porosity and surface roughness of 
the microparticles as well as a reduction in their diameters, indicative of the degradation 
process. These morphological observations were confirmed by weight lost measurements that 
showed that about 70% of the microparticles weight was lost in the presence of α-amylase. 
With prolonged degradation time, a highly porous matrix was obtained leading to an increased 
permeability. This resulted in increased water penetration with possible diffusion of the 
entrapped drug. A faster release of GTM from the CHT-ST microparticles was observed in the 
presence of α-amylase. In addition, an initial evaluation of the cell behavior in the presence of 
the differently produced CHT-ST microparticles samples was studied using an osteoblast-like 
cell line (SaOs-2). Its cytotoxic effect over SaOs-2 cells was dependent on the crosslinking agent 
used and on the amount of starch. Glutaraldehyde (GA) crosslinked microparticles caused 
some cytotoxicity that was dependent on its concentration. On the contrary, a higher 
percentage of starch clearly improved the cell viability. Thus, the developed CHT-ST 
microparticles are biodegradable and non toxic under physiological conditions where 
degrading enzymes are present. Thus, may be used as a sustained/controlled delivery carrier. 
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*This chapter is based on the following publication: 
Balmayor, E. R.; Baran, E. T.; Marques, A. P.; Azevedo, H. S.; Reis, R. L. Highly biodegradable 
starch-conjugated chitosan microparticles as carrier for the controlled release of antibiotic 
drugs: In vitro enzymatic degradation and cytotoxicity evaluation. 2009. Submitted. 
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4.2 INTRODUCTION 
Biomaterials with the ability to perform certain medical functions and subsequently 
degrade, under a controlled mechanism, into easily metabolized products are of great 
importance [1-3]. Among the well known advantages of using biodegradable materials, are the 
elimination of the long term presence of foreign materials and the consequent need for a 
second surgery for implant removal [2, 4].  
Several definitions for biodegradability have been proposed [1, 2, 5-7]. In the context 
of biomedical applications, biodegradation may be defined as the “gradual breakdown of a 
material mediated by a specific biological activity” [5, 7]. When in contact with tissues, 
biomaterials start to degradade as a result of their interaction with biological environments, 
and its stability will define its application in clinics. In drug delivery applications, it is well 
known that biodegradability of the carrier system affects and finally controls the release 
kinetics of the encapsulated drugs [2, 4, 8]. Thus, the polymeric carriers should degrade under 
physiological conditions allowing for the gradual release of the entrapped drug as well as 
facilitate repeating dosages to ensure successful treatments [9, 10]. Another important issue 
related with the use of biodegradable polymers in drug delivery, is the possible toxicity of the 
leachable molecules and degradation products derived from the material processing and 
degradation [11, 12]. Thus, the nature of the materials to be selected as drug delivery carriers 
is also a rather important factor to consider. Polysaccharides are very attractive in this respect 
as the degradation process results in non-toxic end products such as glucose, maltose and 
oligosaccharides. These end products may even be incorporated in the normal metabolic 
pathways of the human body [2, 13-15]. 
In a previous study [16], we have described the preparation and characterization of 
starch-chitosan microparticles and analyzed the release of antibiotic drugs from the polymeric 
carrier in vitro. For the present work, we have investigated the susceptibility of starch-chitosan 
microparticles (CHT-ST) [16] to enzymatic degradation by the hydrolytic enzyme α-amylase. 
Moreover, the effect of the α-amylase degradation on the release kinetics of entrapped 
gentamicin (GTM) from the CHT-ST microparticles was also studied. The extent of degradation 
was evaluated by measuring the weight loss and the presence of reducing sugars in the 
degradation medium. Changes in the chemical structure as well as in their morphological 
features were also analyzed. The cytotoxicity of CHT-ST microparticles produced under 
different processing conditions was assessed over an osteoblast-like cell line. 
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4.3 EXPERIMENTAL 
4.3.1 Materials 
The materials studied in this work were chitosan (the viscosity-average MW was found 
to be 385 kDa and the deacetylation degree 81.25%, [16]) from Sigma-Aldrich (USA) and 
soluble potato starch, supplied by ATO (The Netherlands). Both materials were used as 
received. α-amylase (EC 3.2.1.1) from Aspergillus Oryzae, 215 U/mg protein, was obtained 
from Sigma-Aldrich (USA). Other chemicals were analytical grade, from Sigma-Aldrich (USA) 
and were used as received.  
 
4.3.2 CHT-ST microparticles preparation: variation on the experimental conditions 
CHT-ST conjugate was prepared by an initial reductive alkylation cross-linking method 
[17]. Briefly, starch was oxidized to produce a polyaldehyde that reacts with the amino group 
of chitosan in the presence of a reducing agent. The production of the CHT-ST microparticles 
was then carried out using a water-in-oil emulsion technique, as described previously [16]. In 
brief, equal volumes of chitosan (1.5%, w/v) and oxidized starch (2%, w/v) solutions were 
mixed, and the pH adjusted to 5.5 by using 0.5 M NaOH. The polymeric solution was added 
dropwise into a glass reactor containing mineral oil with 1% of Tween 80 and emulsified with a 
top stirrer at 600 rpm for 30 minutes. After emulsion formation, 30 mL of cold acetone was 
added slowly. The microparticles were then removed from the reaction medium by filtration 
and washed with distilled water/acetone mixture (1:1 v/v). After alkaline (sodium carbonate 
buffer solution, 0.5 M) and reduction (sodium borohydride solution, 0.05%) treatments, the 
microparticles were washed with distilled water and allowed to dry at room temperature.  
Three variations were however introduced to the standard procedure previously 
described (starch-conjugated chitosan microparticles without crosslinking) [16]: i) two 
different crosslinking agents, sodium tripolyphosphate (TPP) and glutaraldehyde (GA), at 
different concentrations (0.5, 1 and 2%) were employed. Crosslinking was achieved by 
immersing the obtained samples for 3 hours into the crosslinker agent solution, ii) the amount 
of starch in the composition of the CHT-ST conjugate polymer solution used for the 
microparticles preparation was varied (1, 2 and 4%), iii) the stirring rate employed to form the 
emulsion was increased from 400 to 800 rpm aiming at producing smaller sizes microparticles 
and to evaluate the influence of the particles sizes over the cytotoxicity of the resulting 
particular biomaterial (Table 4.1). 
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4.3.3 Enzymatic degradation study. In vitro release of GTM in enzymatic environment 
Pre-weighed samples (unloaded and GTM loaded CHT-ST microparticles) were 
incubated in a 1:10 ratio in 0.01 M phosphate buffered saline solution (PBS, pH 7.4) containing 
α-amylase 150.5 U/L, at 37 
o
C and under constant shaking (50 rpm) up to 8 weeks. The 
buffered enzyme solution was changed weekly to maintain the desired level of enzyme activity 
throughout the experiment. For the preservation of the degradation solution, sodium azide 
(0.02%) was added to the buffered enzyme solution (stored at 4 
o
C for further use). As a 
control, the samples were incubated in the presence of PBS only. At the end of each 
degradation time (1, 2, 3, 7, 14, 30 and 60 days), the supernatants were removed and stored at 
-80 
o
C for further analysis. The excess of solution was carefully removed with filter paper and 
the samples were weighed using an analytical balance (±0.01 mg accuracy) for the 
determination of water uptake [18]. Subsequently, the samples were thoroughly washed with 
distilled water and allowed to dry at room temperature until presenting constant weight. The 
final weight of the samples was used for the calculation of the weight loss in relation to the 
initial weight [18]. The supernatants from the degradation solutions were used to quantify the 
amount of released GTM and to determine the concentration of reducing sugars released into 
the solution as a product of the degradation process.  
 
Table 4.1 Experimental conditions used during the preparation of chitosan-starch microparticles. Effect 
of processing conditions over the resulted cytotoxicity, expressed as percentage of cell viability in 
comparison to control (100% viability) 
Sample
a
 
GA
b
 
(%) 
TPP
c
 
(%) 
Starch 
(%) 
Stirring rate 
(rpm) 
Size 
(μm) 
Cell viability 
(% Control)
d
 
CHT-ST 1 0.5 
- 
2 
600 
79.6±6.3 73.21±8.6 
CHT-ST 2 1 75.3±13.4 65.83±5.9 
CHT-ST 3 2 74.3±11.7 55.87±9.1 
CHT-ST 4 
- 
0.5 82.9±9.5 79.21±4.0 
CHT-ST 5 1 70.4±10.4 76.78±7.2 
CHT-ST 6 2 71.3±24.8 78.81±3.8 
CHT-ST 7 
- 
1 87.7±29.1 71.18±9.1 
CHT-ST 8
*
 2 600 96.1±12.4 77.12±6.2 
CHT-ST 9 4 600 91.3±9.8 91.24±1.8 
CHT-ST 10 
2 
400 207.1±11.6 74.70±8.9 
CHT-ST 11 800 60±7.4 76.27±6.6 
Common experimental conditions for all experiments: 
Volume of polymer solution: 10 mL 
Mineral Oil 70 mL (1% Tween 80, (v/v)) 
a
CHT-ST: chitosan-starch microparticles 
b
GA: glutaraldehyde 
c
TPP: sodium tripolyphosphate  
d
percentages of viable cell compared to positive control(100%-DMEM culture medium) as result of the direct contact 
with chitosan-starch microparticles 
*
 standard condition [16] 
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The quantification of the released GTM was performed by an indirect 
spectrophotometric method, as previously described [16]. The amount of reducing sugars in 
the supernatants was estimated by the dinitrosalicylic acid (DNS) method [19], using a 
calibration curve obtained with glucose solutions of known concentrations. Briefly, a DNS 
reagent solution was prepared based on a mixture of 3,5-dinitrosalicylic acid and Rochelle salt, 
under alkaline conditions. Subsequently, standard solutions and samples were mixed with the 
DNS reagent under the appropriate conditions and allowed to react at 100 
o
C for 5 minutes. 
Finally, the absorbance was determined using a microplate reader at 540 nm (EL 312e 
Biokinetics, BioTek Instruments, USA). The amount of reducing sugars was reported as the 
average concentration of three replicate determinations.  
 
4.3.4 Chemical and Physical characterization 
4.3.4.1 Morphological evaluation: scanning electron microscopy (SEM) 
The morphology and surface characteristics of the microparticles were evaluated by 
SEM after the different degradation time points (mentioned in section 4.3.3), to assess the 
changes resulting from the degradation process. Following standard procedures for the 
preparation of the samples [16], the samples were analysed by scanning electron microscopy 
(SEM) (Leica Cambridge S-360 model, UK). 
 
4.3.4.2 Chemical changes: fourier transformed infrared spectroscopy (FTIR) 
To assess eventual changes in the chemical composition of the microparticles as result 
of the enzymatic degradation, the samples were analyzed by fourier transformed infrared 
spectroscopy (FTIR) spectroscopy in a transmission mode (IRPrestige-21 FTIR-8400S, Shimadzu, 
Japan) before and after the degradation process. For the preparation of the samples for FTIR 
analysis, 1 mg of sample was mixed with 40 mg of spectroscopic KBr, and then processed into 
a disc using a manual press (161-1100 hand press, PIKE Technologies, USA). Transmission 
spectra were recorded using at least 32 scans with 4 cm
-1
 resolution and in the spectral range 
4000-600 cm
-1
. 
 
4.3.4.3 Nuclear magnetic resonance spectroscopy (
1
H-NMR) 
Proton nuclear magnetic resonance (
1
H-NMR) spectra were obtained (Varian Unit Plus 
300 MHz spectrometer, USA) under the following experimental parameters: 256 scans, 5200 
Hz filter width, 90
o
 pulse corresponding to a pulse width of 11 μs and 4 s relaxation delay. The 
experiments were run at 60 
o
C. For the sample preparation, 10 mg of each sample were 
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dissolved into a mixture of deuterated solvents, 0.98 mL of deuterium oxide (D2O) and 0.02 mL 
of deuterium chloride (DCL), until complete dissolution, and transferred into a NMR tube 
(φ=0.3 mm).  
 
4.3.5 Evaluation of cytotoxicity 
The human osteoblast-like cell line SaOs-2 (ECACC, UK) was used to evaluate the effect 
of processing conditions over cell viability. The cytotoxicity of both, the extract of the particles 
produced under the standard conditions [16] and the different particles developed in this 
work, was assessed by performing a standard MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay [20, 21]. 
1.3 X 10
4
 cells/well were plated in a 96-well plate in Dulbecco’s Modified Eagle’s 
Medium (DMEM) without phenol red (Sigma-Aldrich, USA), supplemented with 10% heat-
inactivated fetal bovine serum FBS (Biochrom AG, Germany) and 1% antibiotic/antimycotic 
(Gibco
TM
, Invitrogen, CA). Cells were incubated for 24 hours at 37 
o
C in a humidified 
atmosphere containing 5% of CO2 and let to achieve approximately 80% confluence.  
In order to test the cytotoxic potential of the CHT-ST microparticles, the standard 
material was incubated in complete cell culture medium for 24, 48 and 72 hours at 37 
o
C under 
constant shaking (100 rpm). This incubation was performed using 0.5 mg microparticles per mL 
of complete culture medium. Subsequently to the incubation period, the extraction medium 
containing potential toxic leachable and degradation products was filtered (0.45 µm pore size) 
and added to the 80% confluence cell layer. The cells were incubated for further 24 hours with 
this medium at 37 
o
C and in a humidified environment containing 5% of CO2. Latex rubber 
extract and fresh complete culture medium were used respectively as negative and positive 
controls for cell viability assay [18]. 
In a separated experiment, the microparticles obtained from the different 
experimental conditions, and sterilized by ethylene oxide (EtO) using pre-optimized conditions 
[22], were directly added to the 80% cell monolayer in a concentration of 1 mg/mL, and 
incubated for further 72 hours. 
The MTS test was performed for both experiments according to the manufacture 
instructions provided in the CellTiter 96 One Solution Proliferation Assay Kit (Promega, USA), 
and as described previously [13, 21]. Briefly, after the incubation periods, the cell monolayer 
was treated with 200 µL/well of MTS reagent solution (5:1 ratio in serum-free DMEM culture 
medium without phenol red) and incubated for further 3 hours at 37 
o
C and in a humidified 
environment containing 5% of CO2. 100 µL of each well were then filtered (0.45-µm pore size) 
to eliminate the possible presence of solid particles, and transferred to a new 96-well plate. 
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The absorbance was determined in a microplate reader (EL 312e Biokinetics, BioTek 
Instruments, USA) at 490 nm. The results are expressed as the percentage of cell viability in 
comparison with the 100% viability attributed to the positive control. The samples were tested 
in triplicate in three independent assays. 
 
4.4 RESULTS AND DISCUSSION 
4.4.1 Enzymatic degradation 
4.4.1.1 Physicochemical characterization: water uptake and weight loss 
A biomaterial designed for biomedical applications will for sure interact with human 
tissues and fluids after implantation, which might initiate their degradation process. Chemical 
and enzymatic oxidations, non-enzymatic hydrolysis (catalyzed by acids, bases or salts) and 
enzymatic hydrolysis caused by the action of enzymes are some of the routes for degradation 
to occur [2, 23]. α-amylase is a glycosidic hydrolase that acts on the α (1-4) glycosidic bond of 
starch molecules reducing its molecular weight, and yielding maltose, glucose and other small 
sugars molecules. This enzyme is present in many tissues in the human body, including the 
human blood [2], although most prominent in exogenic pancreatic secretions and saliva [24]. 
Therefore, is expected that this enzyme will participate on the degradation of starch-based 
biomaterials that perform their function in contact with human fluids, tissues and organs. In 
this study, the degradation of a previously proposed CHT-ST microparticular system [16] was 
carried out in the presence of α-amylase at a physiological concentration. Weight loss and 
water uptake percentage was followed over time up to 8 weeks of incubation (Figures 4.1 and 
4.2). In comparison to PBS, higher values of water uptake (160.1±5.6 %) were obtained after 
incubation in α-amylase solution (Figure 4.1). This behavior can be related with the presence 
of both polysaccharides (chitosan and starch) in the composition of the blend, providing 
hydrophilic characteristics to the microparticular system. Moreover, it may be also associated 
with the presence of α-amylase in the solution that promotes water absorption, which is in 
accordance with previous reported data [23]. The enhanced permeability of the material over 
the time, caused by the partial degradation resulting from the enzymatic hydrolysis, leads to 
increased water absorption.  
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Figure 4.1 Water uptake profile of chitosan-starch microparticles in PBS, and PBS containing α-amylase 
(37 °C, 100 rpm). The data points in the figure represent the mean of three replicates (n=3) and the 
error bars the standard deviation 
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Figure 4.2 Degradation profiles of chitosan-starch microparticles, expressed as weight loss percentage, 
after incubation in PBS, and PBS containing α-amylase (37 °C, 100 rpm). Error bars represent standard 
deviations (n=3) 
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The results of weight loss confirmed the degradation of the CHT-ST microparticles 
after incubation with α-amylase (Figure 4.2). At initial stages of degradation, considerable 
increase in weight loss was observed. On the contrary, when the microparticles were 
incubated in PBS only, the variation of weight loss over time was not significant. At the end of 
the studied time period, CHT-ST microparticles lost 67.1±5 % of their original weight in 
presence of α-amylase. This clearly indicates a high degree of degradation of the 
microparticles in the presence of this enzyme.  
 
4.4.1.2 Determination of reducing sugars in the supernatants 
It is well known that enzymatic hydrolysis of polysaccharides is accompanied by the 
release of glucose and several other soluble sugar molecules to the degradation media [2, 23]. 
Therefore, the amount of reducing sugars released by the material into the media over time 
will give an indication of the extent of the material degradation. Figure 4.3 shows the 
concentration of reducing sugars released into the solution, after incubation of the CHT-ST 
microparticles with α-amylase. Reducing sugars were found in the supernatants where the 
microparticles were incubated in the presence of the enzyme, but not in the control 
supernatants (PBS only). As expected, prolongation of the incubation time led to increasing 
amounts of reducing sugars. In fact, after 60 days of degradation, the concentration of 
reducing sugars quantified was 18.02±0.86 mg/mL. The absence of α-(1-4) glycosidic linkages 
in chitosan leads to assume that the amount of the quantified reducing sugars correspond to 
the degradation of the starch in the blend. 
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Figure 4.3 Concentration of reducing sugars released from the chitosan-starch microparticles into the 
solution after incubation in PBS, and PBS containing α-amylase (37 °C, 100 rpm). Error bars represent 
standard deviations (n=3) 
 
4.4.1.3 Morphological evaluation of degradation process: scanning electron microscopy (SEM) 
SEM micrographs presented in Figure 4.4 show the morphology of CHT-ST 
microparticles before and after incubation with the enzymatic degradation solution in which it 
is possible to observe the extent of the degradation process in the microparticles when they 
are immersed in the enzymatic solution. The particle size decreases, there is the appearance of 
pores at the surface and the particles lose their spherical shape (Figure 4.4 (e) and (f), (g) and 
(h)) when comparing with the non-degraded control sample (Figure 4.4 (a) and (b)). As a result 
of the degradation process, the material starts to disintegrate leading to the appearance of 
fractures which contribute to the loss of the spherical shape and to a decrease in the size of 
the particles. At higher magnifications, it was possible to observe in detail the surfaces of the 
samples after enzymatic degradation. In that case, a highly porous matrix was obtained (Figure 
4.4 (f) and (h)).  
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Figure 4.4 SEM micrographs showing the morphology of surfaces and the shape of chitosan-starch 
microparticles before (a), (b) and after enzymatic degradation: 8 weeks of incubation in PBS solution (c), 
(d); after 2 weeks of incubation in α-amylase solution (e), (f); after 8 weeks of incubation in α-amylase 
solution (g), (h) 
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After 8 weeks of incubation in PBS, the roughness of the surface of the microparticles 
clearly increased (Figure 4.4 (d)), but no pore formation or any evidence of degradation, such 
as changes in the size or shape of the particles, was observed when compared to the 
enzymatic degraded ones. That roughness on the surface can be a result of the swelling 
process which causes irreversible changes in the surfaces morphology. 
 
4.4.1.4 Chemical evaluation of degradation process: Fourier transformed infrared (FTIR)-
Nuclear magnetic resonance (
1
H-NMR) 
Figure 4.5 shows the FTIR spectra obtained for CHT-ST microparticles before and after 
8 weeks of α-amylase degradation.  
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Figure 4.5 FTIR spectra of chitosan-starch microparticles before (a) and after (b) enzymatic degradation 
with α-amylase for 8 weeks. Symbols: ↑ -indicating a decrease in the intensity of the bands as result of 
the action of α-amylase cleaving the C-O-C glycosidic linkages of starch 
 
Relevant bands assigned to both polysaccharides, chitosan and starch, can be clearly 
identified. In the range of 900-1200 cm
-1
, the carbohydrate fingerprint region, the three major 
starch specific bands, 1030 cm
-1
, 1080 cm
-1
 and 1150 cm
-1
 for the C-O-C stretching, can be 
clearly identified (triplet, broad band). After the enzymatic hydrolysis, a clear decrease in the 
intensity of those bands can be observed, indicating the action of α-amylase in cleaving the 
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C-O-C glycosidic linkages of starch. This FTIR evidence of the enzymatic degradation of starch 
by α-amylase is in concordance with the literature [23, 25-28], where some authors found also 
evidence of an increasing tendency in the so called “water band” that appears at 1640 cm
-1 
as 
an indication of the absorbed water in the starch matrix, rather than any structural change in 
the polymer composition [25]. When CHT-ST microparticles were incubated in PBS only, no 
notorious changes in chemical composition were observed. FTIR technique proved to be useful 
to quantify the biodegradation of polymer mixtures [29-32], and more specifically when starch 
is analyzed due to the presence of very strong absorption in the carbohydrate fingerprint 
region (900-1200 cm
-1
), as any loss in starch content results in a decrease in the absorbance in 
this region. 
The proton NMR spectrum of starch has been widely studied in the literature [33-35]. 
This polysaccharide has a well defined pattern of signals that allows the use of this technique 
for its study and characterization. Figure 4.6 shows the 
1
H-NMR spectrum of CHT-ST 
microparticles before and after α-amylase degradation. The spectrum of chitosan raw material 
is presented for comparison.  
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Figure 4.6 
1
H-NMR spectra of chitosan-starch microparticles before (a) and after 8 weeks of degradation 
in presence of α-amylase (b). Chitosan raw materials used to produce the microparticles (c). Symbols: ↓-
Starch (α (1→4) glycosidic linkages, singlet), -Chitosan (deacetylated unit, doblet), --- Starch (internal 
protons, multiplets) 
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The typical peaks of starch can be identified in the spectrum of the CHT-ST 
microparticles before degradation. A signal at 5.5 ppm can be observed, due to the anomeric 
proton associated with α (1→4) linkages of the molecules. After 8 weeks of α-amylase 
degradation this peak at 5.5 ppm disappears (Figure 4.6) as an indication of the action of the 
enzyme cleaving the α (1→4) glycosidic linkages in starch. Moreover, the multiplet signal at 
4-ppm assigned to the internal protons of starch disappear after α-amylase degradation. This 
provokes changes in the signal structure/shape leading to the clarification of the chitosan 
characteristic peaks that were overlapped with the starch multiplets in the same region of the 
spectrum. At the end of the enzymatic degradation study, the chitosan 
1
H-NMR characteristic 
spectrum was observed (3-4.5 ppm) (Figure 4.6). As a result of the analysis of the obtained
 
1
H-NMR spectra before and after degradation, it can be concluded that the starch molecules 
present in the microparticles composition are being degraded by α-amylase by cleaving its 
α-(1→4) linkages.  
 
4.4.1.5 Effect of α-amylase degradation on the release kinetics of GTM from CHT-ST 
microparticles 
Being the produced CHT-ST microparticles susceptible to enzymatic degradation by 
α-amylase at physiological concentrations, the effect of enzymatic degradation of CHT-ST 
microparticles on the GTM release kinetics was studied. It was expected a significant role of 
the degradation of the polymeric matrix in the release behavior of the entrapped GTM.  
In a previously study [16] we have described the GTM release from the CHT-ST 
microparticles in PBS environment. The data showed that the majority of the released GTM 
(higher than 72% at the end of 9 days) is mainly controlled by diffusion and swelling processes 
and that matrix degradation phenomenon does not play a significant role. This is an expected 
result, since the degradation of the CHT-ST microparticles by spontaneous hydrolysis (PBS) is 
notably slow during short periods of incubation, and as a consequence should not significantly 
affect the release behavior. Figure 4.7 shows the release profiles of GTM from CHT-ST 
microparticles in PBS containing α-amylase, compared to PBS only. The initial burst release (up 
to 12 hours) of the GTM was unaffected by the presence of the enzyme. However, from that 
time point on, the GTM was released faster when α-amylase was present. This effect was more 
pronounced during the diffusion stage, from the second day on, where 71% GTM was released 
from the CHT-ST microparticles in the presence of the enzyme, whereas only 59% was released 
from the sample incubated in PBS only. This indicates that the polymer degradation can affect 
and control the release rate of encapsulated drugs. In fact, from the obtained results it can be 
concluded that the GTM is released by diffusion phenomena mainly at the beginning (as result 
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of the swelling of the highly hydrophilic polysaccharide matrix). Thereafter, the degradation of 
the polymeric microparticles starts to take place accelerated by the presence of enzymes. 
Thus, at later stages the release rate of encapsulated drug is controlled by the enzymatic 
degradation process. 
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Figure 4.7 Release profiles of gentamicin from chitosan-starch microparticles in PBS (a) and α-amylase 
solutions (b) 
 
4.4.2 Cytotoxicity evaluation 
4.4.2.1 Effect of material extracts 
One of the main concerns related to the use of biodegradable polymers is the 
potential toxicity of the leachable molecules or degradation products that are released from 
the material as result of its degradation. Therefore, a first cytotoxicity evaluation was 
conducted using extracts of the CHT-ST microparticles produced under the standard conditions 
[16], by incubating the samples in complete DMEM culture medium. Figure 4.8 (a) shows that 
the extraction time does not significantly influence cell viability which was found to be above 
70%, when compared to positive control (100%). The obtained results are in agreement with 
previous reported cytotoxicity evaluation of chitosan, starch and other polysaccharides based 
microparticles [36-38]. However, it should be taken into consideration that the 
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biocompatibility of biomaterials depends on the processing techniques and conditions used to 
develop the final device, rather than the selected polymer to be used. Therefore, the effect of 
the new processing conditions was further investigated.  
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Figure 4.8 Optical density of the MTS solutions after incubation with SaOs2, grown for 24 h in the 
presence of chitosan-starch microparticles extracts obtained in culture medium for 24, 48 and 72 h (a); 
grown for 72 h in direct contact with chitosan-starch microparticles obtained by the use of different 
concentrations of glutaraldehyde and tripolyphosphate as crosslinking agents (b); grown for 72 h in 
direct contact with chitosan-starch microparticles obtained by the use of different percentages of starch 
in the composition of the microparticles (c); grown for 72 h in direct contact with chitosan-starch 
microparticles with different sizes (d) 
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4.4.2.2 Effect of the crosslinking agent and its concentration 
Although chitosan is a relatively easy to process, its stability is generally low as result 
of hydrophilic character and pH sensitivity. To control both their mechanical and chemical 
properties, various techniques have been used to crosslink chitosan. Chemical reagents such 
glutaraldehyde (GA), known as excellent crosslinking agent for chitosan, is being widely used 
during the processing of this polymer [39]. However, during the last decade its cytotoxicity and 
the possibility of impairing the biocompatibility of its crosslinked products have been 
considered as major concerns [40, 41]. Recently, chitosan materials were obtained by 
treatment with multivalent anions such as sodium tripolyphosphate (TPP). TPP has been 
reported to have no intrinsic cytotoxicity as well as its resulting crosslinked products [42, 43]. 
Therefore, in this study a comparative cytotoxicity analysis was carried out with 
CHT-ST microparticles produced using GA and TPP, at three different concentrations. Table 4.1 
summarizes the percentage of cell viability depending on the concentration and on the 
crosslinking agent. Higher cytotoxicity (55.87% cell viability) was obtained for GA, which 
confirms the previous reported observations [36, 40, 41]. However, a considerable 
improvement in cell viability was observed when decreasing GA concentration (Table 4.1, 
Figure 4.8 (b)). Thus, lowering GA content to 0.5% resulted in more than 70% of cell viability. 
Using the smaller concentration of GA reduces the cytotoxicity of the crosslinked product 
without compromising the structural stability of the developed material. Given that, GA is a 
very effective crosslinker agent even at low concentrations. Similarly, the use of GA vapors to 
crosslink polysaccharide structures, followed by glycine immersion treatment, has been 
reported to reduce the toxicity of crosslinked products [44]. When TPP is used as a crosslinking 
agent, values higher than 75% were obtained for cell viability, independent of the 
concentration used. In fact, the cell viability results are in the same range as the ones obtained 
when no crosslinking agent was used following the previously reported standard procedure 
(chitosan-oxidized starch microparticles) [16]. 
 
4.4.2.3 Effect of the amount of starch in the composition of the CHT-ST microparticles 
Figure 4.8 (c) illustrates the influence of the starch amount in the composition of the 
microparticles on the cell viability. It can be observed that the presence of starch in the CHT-ST 
microparticles does not induce any toxic effect on SaOs-2 cells. Moreover, it is possible to 
observe an enhancement on the cell viability that increased, from 71 to 91%, when the 
concentration of starch was raised from 1 to 4% (Table 4.1). This result demonstrates that the 
use of polysaccharide blends in biomaterial design is an effective strategy to improve their 
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biocompatibility. Furthermore, starch is confirmed as a highly biocompatible natural polymer 
that can be selected to be used alone, as well as a blend component to improve the tissue and 
cell behavior [45].  
 
4.4.2.4 Effect of the size of the CHT-ST microparticles 
One of the most important experimental parameters for microparticles processing 
using emulsion techniques is the stirring rate, which mainly controls the size of the resulting 
particles. By increasing the stirring speeds higher energy is provided to disperse the two 
immiscible phases (emulsion formation), thus producing smaller drops of the polymeric 
solution in the dispersed phase. As a result, particles with smaller size are obtained. We have 
shown that varying the stirring rate from 100 to 1000 rpm, it is possible to produce particles 
from the micro- to the nano scale range [46]. 
Increasing the stirring speed from 400 to 800 rpm, microparticles with sizes from 
207.1±11.6 µm to 60±7.4 µm were obtained. These smaller microparticles, in comparison to 
the standard conditions, did not induce a significant difference in cell viability. 
As final outcome, it can be summarized that all the produced CHT-ST microparticles 
would be suitable as delivery vehicles since they did not exhibit a detrimental effect on SaOs-2 
cells, thus not compromising their application as drug delivery devices. When GA is used as a 
crosslinker agent, it is highly recommended to use the lowest concentration or vapors of this 
chemical to preserve the biocompatibility of the final biomaterial.  
 
4.5 CONCLUSION 
The combination of chitosan and oxidized starch have resulted in very hydrophilic 
microparticles exhibiting high values of water uptake (160%). The in vitro enzymatic 
degradation of the developed CHT-ST microparticles was found to be characterized by an 
increased initial weight loss, resulting in a loss of 67% of their original weight at the end of the 
degradation period (60 days). As a result of matrix degradation, increasing amounts of soluble 
sugars were released to the media. These sugars consist of glucose and other 
maltooligosaccharide which are innocuous, being easily metabolized in the human body. The 
occurrence and extent of the degradation was confirmed by morphological observations 
(SEM), and spectroscopic techniques (FTIR/
1
H-NMR). 
Due to the high hydrophilicity and susceptibility to enzymatic degradation, a highly 
porous microparticular matrix was obtained after degradation. As a consequence, there is an 
increase in matrix permeability, leading to increased water penetration and the diffusion of 
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the entrapped drug being completely released. Thus, the initial stage of drug release is 
controlled by diffusion, where the hydrophilicity of the matrix plays an important role. At a 
certain point, when the degradation process is taking place, the remaining amount of 
entrapped drug is released accordingly. Therefore, the use of the developed biodegradable 
CHT-ST system, as a vehicle for controlled delivery applications, will allow the degradation 
process to control the rate of drug release from the biodegradable carriers.  
The cell viability studies indicated that the CHT-ST microparticles had a negligible 
effect over SaOs-2 cells. The obtained percentages of cell viability indicated that microparticles 
produced using GA as crosslinking agent, caused a significant decrease in cell viability. 
Therefore, it is highly recommended to use the lowest GA concentrations during the 
microparticles formation. Moreover, the best results were obtained when increasing amounts 
of starch in the blend composition were used. This could be especially observed, when no 
crosslinking is used (chitosan-oxidized starch microparticles). The developed CHT-ST materials 
are clearly suitable to be used as drug delivery vehicles. 
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Chapter 5 
Preparation and characterization of starch-poly-ɛ-caprolactone microparticles 
incorporating bioactive agents for drug delivery and tissue engineering applications 
 
5.1 ABSTRACT 
One limitation associated with the delivery of bioactive agents concerns the short half-life of 
these molecules when administered intravenously, which results in their loss from the desired 
site. Incorporation of bioactive agents into depot vehicles provides a means to increase their 
persistence at the disease site. Major issues are involved in the development of a proper 
carrier system able to deliver the correct drug, at the desired dose, place and time. In this 
work, starch-poly-ɛ-caprolactone (SPCL) microparticles were developed for use in drug delivery 
and tissue engineering (TE) applications. SPCL microparticles were prepared by using an 
emulsion solvent extraction/evaporation technique, which was demonstrated to be a 
successful procedure to obtain particles with a spherical shape (particle size between 5 and 
900 μm) and exhibiting different surface morphologies. Their chemical structure was 
confirmed by Fourier transformed infrared spectroscopy (FTIR). To evaluate the potential of 
the developed microparticles as a drug delivery system, dexamethasone (DEX) was used as 
model drug. DEX, a well known component of osteogenic differentiation media, was entrapped 
into SPCL microparticles at different percentages up to 93%. The encapsulation efficiency was 
found to be dependent on the polymer concentration and drug-to-polymer ratio. The initial 
DEX release seems to be governed mainly by diffusion, and it is expected that the remaining 
DEX will be released when the polymeric matrix starts to degrade. In this work it was 
demonstrated that SPCL microparticles containing DEX can be successfully prepared and that 
these microparticular systems seem to be quite promising for controlled release applications, 
namely as carriers of important differentiation agents in TE. 
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*This chapter is based on the following publication: 
Balmayor, E. R.; Tuzlakoglu, K.; Azevedo, H. S.; Reis, R. L. Preparation and characterization of 
starch-poly-ɛ-caprolactone microparticles incorporating bioactive agents for drug delivery and 
tissue engineering applications. Acta Biomaterialia 2009, 5: 1035-1045.  
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5.2 INTRODUCTION 
Materials of natural origin have been studied and proposed for a wide range of 
biomedical applications [1-4]. Materials such as collagen, alginate, hyaluronic acid, silk fibroin, 
chitosan and starch are among the most studied polymers with numerous advantages 
depending on the specific applications [5-13]. One of the most relevant benefits of using 
materials of natural origin is their biodegradability inside the human body. Biodegradable 
systems have the ability to function satisfactorily for a certain time and subsequently to 
degrade into products easily cleared from the body, with no need for surgery for their 
removal. This is a particularly desirable property for the design of carriers for the controlled 
delivery of therapeutic drugs, since it will permit the entrapped drug to be released slowly, 
allowing repeating dosages and ensuring the successful effect of the treatments [14] as the 
polymer carrier degrades.  
Starch-based polymers have been studied and proposed in the last decade by Reis and 
coworkers [13, 15-21] for several biomedical applications, such as drug delivery carrier 
systems, hydrogels and partially degradable bone cements, materials for bone 
replacement/fixation or fillers for bone defects, and porous structures to be used as scaffolds 
in tissue engineering of bone and cartilage. These materials were found to be biocompatible 
[16, 22, 23], non-cytotoxic, biodegradable [24-27] and have shown a great processing 
versatility [13]. These blended materials have potential application as carriers for the 
controlled release of different bioactive agents in the form of microparticular systems. Indeed, 
biodegradable starch-based microparticles have been widely investigated and proposed as 
drug delivery systems [28-30]. For instance, starch microparticles using soluble potato starch 
have been developed and proposed for the release of a non-steroidal anti-inflammatory drug 
[21]. Moreover, a blend of starch and polylactic acid have been used for the encapsulation of 
steroids, growth factors and bioactive glass in a microparticle system [31-33]. These studies 
showed that the starch-polylactic acid microparticles are suitable carriers for the controlled 
release of bioactive agents for bone tissue engineering applications. In addition, derivatives of 
starch, such as starch acetate or poly(acryl starch), have been described for the incorporation 
and release of peptides and proteins [34-36]. However, to our knowledge there has so far been 
no report in the literature on the development of microparticle systems based on starch-poly-
ɛ-caprolactone blended materials. The combination of a hydrophilic natural material (starch) 
with a hydrophobic synthetic polymer (poly-ɛ-caprolactone), both biodegradable and 
biocompatible, in a single blended material constitutes the major advantage of these 
microparticles. 
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Numerous controlled release systems have been developed, ranging from implants 
[37, 38] to novel osmotically driven pills [38]. The use of non-invasive delivery methods, such 
as injectable systems in the form of nano and microparticles, will bring substantial benefits 
when compared with some surgical techniques. It has already been reported that injectable 
systems made of nano and microparticles could be applied as carriers of different drugs and 
bioactive agents within the field of tissue engineering (e.g. differentiation agents and growth 
factors [39, 40]). Dexamethasone (DEX) has been widely used in clinical applications to treat 
immuno-disorders [41, 42], but a more specific and common use has been the control of the 
inflammatory response and tissue repair during organ transplantation [43]. In the last years, 
the use of this corticosteroid as an osteogenic agent has increased considerably in in vitro cell 
culture to induce the differentiation of stem cells into an osteoblastic lineage [41, 44-46]. 
This study aims to establish experimental conditions for the production of a 
biodegradable and biocompatible microparticular system with different characteristics (e.g. 
size, size distribution, surface morphology) that can be used as a potential carrier for the 
delivery of important bioactive agents. For that, we have used a polymeric blend of starch with 
poly-ɛ-caprolactone. The microparticular system was characterized in terms of particle size, 
size distribution, surface morphology and chemical structure. The carrier potential was 
evaluated by encapsulating DEX into the microparticles and its release behavior studied in 
vitro. 
 
5.3 EXPERIMENTAL 
5.3.1 Materials 
A polymeric blend of corn starch with poly-ɛ-caprolactone (SPCL, 30-70 wt %) was used 
in this study. More details about the thermal properties of this polymeric blend can be found 
elsewhere [47]. Methylene chloride and polyvinyl alcohol (PVA) were obtained from Sigma-
Aldrich (USA), and used as received. Unless otherwise indicated, the molecular weight (MW) of 
the PVA used was in the range 30 000-70 000 g/mol. DEX (97%, cell culture tested, Sigma-
Aldrich, USA) was used as bioactive molecule for the encapsulation studies. Solvents for high-
performance liquid chromatography (HPLC) (acetonitrile and water) were HPLC grade 
(LABSCAN, Ireland). Triamcinolone was used as internal standard for DEX quantification. 
Potassium bromide (KBr) for IR spectroscopy (≥99.5%) was obtained from Sigma-Aldrich (USA). 
Other chemicals were of reagent grade, all from Sigma-Aldrich (USA), and used as received. 
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5.3.2 Preparation of SPCL microparticles 
SPCL microparticles were prepared by using an emulsion solvent 
extraction/evaporation technique [48]. Briefly, SPCL was dissolved in 5 mL of methylene 
chloride under vigorous stirring. This solution was dropped into a 200 mL PVA solution, and 
emulsified for 4 h at different stirring rates. Different experimental conditions were evaluated, 
and the details of each condition are summarized in Table 5.1. The microparticles where then 
collected by filtration, washed with distilled water and vacuum dried in a desiccator. For the 
selected condition to be loaded with DEX, SPCL was mixed with the steroid at different 
percentages (5, 10 and 15% (w/w), relatively to polymer weight) and dissolved in methylene 
chloride. The same procedure was performed as described for unloaded microparticles. The 
reaction medium was stored at 4 
o
C for later quantification of unloaded DEX. All experiments 
were carried out in triplicate.  
 
Table 5.1 Effect of the experimental conditions employed during microparticles production on the size 
and morphology of the resulting microparticles 
Condition 
SPCL
a
 
(%) 
Emulsification medium 
PVA
b
 (%) 
[MW (g/mol)]
c
 
Stirring rate 
(rpm) 
Reaction time 
(h) 
Particle Size 
(μm) 
Shape/ 
Surface
d
 (SEM) 
I 5 1 600 4 102.3±4.1 s/s 
II 5 0.5 600 4 200.4±3.7 s/s 
III 10 0.5 600 4 575.1±4.6 r/p 
IV 10 
1 
[30 000-70 000] 
600 4 499.6±4.8 r/p(HP) 
V 10 
1 
[70 000-100 000] 
600 4 702.1±19.0 r/p(HPD) 
VI 10 1 800 4 283.0±21.0 r/p(HPD) 
VII 10 1 400 4 913.7±9.8 r/p(HPD) 
VIII 10 2 600 4 376.0±3.2 r/p 
IX 10 5 600 4 324.1±15.3 r/p(HPD) 
X 15 1 600 4 770.0±8.7 r/p 
XI 20 1 600 4 810.0±16.2 r/p(HPD) 
XII 10 1 20 000 4 5.73±8.19 s/s 
a
SPCL: polymeric blend of corn starch with poly-ɛ-caprolactone 
b
PVA: polyvinyl alcohol 
c
PVA MW: The molecular weight of the PVA used was in the range 30 000-70 000 g/mol for all the experiments, but in 
the case of the experimental condition V the MW was increased (70 000-100 000 g/mol) for comparison.  
d
s/s: spherical/smooth, r/p: round/porous, HPD: High polidispersity, HP: Highly porous 
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5.3.3 Physicochemical characterization of SPCL microparticles 
5.3.3.1 Morphological analysis: scanning electron microscopy (SEM) and micro-computed 
tomography (μ-CT) 
To analyze the morphology and surface of the microparticles obtained under the 
different experimental conditions, the samples were mounted onto aluminium stubs with a 
carbon tape and gold sputter-coated (Fisons Instruments, Sputter Coater SC502, UK). All 
images were collected with a Leica Cambridge S-360 model (UK) scanning electron microscope.  
Microparticle samples with porous surfaces (experimental condition III, Table 5.1) 
were scanned by micro-computed tomography (μ-CT) using a μ-CT 20 equipment (SCANCO 
Medicals, Switzerland). The energy of the scanner used was 100 kv/ 98 μA intensity. A 
threshold range of values of 141-255 was used to estimate the porosity of the samples. 
Approximately 40 slices of the sample were obtained. Mimics (Materialise, Belgium), CT 
Analyser and CT Vol Realistic 3D Visualization (SkyScan, Belgium) software were used for image 
processing and to create and visualize the three-dimensional representation.  
 
5.3.3.2 Size distribution 
To determine the size distribution of the microparticles obtained under the different 
experimental conditions, the microparticles were separated through a series of standard sieves 
(20, 60, 100, 125, 150, 250, 450, 500, 650, 900 and 1000 μm; Linker Industrie-Technik, 
Germany). The microparticle fraction that passed through a sieve and was retained on the 
sieve with a certain pore size was collected and weighed, and finally correlated with the total 
mass of the microparticles sample analyzed. 
 
5.3.3.3 Fourier transformed infrared spectroscopy (FTIR) 
The chemical structure of the microparticles (unloaded, loaded with DEX and after 
release) was analyzed by fourier transformed infrared spectroscopy (FTIR) (IRPrestige-21 FRIT-
8400S, Shimadzu, Japan) in transmission mode. For that, microparticles (1 mg) were mixed 
with KBr (40 mg) and then formed into a disc in a manual press (161-1100 hand press, PIKE 
Technologies, USA). Transmission spectra were recorded using at least 32 scans with 4 cm
-1
 
resolution, in the spectral range 4000-600 cm
-1
. 
 
5.3.3.4 X-ray diffraction (XRD) 
In order to confirm the encapsulation and release of DEX into and from the SPCL 
microparticles, and to access the physical state of the entrapped drug, X-ray diffraction 
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patterns of DEX and SPCL microparticles (unloaded, loaded with DEX and after the release 
studies) were obtained in a X-ray diffractometer (X’Pert MPD, Philips, The Netherlands). The 
data collection was performed with a Cu anode and monochromator used at a voltage of 
40-kV. The samples were analyzed over the angle range (2θ) 2
o
-60
o
. 
 
5.3.4 Determination of DEX encapsulation efficiency and release profile from SPCL 
microparticles 
5.3.4.1 Encapsulation efficiency 
The encapsulation efficiency (EE) of DEX into the SPCL microparticles was calculated 
using the following equation: 
 ( )[ ] 100/)(% ×−=
−−− DEXiDEXunloadedrDEXi CCCDEXEE    (5.1) 
 
Where Ci is the initial concentration of DEX added, and Cr is the concentration of 
unloaded DEX (remaining in the reaction medium: PVA solution where loaded microparticles 
were produced). DEX concentration was determined by HPLC (please see section 5.3.5). 
Determinations were made in triplicate and the average is reported. 
 
5.3.4.2 In vitro release of DEX from SPLC microparticles 
Pre-weighed SPCL-DEX-loaded microparticles were suspended in 40 mL of phosphate 
buffered saline solution (PBS, pH 7.4, 0.01 M) at a concentration of 2.5 mg/mL. The 
microparticles were maintained at 37 
o
C under constant agitation (50 rpm) for 30 days in a 
shaking bath. At predetermined time points, first each 30 min, then each 1 and 2 h, and 4, 5, 7, 
10, 14, 30 days, 1 mL aliquots of the supernatant were taken and replaced with the same 
volume of fresh PBS solution. DEX concentration was quantified by HPLC. All the release 
experiments were carried out in triplicate and the average is reported.  
 
5.3.5 Quantification of DEX by HPLC 
Before HPLC analysis, samples from the reaction medium were extracted three times 
with a mixture of hexane and ethyl acetate in the same proportions. The final extract was 
collected and the solvent allowed to evaporate under nitrogen flow. The dry extract was 
reconstituted in a mixture of acetonitrile/water (50:50 v/v, mobile phase) before analysis. The 
aliquots from the release medium (PBS solution containing released DEX) were analyzed 
directly as taken.  
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DEX was quantified by reverse-phase (RP) HPLC. HPLC was performed on a Jasco PU-
2080 Plus system using a RP-18 column (LiChrospher, 5 μm, Merck, Germany) with 
acetonitrile/water (50:50 v/v) as mobile phase at a flow rate of 0.5 mL/min. Absorbance was 
monitored at 254 nm (UV detector Jasco 870-UV). The column was eluted in isocratic 
conditions over 20 min. Data acquisition and peak areas were determined with a Shimadzu C-
R6A Chromatopac software. The concentration of DEX was calculated by using a calibration 
curve (y = 8697.18 + (1.65 X 10
7
)x, R
2
= 0.9995). Triamcinolone was used as internal standard.  
 
5.4 RESULTS AND DISCUSSION 
5.4.1 Preparation of SPCL microparticles: evaluation of the effect of different experimental 
conditions on particle size and morphology 
In order to optimize the proposed methodology for the production of SPCL 
microparticles with different morphological characteristics and sizes, several experimental 
conditions were tested (summarized in Table 5.1).  
Four different polymeric (SPCL) concentrations were studied to investigate the effect 
of this parameter on the size and morphology of the microparticles. Figure 5.1 shows the 
morphological characteristics of the SPCL microparticles obtained with different polymeric 
concentrations. The viscosity of the SPCL solution is directly related to the polymeric 
concentration [49]. Consequently, at higher concentrations of SPCL, there is a rather significant 
increase in the viscosity of the solution and, as result, the size of the drops in the 
emulsification medium is higher, which leads to an increase in the microparticle size 
(experimental conditions I, IV, X, XI: Table 5.1). It was found that at polymer concentrations 
higher than 10% the polidispersity increases due to the higher particle size obtained in these 
conditions. It was also observed that at higher polymeric concentrations, the microparticles 
exhibit a porous surface, as shown in Figure 5.2 (b) and (c), when compared with the smooth 
morphology of the microparticles obtained at lower polymer concentration (Figure 5.2 (a)). A 
representative sample (experimental condition IV: Table 5.1) from porous microparticles was 
analyzed by micro-CT scan (Figure 5.3). As result, 44% porosity was obtained, which indicated 
that 10% of polymer concentration is adequate for the production of microparticles with a 
porous structure.  
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Figure 5.1 SEM micrographs of SPCL microparticles obtained under different experimental conditions: 
condition I-SPCL 5% (a), (b) and condition IV-SPCL 10% (c), (d) (Table 5.1) 
 
Figure 5.2 SEM micrographs of the surface of SPCL microparticles showing different morphologies when 
using different polymer concentrations: condition I-SPCL 5% (a), condition IV-SPCL 10% (b), condition XI-
SPCL 20% (c) (Table 5.1) 
 
By means of selecting the polymer concentration in the range of 5-10%, it is possible to 
obtain microparticles with a desired size range (100-600 μm), a narrow size distribution as 
illustrated in Figure 5.4, and different surface morphologies.  
200 μm 50 μm 
500 μm 200 μm 
(a) 
(a) (b) 
(c) (d) 
(b) (c) 
20 μm 20 μm 20 μm 
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The effect of the reaction medium composition was also studied, by the varying the 
concentration of PVA in the emulsification medium from 0.5 to 5%. The use of PVA as an 
emulsion stabilizer results in a quite successful preparation of SPCL microparticles. By 
analyzing the results presented in Table 5.1, it can be observed that the size of the 
microparticles slightly decreases as the PVA concentration increases (experimental conditions 
III, IV, VIII, IX: Table 5.1), but this effect was not as significant as the one observed for the 
polymer concentration. The spherical shape of the microparticles is lost as the concentration 
of PVA becomes higher than 2%, and the surface of the microparticles becomes more porous. 
Analyzing the effect of PVA molecular weight (MW), it was found a noticeable increase in the 
size of the microparticles (experimental conditions IV, V: Table 5.1), when the PVA MW range 
increased from 30 000-70 000 to 70 000-100 000 g/mol. Therefore, a concentration of 0.5 and 
1% of PVA with a MW range 30 000-70 000 g/mol was selected as optimum, avoiding loss of 
spherical shapes, deformation of particles and uncontrolled particle size. 
 
Figure 5.3 Micro-CT three-dimensional reconstruction of the SPCL microparticle illustrating the porosity 
of the obtained particulate structure (experimental condition IV: Table 5.1) 
 
One of the most important factors affecting the microparticle size is the stirring speed 
during their preparation [50]. It has been already shown in the literature [51] that by varying 
the stirring speed from hundreds to thousands of rpm, micro to nanoparticles can be 
produced. In our experiments, we observed that by increasing the stirring rate, the size of the 
microparticles drastically decreased (experimental conditions VII (400 rpm), IV (600 rpm), VI 
(800 rpm) and XII (20 000 rpm): Table 5.1). In fact, an increase in the stirring speeds provides 
higher energy to disperse two immiscible phases (oil in water phase) and form the emulsion, 
_____ 
0.15 mm 
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producing smaller drops of oil phase in the water (because it is breaking the oil phase into 
smaller drops) and as a result smaller particles are obtained. Figure 5.5 shows the 
morphological characteristics and the size of the SPCL microparticles obtained with higher 
stirring speeds. 
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Figure 5.4 Size distribution of the SPCL microparticles (experimental condition I: Table 5.1) 
 
 
Figure 5.5 SEM micrographs of SPCL microparticles obtained at higher stirring speed, at lower (a) and 
higher (b) magnification. Condition XII-20 000 rpm, resulting in a stronger decrease in the size of the 
resulting microparticles 
 
5.4.2 Physicochemical characterization of unloaded SPCL microparticles 
Iodine-potassium solution (Lugol) is a well-known and useful solution for chemically 
identifying the presence of starch molecules [31]. The amylose present in the starch molecule 
5 μm 
(a) (b) 
20 μm 
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has a helical secondary structure [52], where substances such as iodine can lodge, forming a 
complex as an inclusion compound. This starch-iodine forms a coloured complex (dark blue), 
and this property can be used to identify the presence and distribution of starch in complex 
polymeric blends. Staining with Lugol solution was performed for all experimental conditions. 
These experiments revealed the presence of starch in the microparticles, since a dark blue 
staining was observed in all conditions. A more intense staining was observed in the 
microparticles with porous surface. This may due to the diffusion of iodine to the interior of 
the microparticles in this case, while in the microparticles with smooth surface the iodine is 
mainly reacting with the starch molecules present at the surface of the microparticles. 
The infrared spectrum of SPCL microparticles exhibits the same characteristics peaks of 
the raw material before processing (the infrared spectrum of SPCL raw material has been 
described in previous publications [25, 53-55]). The bands from PCL and starch were easily 
identified. The strongest bands and their assignments are summarized in Table 5.2. This 
demonstrates that both components of the blend remained present in the chemical structure 
of the obtained microparticles. 
 
Table 5.2 Characteristics IR bands of the microparticle components (starch and poly-ɛ-caprolactone) [12, 
27] 
cm
-1
 Vibration Abbreviation 
 
2944/2864 
(from PCL) 
Asymmetric/Symmetric CH2 stretching 
 
υas(CH2), υs(CH2) 
1724 C=O stretching υ(C=O) 
1244 Asymmetric COC stretching υas(COC) 
1195 OC-C stretching/Symmetric COC stretching υ(OC-O), υs(COC) 
 
3362 
(from starch) 
OH stretching 
 
υ(OH) 
1021/1048 C-O-C glycosidic bond υ(COC) 
 
5.4.3 Determination of DEX encapsulation efficiency and in vitro release profile 
For the loading of DEX and in vitro release experiments, conditions I-IV (Table 5.1) 
were selected for the preparation of SPCL microparticles. Using these conditions, DEX-loaded 
microparticles were successfully produced. The obtained microparticles exhibited a 
morphology very similar to unloaded microparticles (Figures 5.1 (d) and 5.6 for morphological 
comparison). A more compact surface was found and the particle size slightly increased as 
result of DEX entrapment. The quantification of the DEX, before and after loading, was 
performed by HPLC. 
 
Chapter 5 – Preparation and characterization of starch-poly-ɛ-caprolactone microparticles 
107 
 
Figure 5.6 SEM micrographs of SPCL-DEX-loaded microparticles (experimental condition IV-DEX: Table 
5.3) 
 
5.4.3.1 Encapsulation efficiency 
For the determination of the encapsulation efficiency (EE), the amount of DEX 
remaining in the reaction medium (unloaded DEX) was quantified. Table 5.3 shows the EE 
values as a function of the initial amount of DEX added to the polymer solution. Higher values 
were obtained when 15% of DEX was added. There is a notable increase in the EE values when 
there is an increment from 5 to 10% in the initial DEX amount. However, increasing the initial 
amount of DEX higher than 10%, yielded no significant increase in EE values. Taking these 
results into account, 15% was used as the initial amount of DEX (1:5 drug/polymer ratio) for 
the release studies.  
 
Table 5.3 Effect of the initial amount of DEX on its encapsulation efficiency in the SPCL microparticles 
Condition % SPCL Particles size (μm) Drug/polymer ratio (w/w) Encapsulation efficiency (%) 
IV-DEX 10 525.3±7.9 
1:20 74.99 
1:10 90.72 
1:5 93.65 
 
5.4.3.2 In vitro release of DEX from SPLC microparticles 
Drug release from a polymeric matrix is controlled by a variety of factors, such as the 
solubility of the drug within the surrounding fluid, the size of the drug molecule and its 
mobility within the swollen polymeric network, and the dissolution rate of the polymer and 
polymer-drug interactions. Moreover, several authors have reported that the release kinetic is 
dependent on different characteristics of the microparticles (e.g. type of polymer, particle size 
and size distribution, surface morphology) [56-61], and these features can be controlled by the 
200 μm 
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fabrication conditions. A number of studies in the literature have investigated the effect of 
fabrication conditions (e.g. interconnected pores and channels, emulsification medium 
concentration and polymer concentration) on the morphology of obtained microparticles, drug 
distribution and release kinetics [56-58, 60, 61]. Thus, understanding the influence of 
microparticles characteristics on the release behavior is important for yielding useful products 
that can meet different clinical applications. 
The release profiles of DEX from SPCL microparticles during 30 days in PBS are 
illustrated in Figure 5.7. The release in the first day is shown in more detail in the insert graph. 
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Figure 5.7 In vitro release profiles of DEX from SPCL microparticles in PBS (pH 7.4, 0.01 M), at 37 
o
C and 
50 rpm, for a period of 4 weeks. DEX-loaded SPCL microparticles obtained by the use of different 
polymer concentrations are compared. The insert graph shows the DEX release for a period of 11 h 
 
The initial burst release is attributable to the release of the drug that is present at the 
outermost layer of the microparticles and is released quickly [4, 27, 62, 63]. The burst release 
is then followed by a sustained release stage, which is most likely due to the hydrophobic 
character of poly-ɛ-caprolactone (PCL) polymer present in the microparticles and consequently 
its corresponding low permeability to water. The hydrophobicity of PCL (70% in the blend) can 
cause a delay in water penetration and, consequently, the diffusion of the drug through the 
polymeric matrix into the aqueous release medium was retarded. On the other hand, it is 
necessary to take in consideration that the biodegradation of SPCL in PBS medium is slow [25] 
when compared with other biodegradable polymers. Therefore, at the initial stages, the 
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release of DEX from the SPCL microparticles is mainly controlled by diffusion mechanisms, and 
it is expected that the remaining drug in the polymeric matrix will be released as the 
degradation process becomes more significant.  
When using higher polymer concentrations in the preparation of the microparticles 
(Figure 5.7) the drug release profile shows a more sustained pattern. This may be due to the 
fact that as the SPCL concentration increases, the particle size also increases, leading to a 
decrease in the total surface area of the microparticle system, reducing the area that is in 
direct contact with the water.  
Further evidence of the loading and release of DEX from the SPCL microparticles was 
shown by FTIR analysis (Figure 5.8). The FTIR spectrum of DEX-loaded SPCL microparticles 
(Figure 5.8 (b)) shows the characteristics bands of DEX, indicating the successful loading of the 
drug into the microparticles. After the release studies, it can be observed that there is a 
reduction in the intensity of the characteristic bands of DEX in the IR spectrum (Figure 5.8 (c)), 
due to the partial release of the drug from the microparticles. This result further indicates that 
the DEX present at the outermost layer of the microparticles is released quickly. The release 
profile obtained in this study, with an initial burst stage followed by a sustained release (typical 
of first-order release kinetic systems), is in accordance with the release behavior obtained with 
other delivery systems with similar composition [64]. 
The structure of the entrapped drug is also an important aspect to take into 
consideration in drug delivery systems, since it is known that transitions from an amorphous to 
crystalline structures may occur. These transitions may affect the rate of drug release. For this 
purpose, XRD studies can show the physical nature of the encapsulated material. In Figure 5.9 
XRD diffractograms of DEX, unloaded SPCL microparticles and SPCL microparticles loaded with 
DEX after 30 days of in vitro release are presented. The XRD pattern of DEX shows several 
crystalline peaks, as marked in Figure 5.9 (d). For the DEX-loaded SPCL microparticles it is 
possible to see the appearance of the characteristics peaks from the drug at low 2θ, between 
10
o
 and 20
o
, indicating the crystalline state of the DEX entrapped in the SPCL matrix. The 
maintenance of the crystalline structure may be due to the space available in the polymeric 
matrix (e.g. pore formation). Another confirmation of the in vitro DEX release can be observed 
in Figure 5.9 (c), where the characteristics peaks of DEX are not observed after 30 days in PBS.  
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Figure 5.8 FTIR spectra of DEX and SPCL microparticles: DEX (a), DEX-loaded microparticles (b), DEX-
loaded microparticles after 30 days of in vitro release (c), unloaded SPCL microparticles (d). The 
characteristics bands of DEX are marked (*) 
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Figure 5.9 XRD diffractograms of SPCL microparticles: unloaded (a), loaded with DEX (b), DEX loaded 
microparticles after 30 days of release (c), DEX (d). The characteristics peaks of DEX are marked () 
 
Several research groups are currently developing controlled release systems in the 
context of bone tissue engineering with the main goal of inducing in vitro the osteogenic 
differentiation of stem cells. A common problem associated with some of these systems is still 
in the lack of control over the drug release. Therefore, in this study we propose a very 
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attractive drug delivery system, consisting of SPCL microparticles that can present diverse 
characteristics depending on the experimental conditions used during processing. The 
processing method can be adjusted to obtain particles with different sizes in the micron range, 
as well as with distinct surface morphologies from smooth to porous. Moreover, the 
developed SPCL microparticles were found to be biodegradable, non-cytotoxic and 
biocompatible, as reported in a previous study [27]. The in vitro release studies of DEX, a 
widely used osteogenic agent, showed a sustained release pattern for a period of 30 days, 
indicating that the developed system might be very useful for the induction of osteoblastic 
differentiation of stem cells. 
Further studies will be carried out in order to study the release behavior of DEX or 
other bioactive agents in presence of enzymes in order to investigate the effect of matrix 
degradation on the release kinetics. 
 
5.5 CONCLUSIONS 
In this work the production of polymeric microparticles made from a blend of starch 
with poly-ɛ-caprolactone (SPCL) by means of an emulsion solvent extraction/evaporation 
technique was evaluated. Microparticles with different morphologies (smooth and porous) and 
sizes between 5 and 900 µm could be obtained by using this methodology. Encapsulation of 
DEX into SPCL microparticles was performed with high encapsulation efficiencies, up to 93%. 
The in vitro release studies showed a sustained release pattern for a period of 30 days, 
indicating the carrier potential of SPCL microparticles for the delivery of important bioactive 
agents. The developed system might be very useful in the in vitro culturing of stem cells aimed 
at being committed into the osteoblastic lineage.  
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Chapter 6 
A Novel Enzymatically-Mediated Drug Delivery Carrier for Bone Tissue Engineering 
Applications: Combining Biodegradable Starch-based Microparticles and 
Differentiation Agents 
 
6.1 ABSTRACT 
In many biomedical applications, the performance of biomaterials depends largely on their 
degradation behavior. For instance, in drug delivery applications, the polymeric carrier should 
degrade under physiological conditions slowly releasing the encapsulated drug. The aim of this 
work was, therefore, to develop an enzymatic-mediated degradation carrier system for the 
delivery of differentiation agents to be used in bone tissue engineering applications. For that, a 
polymeric blend of starch with poly-ɛ-caprolactone (SPCL) was used to produce a microparticle 
carrier for the controlled release of dexamethasone (DEX). In order to investigate the effect of 
enzymes on the degradation behavior of the developed system and release profile of the 
encapsulated osteogenic agent (DEX), the microparticles were incubated in phosphate buffer 
solution in the presence of α-amylase and/or lipase enzymes (at physiological concentrations), 
at 37
o
C for different periods of time. The degradation was followed by gravimetric 
measurements, scanning electron microscopy (SEM) and Fourier transformed infrared 
spectroscopy (FTIR) and the release of DEX was monitored by high performance liquid 
chromatography (HPLC). The developed microparticles were shown to be susceptible to 
enzymatic degradation, as observed by an increase in weight loss and porosity with 
degradation time when compared with control samples (incubation in buffer only). For longer 
degradation times, the diameter of the microparticles decreased significantly and a highly 
porous matrix was obtained. The in vitro release studies showed a sustained release pattern 
with 48% of the encapsulated drug being released for a period of 30 days. As the degradation 
proceeds, it is expected that the remaining encapsulated drug will be completely released as a 
consequence of an increasingly permeable matrix and faster diffusion of the drug. 
Cytocompatibility results indicated the possibility of the developed microparticles to be used 
as biomaterial due to their reduced cytotoxic effects. 
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Balmayor, E. R.; Tuzlakoglu, K.; Marques, A. P.; Azevedo, H. S.; Reis, R. L. A Novel Enzymatically-
Mediated Drug Delivery Carrier for Bone Tissue Engineering Applications: Combining 
Biodegradable Starch-based Microparticles and Differentiation Agents. Journal of Materials 
Science-Materials in Medicine 2008, 19 (4): 1617-1623. 
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6.2 INTRODUCTION 
Development of materials in the particulate form has been a subject of great interest 
for several decades. In fact, nowadays polymeric microparticles have been used in several 
applications, including chemical, biological and medical uses [1-4], and more recently in Tissue 
Engineering research [1, 5-7]. Since the early 80’s, the possibility of incorporating different 
drugs and bioactive agents into small polymeric vehicles, was predicted as a promising 
approach for the administration of those agents [1, 8-10]. More recently, the use of 
biodegradable polymers to design controlled drug delivery carriers, having the additional 
advantage of minimizing the need for device removal after the release of the bioactive agent, 
has been reported [9].  
The fact that the degradation process affects, and ultimately controls the rate of drug 
release from biodegradable carriers, controlling the degradation rate of polymeric materials 
has been one of the critical issues in general biomaterials research [11]. A potential 
disadvantage of using biodegradable polymers in biomedical applications is the eventual 
toxicity of the degradation products, which are aimed at being non-toxic leachables and easy 
metabolized molecules [12].  
Biodegradable starch-based polymers have been proposed for several biomedical 
applications such as drug delivery systems [13, 14], bone cements [15] and bone tissue 
engineering scaffolding [16, 17], due to their great processing versatility [17] and to their 
promising properties regarding biodegradability [18] and biocompatibility [12, 19]. 
The aim of this study was to develop an enzymatic-mediated degradation carrier 
system, based on a blend of starch with poly-ɛ-caprolactone in microparticulate form, for the 
controlled release of differentiation agents for bone tissue engineering applications. For this 
purpose, the degradation behavior of the developed system was investigated in presence of 
relevant enzymes and the release of dexamethasone was studied under these conditions. The 
cytotoxicity of the developed system was also assessed by culturing osteoblast-like cells in 
extracts of the materials after increasing incubation periods in cell culture medium.  
 
6.3 EXPERIMENTAL 
6.3.1 Materials 
The studied material was a polymeric blend of corn starch with poly-ɛ-caprolactone 
(SPCL, 30-70 wt%). The material was originally in a granular form. More details on this material 
can be found elsewhere [20]. Dexamethasone (DEX, 97%, cell culture tested, Sigma-Aldrich, 
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USA) was used as a bioactive molecule for the encapsulation studies. Solvents used in HPLC 
analysis were HPLC grade. Other chemicals were of reagent grade and used as received. 
The enzymes selected for this study were α-amylase (EC 3.2.1.1) from Aspergillus 
Oryzae and lipase (EC 3.1.1.3) from Aspergillus Oryzae, both purchased from Sigma-Aldrich 
(USA). 
 
6.3.2. Preparation of SPCL microparticles 
The SPCL microparticles were prepared as previously described [21]. Briefly, SPCL was 
dissolved in methylene chloride under vigorous stirring. This solution was dropped into a 
200-mL polyvinyl alcohol (PVA) solution, and emulsified under agitation (600 rpm) for 4 hours. 
The microparticles were then collected by filtration, washed with distilled water and dried 
under vacuum. For encapsulation of DEX, the drug was directly added to the polymeric 
solution at 15% (wt%, relatively to polymer weight).  
 
6.3.3 In vitro enzymatic degradation study 
The enzymatic degradation of the developed carrier system was investigated by 
incubating the microparticles in a ratio 1:10 with phosphate buffered saline solution (PBS, 
0.01-M, pH 7.4) containing α-amylase (150.5 U/L) and/or lipase (102 U/L), at 37 
o
C and 60 rpm 
up to 12 weeks. To avoid microbial growth, sodium azide (0.02%) was added to the 
degradation solution. As a control, the samples were also incubated in PBS solution without 
enzymes. At the end of the pre-selected degradation times, the supernatants were removed 
and stored at -80 
o
C until further analysis. The microparticles were then thoroughly washed 
with distilled water and allowed to dry at room temperature until constant weight. The final 
weight of the samples was used for the calculation of the weight loss [14]. The supernatant 
solutions were used to determine the concentration of reducing sugars released into the 
solution as a result of starch degradation (hydrolysis of glycosidic linkages in starch molecule 
with the consequent release of soluble oligosaccharides). The amount of reducing sugars was 
estimated by the dinitrosalicylic acid (DNS) method [22]. Experiments were performed in 
triplicate for all the conditions. 
 
6.3.4. Physicochemical characterization 
The changes on the surface morphology of the microparticles after degradation were 
analyzed by Scanning electron microscopy (SEM, Leica Cambridge S-360 model, UK). The 
samples were fixed to the support using a carbon tape and gold sputter-coated (Fisons 
Instruments, Sputter Coater SC502, UK) prior to observation.  
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To assess eventual changes in the chemical composition caused by the degradation 
process, the microparticles were analyzed by Infrared spectroscopy in transmission mode (FTIR 
- IRPrestige-21 FRIT-8400S, Shimadzu, Japan). Pre-weighed microparticles (1 mg) were mixed 
with KBr (40 mg) and then formed into a disc in a press. Transmission spectra were recorded 
using at least 32 scans with 4 cm
-1
 resolution, in the spectral range of 4000-600 cm
-1
. 
 
6.3.5 In vitro release of DEX from SPLC microparticles 
The release of DEX encapsulated in the SPCL microparticles was assessed in PBS only 
and in PBS containing α-amylase and lipase enzymes in order to investigate the effect of 
enzymatic degradation on the release kinetics of DEX. For that, the microparticles were 
suspended in the release solution (2.5 mg/mL). Samples were maintained at 37 
o
C and 50 rpm 
up to 4 weeks. At pre-determined time periods, 1 mL aliquots were taken from the 
supernatant and replaced with the same volume of fresh medium solution. All the release 
experiments were carried out in triplicate. 
Released DEX was quantified by reverse phase high-performance liquid 
chromatography (RP-HPLC). Before chromatographic analysis, samples were extracted three 
times with a mixture of hexane and ethyl acetate in the same proportions. HPLC was 
performed on a Jasco PU-2080 Plus system using a RP-18 column (LiChrospher, 5 μm, Merck, 
Germany) and acetonitrile-water (50:50 v/v) as mobile phase (0.5 mL/min). Absorbance was 
monitored at 254 nm (UV detector, Jasco 870-UV). The column was eluted in isocratic 
conditions over 20 min. Data acquisition and peak areas were determined with the Shimadzu 
C-R6A Chromatopac software. The concentration of DEX was calculated from a calibration 
curve of known DEX concentrations and using triamcinolone as internal standard.  
 
6.3.6 Cytotoxicity evaluation on materials extract 
The cytotoxicity evaluation of the SPCL microparticles, was conducted 
by-the-use-of-MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) test, which is extensively used to quantify the number of viable cells [23, 24]. 
SPCL microparticles were sterilized by ethylene oxide (EtO) using pre-optimized conditions 
[25]. Each sample was incubated in Dulbecco’s Modified Eagle’s Medium without phenol red 
(DMEM, Sigma-Aldrich, USA) (0.5 mg/mL) supplemented with 10% of heat-inactivated fetal 
bovine serum (FBS; Biochrom AG, Germany) and 1% of antibiotic/antimycotic (Gibco, USA), for 
24, 48, and 72 hours at 37 
o
C and 60 rpm, in order to obtain the extract of the materials 
containing potential toxic leachables and degradation products. Latex rubber extract and fresh 
complete culture medium were used respectively as negative and positive controls for cell 
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viability [24]. A Human Osteoblast-like cell (SaOs-2, ECACC, UK) suspension was plated in 96-
well plates, at density of 6.6 X 10
4
 cell/mL, 0.2 mL/well, and incubated at 37 
o
C in a humidified 
atmosphere containing 5% of CO2 for 24 hours to allow about 80% of confluence. After this 
period, the culture medium was replaced by the material extract and the plates were 
incubated for further 24 hours. The MTS test was performed according to the CellTiter 96 One 
Solution Proliferation Assay Kit (Pormega, USA) manufactures instructions and as described 
previously [24]. The absorbance was determined in a microplate reader (EL 312e Biokinetics 
reader, Biotek Instruments, USA) at 490nm. The results are expressed as the percentage (%) of 
cell viability in comparison with the 100% proliferation attributed to the positive control. The 
samples were tested in five replicated, and three independent experiments.  
 
6.3.7 Statistical analysis 
In order to confirm the difference in the rate of release of DEX in PBS only and in PBS 
containing α-amylase and lipase enzymes, the release data was analyzed for statistical 
significant differences. The statistical analysis was performed with the OriginPro® 7.0 (Microcal 
software, USA), fixing the level of significance at p < 0.05. The normality of the data was 
checked by applying the Shapiro-Wilk test implemented by Origin for this purposes. The 
statistical analysis (Student´s t-test for two independent samples) was used to test the two 
different data (DEX release in PBS, and DEX release in enzymatic environment) for the 
hypotheses of the release rate in the presence of enzymes to be significant higher than the 
release rate in PBS alone.  
 
6.4 RESULTS 
The microcarriers used in this work are shown in Figure 6.3 (a) where microparticles 
with round shape, porous surface and diameter of about 400 µm can be observed.  
The degradation behavior of the developed microparticles was studied by incubating 
them in different degradation solutions containing relevant enzymes and their weight loss was 
followed over time (Figure 6.1). It is well known that starch is degraded by α-amylase and that 
PCL hydrolysis can be catalysed by lipase enzymes [11]. An increase in weight loss was 
observed at initial stages of degradation for all conditions, which then remains constant for the 
samples incubated in PBS and α-amylase solution. In the same figure, significant differences in 
the percentage of weight can be observed, depending on the degradation media. The samples 
incubated in presence of enzymes show higher percentages of weight loss, when compared 
with the control (PBS), being this effect more notorious for the degradation solutions 
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containing lipase enzyme. At the end of the degradation period, the SPCL microparticles lost 
approximately 15% of their original weight when incubated in PBS, 45% in presence of 
α-amylase and 70% in the presence of lipase. These results clearly indicate a high degree of 
degradation of the SPCL microparticles in the presence of the enzymes.  
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Figure 6.1 Weight loss of SPCL microparticles after incubation in different degradation solutions at 37 
o
C. 
Error bars are standard deviations (n=3) 
 
In order to estimate the degradation of the starch component of the blend in the 
various degradation conditions, the amount of reducing sugars released in the solutions, as 
result of starch hydrolysis, was measured (Figure 6.2). The supernatants where the SPCL 
microparticles were incubated in the presence of α-amylase showed the highest concentration 
of reducing sugars, whereas a negligible amount of sugars was observed in the control. This 
result confirms the susceptibility of the starch present in the blend to be hydrolyzed by 
α-amylase enzyme at physiological concentrations. In the presence of lipase, the amount of 
detected reducing sugars was very low but a decrease on the solution pH was observed over 
time (from pH 7.4 at day 0 to pH 5.2 at the end of the degradation period). This drop in the 
solution pH is due to the release of carboxylic end groups to the solution as consequence of 
the ester hydrolysis in the PCL chain catalyzed by lipase. 
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Figure 6.2 Concentration of reducing sugars released from SPCL microparticles when incubated in 
different degradation solutions at 37 
o
C. Error bars are standard deviations (n=3) 
 
The extent of the enzymatic degradation is well illustrated in the SEM micrographs 
shown in Figure 6.3. After degradation in lipase-containing solution, the diameter of the SPCL 
microparticles decreased significantly and a highly porous matrix was obtained.  
The chemical changes resulting from the enzymatic degradation of the particles were 
detected by FTIR (Figure 6.4). A decrease of the intensity of the band at 1040-1100 cm
-1
 was 
detected when samples were incubated with α-amylase, indicating the action of the enzyme in 
cleaving the glycosidic linkages of starch. A reduction on the intensity of the PCL ester band at 
1700-1740 cm
-1
 was observed for the samples incubated with lipase, confirming the lipase 
activity in hydrolyzing ester bonds. The differences on the bands of starch and PCL 
demonstrated the degradation of the two components of the material as a consequence of the 
combination of α-amylase and lipase activities. 
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Figure 6.3 SEM micrographs of SPCL microparticles before (a) and after degradation for 90 days in PBS 
(b), α-amylase (c), lipase (d), α-amylase and lipase (e) solutions 
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Figure 6.4 FTIR spectra of SPCL microparticles before (a) and after degradation in presence of α-amylase 
(b), lipase (c), and α-amylase and lipase (d) solutions 
 
The release profile of DEX from SPCL microparticles for a period of 4 weeks, in PBS and 
in presence of enzymes (α-amylase+lipase) is illustrated in Figure 6.5. As a general observation, 
the release profiles are characterized by two main stages: the initial burst release, mainly 
during the first day where more than 20% of the drug was released, and a sustained release of 
almost 45% of the DEX at the end of a 4 weeks period. The release profile obtained in an 
enzymatic environment showed a higher amount of the released DEX into the medium. The 
statistical analysis of the data reveals no significant differences between the two release 
conditions (PBS and enzymatic environment) for the first 3 hours (p values (0.70) > 0.05). For 
time periods up to this time (more than 3 hours) and until the end of the release study, the 
statistical calculations confirm the hypothesis, at the 0.05 level, the release rate of DEX in the 
presences of enzymes is significantly greater than the release in PBS alone (p values (0.018) < 
0.05). A confidence interval of 95% was fixed for all the calculations.  
The MTS results depicted in Figure 6.6 showed that 48% of the cells remained viable 
when incubated with the extracts from the SPCL microparticles and the extraction time did not 
show any influence on the cytotoxicity results. The percentage of cell viability may be related 
with the presence of residual solvent, used during the preparation of the microparticles, that 
might be released to the extract solution and causing cell death. Additional washing steps will 
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be included in the microparticle’s preparation to ensure complete removal of solvents or other 
toxic reagents. 
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Figure 6.5 Release profiles of dexamethasone from SPCL microparticles in PBS and in presence of 
enzymatic activity at 37
o
C for a period of 4 weeks. The insert graph shows the DEX release for a period 
of 24 hours. The release rate of DEX in the presence of enzymes is significantly greater than the release 
in PBS alone, for time periods longer than 3 hours (p < 0.05). Error bars are standard deviations (n=3) 
 
6.5 DISCUSSION 
Polymeric biomaterials when exposed to body fluids or placed in contact with tissues, 
may undergo several physicochemical changes as result of the most diverse interactions with 
the surrounding environment [1, 2, 11]. The degradation tests performed in this study showed 
a higher degradation rate when α-amylase and lipase are present in the degradation solution. 
The samples incubated with lipase enzyme completely lost their spherical shape at the end of 
degradation period. The degradation products in the presence of α-amylase are mainly sugars 
resulting from the cleavage of the glycosidic bonds in the starch structure. On the other hand, 
lipase acts in the polyester component in the blend, at a specific position on the ester bond of 
the macromolecule. As result of the degradation process, carboxylic acid units are released to 
the solution, which explain the observed decrease of the pH. The combination of the two 
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enzymes resulted in higher values of weight loss and reducing sugars in solution, indicating the 
degradation of both components of the blend.  
The SEM analysis confirmed the results discussed above. The appearance of porosity, 
cavities and fractures, and the decrease on the diameter of the SPCL microparticles as result of 
degradation process, was more notorious in the presence of lipase and of both enzymes.  
There are two main ways for a drug to be released from a polymeric carrier [26]: i) 
diffusion through the polymer, which depend on the ability of the aqueous environment to 
penetrate the drug-containing polymer, inducing the swelling of the matrix and consequently 
the release of the entrapped drug ; ii) degradation of the material containing the drug, by 
water, enzymes and acidic or basic conditions . In this case, the drug starts to be released by 
diffusion until a gradual degradation of the polymer takes place thus controlling the release 
process. The remaining drug in the polymeric matrix is released as the degradation process 
becomes more significant. For the developed DEX loaded SPCL microparticles, the initial burst 
effect was clearly observed in both studied environments, associated with the fast release of 
the drug located close to the surface of the particles, mainly by the diffusion phenomena. This 
burst was followed by a period of minimal release due to the hydrophobicity of PCL (major 
component of the blend: 70%), which causes a barrier for water penetration and consequently 
preventing the diffusion of the drug through the polymer matrix. At this stage, the drug was 
released faster from the sample in presence of enzymes, indicating that the enzymatic 
degradation of the SPCL microparticles increases the release rate of the entrapped DEX. These 
results indicate that the release of DEX from the SPCL microparticles is firstly controlled by 
diffusion and then by the degradation of the polymeric matrix. The dependence of the drug 
release with the degradation of the system along the time makes the SPCL microparticulate 
system more adequate for sustained rather than controlled drug release. 
The main concern of biodegradable polymers when proposed for biomedical 
applications, is the potential toxicity of their leachables and degradation products. The slightly 
cytotoxicity of the developed system for osteoblast-like cells, may be due to the presence of 
residual solvent. Previous studies [12] have attributed similar results to components added 
and or formed during the processing.  
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Figure 6.6 Optical density of the MTS solutions after incubation with SaOs-2 grown for 24 hours in the 
presence of SPCL microparticles extracts obtained in culture medium for 24, 48 and 72 hours. 
Percentages of viable cells, compared to positive control, are presented 
 
6.6 CONCLUSIONS 
Considering the overall results obtained in this study, it is expected that the developed 
SPCL microparticulate system is a suitable carrier for the sustained release of drugs, with the 
advantage of being susceptible to enzymatic degradation, thus being ultimately digested in the 
body, avoiding the surgical removal. These results are indicative of the potential of the 
developed system to be used in the controlled release of growth and differentiation factors 
with relevance in the field of bone regeneration.  
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Chapter 7 
Biodegradable microparticles deliver bioactive Dexamethasone and BMP2 for bone 
tissue engineering 
 
7.1 ABSTRACT 
We have established earlier, a method to produce starch-poly-ɛ-caprolactone (SPCL) 
microparticles as biodegradable carriers for the controlled release of dexamethasone (DEX). 
The present study aims to investigate the potential of the previously developed system to 
support the delivery of bone morphogenetic protein-2 (BMP-2). The system was characterized 
regarding morphology and size distribution. BMP-2 encapsulation efficiency as well as the in 
vitro release profile was evaluated by ELISA. BMP-2 was rapidly released during the first 12 
hours, followed by a more sustained release for up to 10 days. The osteogenic activity of DEX 
and BMP-2, after incorporation and during release was evaluated using a myoblast cell line 
(C2C12). Alkaline phosphatase (ALP) activity was increased by released BMP-2. Alizarin red and 
von Kossa and staining were used to evaluate mineralization by adherent cells in culture upon 
stimulation with BMP-2 loaded microparticles, which showed the presence of calcium 
deposits. A luciferase assay, for osteocalcin promotor activity, showed high levels of activity in 
C2C12 cells treated with the BMP-2 loaded microparticles. In contrast, no evidence of 
osteogenesis in C2C12 cells was observed after exposure to DEX loaded microparticles. 
However, human adipose stem cells exposed to these microparticles were characterized by 
high values of ALP. The results clearly demonstrate that SPCL microparticles are suitable 
carriers for the incorporation and controlled release of glucocorticoids and growth factors with 
relevance in bone related applications. 
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7.2 INTRODUCTION 
In general, bone possesses a good healing capacity and the majority of bone defects 
are spontaneously cured. This requires, however, optimal biological and micro-environmental 
conditions. Treatment of complex fractures and other bone defects caused by high energy 
trauma, disease, developmental deformity, revision surgery, and tumor resection, have been 
improved due to advances in surgical techniques, orthopedic implant and peri-operative 
management [1-6]. However, detrimental wound healing circumstances (e.g. co-morbidities 
like diabetes mellitus, infections, improper vascular supply etc.), sub-optimal surgical 
techniques or biomechanical instability can result in impaired healing capacity (e.g. non-
unions, large remaining bone gaps) [7]. Such defects create major surgical and socio-
economical challenges [8]. Tissue engineering (TE) has emerged as a possible new alternative 
to traditional medical technology, improving treatments for human diseases and disorders. TE 
is a technology based on the development of biological substitutes for repair, reconstruction, 
regeneration, or replacement of tissues during illness or malfunction [9]. TE involves the 
culture of living cells, using a support material (e.g. scaffold) in combination with biologically 
active molecules (e.g. growth factors [GFs]) [10]. To be successful, a three-dimensional 
supporting biomaterial (construct) is typically required which must be biocompatible, 
preferably biodegradable, with the ability of entrapping and releasing bioactive molecules 
capable of stimulating cellular growth, proliferation and differentiation into specialized cell 
types [11]. 
GFs are naturally occurring proteins capable of stimulating cellular proliferation, 
migration, and/or differentiation into a specialized phenotype [12, 13]. During the 
differentiation process of stem cells, various hormones and cytokines regulate osteoblast 
differentiation. Among these, bone morphogenetic proteins (BMPs) are probably the most 
important GFs involved [14-16]. BMPs are local factors that upregulate Cbfa1 expression, an 
important transcription factor that influences bone development [17, 18]. BMPs regulate 
osteogenesis at two different levels: (1) the commitment of skeletal progenitor cells and (2) 
the maturation of osteoblasts in postnatal development [18]. BMPs, and more specifically 
BMP-2, have potent effects in inducing osteoblast differentiation of different cell sources [19-
23]. In conjunction with GFs, certain cell-permeable small molecules have shown to control cell 
proliferation and to induce the differentiation of various stem cells [24]. One example is 
dexamethasone (DEX), which in combination with ascorbic acid and β-glycerophosphate, 
promotes osteogenesis under defined conditions [24-26]. Several studies have demonstrated 
that DEX can induce terminally differentiated osteoblasts [27-29]. The intimate interaction 
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between those bioactive molecules plays a crucial role in osteoblast differentiation and bone 
formation. 
Although direct application of these bioactive molecules can be beneficial, repeated 
administration and high doses are often required due to their short half-lives (i.e. 7 to 16 
minutes for BMP-2 (INFUSE product) and 10-15 hours for BMP-7 (Osigraft STRYKER)) [30]. 
Simultaneously, the difficulty of the proper delivery to the specific injury site, causes the need 
of controlled delivery techniques that will ensure constant levels of BMP-2 at the desired site 
for an extended time period. Osteo-inducing factors, such as BMP-2, are needed to be 
delivered to the site of interest in the suitable concentration. Therefore, their sustained 
delivery at the site of injury should prolong the bioavailability of these molecules, and 
therefore, the duration of their therapeutic action. This constitutes an important challenge 
nowadays for the development of delivery systems for BMP-2. For instance, BMP-2 is currently 
administered clinically using collagen. But, large amounts of BMP-2 are needed in order to 
overcome the instability due to its short half life. BMP-2 remains around 8 days in the collagen 
carrier. Thus, the possibility of developing biodegradable microparticles capable of releasing 
bioactive BMP-2 in a sustained manner, for longer periods, is highly interesting and has been 
widely investigated. In this study, we developed and tested a novel injectable drug delivery 
system consisting of starch-poly-є-caprolactone microparticles for induction of osteogenesis 
aiming to decrease the amounts of GF used in clinical application. Proper delivery requires 
controlled release techniques that will ensure constant levels of osteogenic factors at the site 
of interest at adequate concentrations over an appropriate time period. 
Therefore, this study aims to investigate (1) whether biodegradable starch-poly-є-
caprolactone (SPCL) microparticles can serve as a carrier for controlled release of BMP-2 and 
DEX; and if this hypothesis is confirmed, (2) whether the entrapped drugs, i.e., DEX and BMP-2, 
remain bioactive during encapsulation and upon release; and (3) whether the released DEX 
and BMP-2 are equally active concerning osteogenesis in an osteo/myo-blast cell line (C2C12). 
 
7.3 EXPERIMENTAL 
In order to answer the formulated questions, DEX and BMP-2 were first encapsulated 
in SPCL microparticles. Subsequently, the encapsulation efficiency and the release kinetics 
were investigated in vitro. Furthermore, the cytotoxicity of the microparticles per se was 
determined. Secondly, the bioactivity of the released molecules was investigated in cell culture 
experiments. For this, a bone precursor cell line was used in order to observe the osteogenic 
activity of the system. As DEX was not able to induce osteogenesis in the osteoprecursor cell 
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line, its osteogenic potential was tested in mesenchymal stem cells derived from adipose 
tissue.  
 
7.3.1 Preparation of BMP-2 loaded SPCL microparticles 
A biodegradable microparticulated system made of a polymeric blend of starch and 
poly-є-caprolactone (SPCL, 30–70 wt %) [31] containing DEX was produced as described 
previously [32, 33]. In this study, BMP-2 (Recombinant human BMP-2, > 95%, R&D systems, 
USA) was loaded in the SPCL microparticles using an emulsion solvent extraction/evaporation 
technique [32, 34]. Briefly, 0.25 g SPCL was dissolved in 5 mL methylene chloride (Sigma-
Aldrich, USA) under vigorous stirring. This solution was dropped into a 200 mL polyvinyl 
alcohol solution (0.5% v/v, molecular weight: 30-000–70 000 g/mol; Sigma-Aldrich, USA) and 
emulsified at a speed of 600 rpm for 4 hours at room temperature to evaporate/extract the 
organic solvent, providing structural integrity to the microparticles. For the microparticles to 
be loaded with BMP-2, a co-encapsulation process was performed using bovine serum albumin 
(BSA) (≥ 96%; Sigma-Aldrich, USA). BSA protects bioactive molecules such as growth factors 
and peptides, from inactivation [35-37], e.g., as a result of exposure to harsh organic solvents. 
BSA (200 mg) and BMP-2 (10 µg) were mixed and added to the SPCL solution just before 
addition to the stirring polyvinyl alcohol emulsification medium. At the end of BSA and BMP-2 
loading, the reaction medium was collected and stored at 4 °C for quantification of unloaded 
proteins (please see section 7.3.3). The microparticles were thoroughly washed with distilled 
water and freeze-dried. The encapsulation efficiency was determined by establishing a relation 
between the amounts of BMP-2 and BSA remaining in the reaction medium (unloaded) after 
loading and the initial amount available for incorporation [32, 38]. 
 
7.3.2 Characterization of BMP-2 loaded SPCL microparticles: scanning electron microscopy 
(SEM) and size distribution 
A fraction of BMP-2 loaded microparticles was collected and separated through a 
series of standard sieves (60–450 μm; Linker Industrie-Technik GmbH, Germany) to determine 
their size distribution. Particles with a size in the range of 100 to 150 μm were selected to 
study the in vitro release of BMP-2 and its effect on cells. Unloaded SPCL microparticles and 
loaded with BSA alone were also produced to be used as controls. These unloaded SPCL 
microparticles had an average size distribution of 102.3±4.1 µm [32].  
To examine the surface morphology, shape, and size of the obtained microparticles, 
scanning electron microscopy (SEM; Leica Cambridge S-360 model, UK) was performed. Dry 
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samples were mounted onto aluminum stubs, gold sputter-coated (Fisons Instruments, UK), 
and viewed at magnifications of 150X and 400X. 
 
7.3.3 In vitro release of entrapped BMP-2 
The release of BMP-2 from the loaded SPCL microparticles was assessed in vitro. For 
that purpose, 150 mg BMP-2 loaded microparticles were suspended in 5 mL 0.01 M phosphate 
buffered saline (PBS; pH 7.4) solution. All the samples were maintained at 37 °C in an orbital 
shaker under constant agitation at 100 rpm. At predetermined time points, up to 10 days, 1 mL 
aliquots of the supernatant were taken and replaced with the same volume of fresh PBS 
solution. Collected supernatants were then stored at −80 °C for BMP-2 quantification. 
Released BMP-2 was quantified by enzyme-linked immunosorbent assay (ELISA) (Human 
BMP-2 Quantikine® ELISA Kit, R&D Systems, USA) according to the manufacturer’s instructions. 
 
7.3.4 Effect of unloaded SPCL microparticles on C2C12 cell viability 
A mouse skeletal osteo/myoblast cell line (C2C12) obtained from the German 
Collection of Microorganisms and Cell Cultures DSMZ-ACC565 (Germany) was cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose (Lonza, Switzerland), 
supplemented with 5% heat inactivated fetal calf serum (FCS) (Lonza, Switzerland) and 
2-mmol/L L-glutamine (Lonza, Switzerland).  
Before use in cell culture experiments, the microparticles (unloaded and loaded) were 
sterilized by ethylene oxide using preoptimized conditions as described by Reis et al. [39]. 
 
7.3.4.1 Cell viability 
Cell viability was determined by bringing C2C12 cells in contact with unloaded SPCL 
microparticles. A standard 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) assay was used. The MTS test was performed according to 
the manufacturer’s instructions (Promega, USA) and modified using protocols previously 
described [40, 41]. Briefly, C2C12 cells were plated in 24-well plates at 0.5 x 10
5
 cells/mL 
(1-mL/well) and incubated at 37 °C in a humidified environment containing 5% CO2 for 24 
hours. Subsequently, the culture medium was replaced by DMEM supplemented with a 
suspension of the SPCL microparticles (1 mg/mL). After 1, 3, and 7 days, the supernatants 
(containing the particles) were removed. Cells were incubated with 200 µL MTS reagent 
solution (5:1 ratio in serum-free DMEM culture medium without phenol red) per well at 37 °C 
in a humidified environment containing 5% CO2 for 3 hours. From each well, 100 µL medium 
was transferred to a 96-well plate and the absorbance at 490 nm was measured in a 
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microplate reader (BioTek Instruments, USA). The results are expressed as the percentage of 
cell viability in comparison to the 100% viability attributed to the complete DMEM culture 
medium control (positive control). 
 
7.3.5 Effects of BMP-2 and DEX loaded SPCL microparticles on osteogenesis 
This study was focused on evaluating the effect of DEX and BMP-2 loaded 
microparticles on the cells for their potential to induce osteogenesis. For that, different assays 
were performed namely: Osteocalcin (OCN) promotor activity, alkaline phosphatase (ALP) 
activity and specific staining assays for the detection of mineralized matrix. 
 
7.3.5.1 Osteocalcin (OCN) promotor activation assay 
To determine osteocalcin (OCN) (indirectly via promotor activity), a well known gene 
expressed during late osteogenesis, C2C12 cells were identically plated in 24-well plates 
following the same procedure described above (please see section 7.3.4.1) for 24 hours. 
Subsequently, the cells were transfected by a standard lipofectamine transient transfection, 
using a vector expressing the OCN promotor driving a luciferase reporter gene. Reporter 
vector DNA (1 µg) together with lipofectamine (2 µg; Invitrogen, Germany) was used per well. 
The DNA was mixed with the lipofectamine transfection agent under serum-free conditions 
following the manufacturer’s instructions. The cells were incubated with the transfection 
solution at 37 °C in a humidified atmosphere containing 5% CO2 in DMEM containing 5% FCS 
for 4 hours. After transfection, the FCS content was reduced to 1% and the medium was 
supplemented with 50-µmol/L ascorbic acid and 10 mmol/L β-glycerophosphate (osteogenic 
differentiation medium). The cells were further cultivated for 24 hours at 37 °C in a humidified 
atmosphere containing 5% CO2. Finally, the culture medium was changed with the different 
samples to be tested. Two different samples were used for this assay: (samples 1) collected 
supernatants from the BMP-2 and DEX in vitro release study (release time points: 1, 5 and 10 
days) and (samples 2) a suspension of BMP-2 and DEX loaded microparticles in osteogenic 
differentiation medium. For the first mentioned samples (samples 1), aliquots of 1 mL 
(supernatants) were collected from the in vitro release studies and stored (−80 °C) until 
analyzed. The collected aliquots were freeze dried and resuspended for stimulating the cells 
using the same volume of osteogenic differentiation medium to maintain the released 
concentrations for each time point selected (DEX: 4, 9 and 10.5 mg/mL after 1, 5 and 10 days 
respectively [32]). When the samples were placed in direct contact with the cells (samples 2), 
the amounts of microparticles used ranged from 1 to 10 mg per mL of osteogenic DMEM 
culture medium. As controls, BMP-2 (100 ng/mL), BMP-2/BSA (at a ratio of 1:20 000; 100 ng of 
Chapter 7 – Starch-poly-ɛ-caprolactone microparticles deliver dexamethasone & BMP-2 for bone TE 
138 
BMP-2 and 2 mg of BSA per mL) and DEX (10
-8
 M) solutions were used. Additionally, transwell 
experiments were carried out in parallel. This experiment aims to evaluate any differences on 
cell behavior as a result of direct/indirect contact of the microparticles over the cells. In this 
case, 10 mg/mL loaded particles were added to the transwell inserts, ensuring that the cells 
were only exposed to soluble factors released from the particles. For this purpose, 12-mm 
Transwell
®
 inserts (0.4-µm pore size; Corning, USA) were used. The cells were then cultured for 
5 days without any medium change. At the end of the 5 days, the activation of the OCN 
promotor was measured using luminescence imaging (Xenogen, USA) upon administration of 
luciferin. The amount of photons was measured and established a relative measure of OCN 
promotor activity. The cell monolayer was washed twice with PBS without calcium (Lonza, 
Switzerland) and stored at −80 °C with 100 µL PBS for further alkaline phosphatase (ALP) assay. 
 
7.3.5.2 Alkaline phosphatase assay (ALP) 
The effect of the released molecules and loaded microparticles on the activity of 
alkaline phosphatase (ALP), a marker expressed by the cells in a more osteoblast-differentiated 
stage, was evaluated in C2C12 after 5 days of culture using a p-nitrophenol (pNP) assay [42]. 
Briefly, cells were lysed by osmotic (0.25% Triton X-100™ solution in PBS) and heat shock. 
Subsequently, 50 µL substrate solution was added per well (containing p-nitrophenyl 
phosphate disodium salt) for 30 minutes at room temperature. The optical density was 
determined at 405 nm in a microplate reader and the activity of ALP calculated according to a 
standard curve. The standard curve was constructed using pNP solutions of known 
concentrations.  
In addition to the use of C2C12 cells, DEX samples (collected supernatants from the 
DEX release study and DEX loaded microparticles) were also tested in human adipose-derived 
stem cells (ASCs) for ALP activity to determine DEX bioactivity per se in primary stem cells. For 
these experiments, human-ASCs were obtained from three different donors from the Blood 
Bank of the upper Austrian Red Cross (Austria). 
 
7.3.5.3 Mineralization assay 
Mineralized matrix and calcium deposition were assessed as an indication of 
osteogenic differentiation. C2C12 cells were seeded at a density of 0.5 x 10
4 
cell/mL 
(1-mL/well) using osteogenic differentiation medium supplemented with the DEX and BMP-2 
loaded microparticles up to 14 days. After different time points (3, 7, 14 days), the supernatant 
was removed and the cells were washed twice with PBS solution (without calcium and 
magnesium) and fixed with 4% formaldehyde solution in PBS. Von Kossa staining was 
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performed to visualize the presence of mineralized deposits. Briefly, fixed cells were incubated 
with 5% silver nitrate solution for 30 minutes at room temperature. After cells have been 
washed several times with distilled water, staining was developed using 5% sodium carbonate 
solution in 25% formaldehyde followed by the a 5% sodium thiosulfate solution in distilled 
water. After washing the cells with water, the staining was observed by phase-contrast 
microscopy (Zeiss, Germany). Alizarin red staining was performed for examination of calcium 
deposition. Briefly, the fixed cells were incubated for 5 minutes in a 0.05% alizarin red solution 
in PBS at room temperature. The stained cells were washed with distilled water before 
microscopic observation.  
As controls, C2C12 cells were seeded using plain osteogenic differentiation medium 
(without microparticles) and medium supplemented with the unloaded microparticles. 
 
7.3.6 Statistical analysis 
All the experiments were independently performed three times. Each experiment 
employed three replicates for each condition, sample tested or different time points. Thus, 9 
separate measurements were taken into account for each single condition. All the obtained 
values are reported as mean value ± standard deviation.  
The statistical analysis was performed with OriginPro
®
 7.0 (Microcal software, 
OriginLab, USA). Normal distribution of the data was analysed by applying the Shapiro-Wilk 
test implemented by Origin for this purposes. Differences in averaged size of the 
microparticles between DEX and BMP-2 loaded microparticles were determined using the 
Student´s t-test for two independent samples. The same statistical analysis was performed to 
determine differences for encapsulation efficiency between BSA and BMP-2 during BSA/BMP-2 
co-encapsulation process; and for OCN (quantified luminescence levels) and ALP activity 
between DEX and BMP-2 loaded microparticles incubated with C2C12. 
 
7.4 RESULTS 
7.4.1 BMP-2 loaded SPCL microparticles 
The first goal of the study was to test whether SPCL microparticles are suitable as 
delivery carrier for the controlled release of BMP-2 and DEX. SPCL microparticles with spherical 
shapes and smooth surfaces, as confirmed by SEM observations, could be produced (Figure 7.1 
(a)). DEX and BMP-2 loaded SPCL microparticles exhibited a surface morphology similar to the 
unloaded ones (Figure 7.1 (c) and (d)). The microparticles loaded with DEX (p = 0.0070) and 
BMP-2 (p= 0.0007) were larger in size than the unloaded SPLC microparticles (102.3 ± 4.1 µm 
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[32]). Furthermore, the DEX loaded microparticles had a larger (p = 0.0113) average size than 
the BMP-2 loaded ones (Figure 7.1 (b)).  
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Figure 7.1 Starch-poly-ε-caprolactone (SPCL) microparticles characterized by spherical shapes and 
smooth surfaces. SEM micrographs of unloaded microparticles (a). Size distribution of the DEX and 
BMP-2 loaded SPCL microparticles: Pair of values statistically compared is indicated in the graph with 
the correspondent p value (0.0113) (b). SEM micrographs of DEX loaded (c) and BMP-2 loaded (d) SPCL 
microparticles (inserted micrographs at lower magnification, 150X, for general observation)  
 
The encapsulation efficiency (EE) values for BSA and BMP-2 during the co-
encapsulation process were relatively low and very similar each, 27.02±3.4 % and 24.86±0.7 %, 
respectively (p = 0.3418). The in vitro release studies indicated the presence of a burst release 
during the first 12 hours, which continued up to 2 days (Figure 7.2). After this period, a plateau 
was reached and maintained until the end of the release period. After 10 days, more than 60% 
of the entrapped BMP-2 was released. Incubating C2C12 cells with the SPCL microparticles 
maintained cell viability up to 87% (Figure 7.3).  
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Figure 7.2 BMP-2 released from SPCL microparticles during a 10 days period. The in vitro release profiles 
of BMP-2 is shown after incubation of the loaded particles in PBS medium, as quantified by ELISA assay. 
The open circles correspond to the SPCL unloaded microparticles used as control sample for this 
experiment. The insert graph shows the BMP-2 release for a period of 1 day (burst release) 
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Figure 7.3 Cell viability of C2C12 cells upon exposure to SPCL microparticles as determined by the MTS 
test. The indicated values refer to the cell viability percentage compared to the values obtained for the 
cells cultivated in DMEM (used as control), which were set at 100% at each respective time point. Values 
are mean ± standard deviation (n=3). Pairs of values statistically compared are indicated in the graph 
with the correspondent p values 
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7.4.2. Bioactivity of entrapped/released DEX and BMP-2 in/from SPCL microparticles: 
Osteogenesis 
Released BMP-2 was bioactive as shown by activation of the osteocalcin promotor in 
C2C12 cells. Administration of BMP-2 loaded particles increased (p = 0.0112) expression of 
OCN promotor activity as determined by luminescence measurements (Figure 7.4 (a)). The 
levels of luminescence for the supernatants collected after 10 days of BMP-2 in vitro release 
(85.4±1.6 ng/mL BMP-2 released) were similar (p = 0.2771) to the ones obtained for the BMP-2 
control solution (100 ng/mL). These values were lower (p = 0.0019) than those obtained for 
the cells incubated directly with the BMP-2 loaded microparticles. However, increasing the 
concentration of incubated BMP-2 loaded microparticles did not further enhance (p = 0.5552) 
OCN promotor activity. On the other hand, neither DEX samples nor DEX control solution 
induced the expression of the OCN promotor in the C2C12 cells (Figure 7.4 (b)). The 
luminescence levels of DEX related samples were even lower (p = 0.0104) than the values for 
DMEM culture media used as negative control for this assay. In addition, the levels of 
luminescence quantified for DEX loaded microparticles were very similar (p = 0.1231) to those 
obtained when transwell experiments were performed. Thus, indicating no influence on the 
DEX action as result of indirect/direct contact of the loaded microparticles over the cells. 
Finally, it was shown that BMP-2 is more bioactive than DEX in C2C12 cells. DEX was 
bioactive as shown by the possibility to induce osteogenic differentiation in ASC. ALP activity of 
C2C12 cells increased upon incubation with BMP-2 loaded microparticles (Figure 7.5). It can be 
observed higher levels of ALP activity for cells treated with BMP-2 loaded microparticles than 
for cells treated with the DEX loaded microparticles (p = 0.000002) and unloaded 
microparticles (p = 0.000001). In addition, it was found that the ALP activity in C2C12 cells 
treated with SPCL unloaded microparticles was similar (p = 0.2409) to the levels in DMEM 
culture media. Similarly, no change in ALP activity was obtained when the cells were treated 
with BMP-2 compared to BSA/BMP-2 control solutions (p = 0.4135). This suggests that the 
increase in ALP levels results, solely, from the release of bioactive BMP-2 from the SPCL 
microparticles. Furthermore, this is an indication that BSA did not interfere with the 
osteogenic potential of BMP-2.  
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Figure 7.4 OCN promotor activity as determined by luciferase activity in C2C12 cells after administration 
of: BMP-2 (a) or DEX (b). Controls include culture medium only (DMEM), BSA/BMP-2 (2 mg/100 ng per 
mL), BMP-2 (100 ng/mL) or DEX (10
-8
 M) solutions. Samples include supernatants from the in vitro 
release of BMP-2 and DEX after 1, 5 and 10 days, and BMP-2 and DEX loaded microparticles incubated 
directly with the cells (5 mg/mL and 10 mg/mL). In addition, transwell experiments using DEX loaded 
microparticles (10 mg/mL) are represented for comparison. Values are mean ± standard deviation (n=3). 
Each pair of values compared are indicated: (*) when compared to DMEM control, (**) to BMP-2 or DEX 
control solutions and ( ¯ ) when a comparison was established between the tested samples 
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Figure 7.5 Alkaline Phosphatase activity in C2C12 cells as determined using pNP assay. Controls include 
unloaded SPCL microparticles (SPCL MP), BSA/BMP-2 (2 mg/ 100 ng per mL), and BMP-2 (100 ng/mL) 
solutions or DEX (10
-8
 M) solution. Samples include BMP-2 and DEX loaded microparticles incubated 
directly with the cells (1-10 mg/mL). Values are mean ± standard deviation (n=3). Each pair of values 
compared are indicated: (*) when compared to SPCL unloaded microparticles, (**) to DMEM control 
and ( ¯ ) when a comparison was established between a pair of controls or samples ALP values 
 
von Kossa staining demonstrated the presence of mineralization nodules in C2C12 
treated with BMP-2 loaded microparticles (Figure 7.6 (b), (c), (d)). Similarly, alizarin red 
staining for calcium deposits revealed a higher staining intensity of C2C12 cells that where 
incubated with BMP-2 loaded microparticles compared to both SPCL unloaded microparticles 
and DMEM culture medium alone (Figure 7.6 (e), (f), (g)). Furthermore, the intensity of von 
Kossa and alizarin red stained zones increased with culture time. Moreover, staining was more 
intense with increasing concentrations of BMP-2 loaded microparticles. In contrast, no 
mineralization nodules or calcium deposits were detected for C2C12 treated with DEX loaded 
microparticles. This is in agreement with the observation that C2C12 cells incubated with DEX 
released supernatants, DEX loaded microparticles, and DEX control solutions do not exhibit 
activation of the OCN promotor (Figure 7.4 (b)) or ALP activity (Figure 7.5). However, when 
ASCs were used, DEX was bioactive as shown by a significant increase of ALP activity (p = 
0.000004) upon incubation of DEX loaded microparticles with these cells (Figure 7.7). 
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Figure 7.6 Photomicrographs illustrate mineralization and calcium deposits of C2C12 cells upon 
incubation with BMP-2 loaded microparticles stained with von Kossa (3 days (b), 7 days (c) and 14 days 
of culture(d)) and Alizarin red (3 days (e), 7 days (f) and 14 days of culture (g)). Control cells (a): Bar = 50 
µm. Staining zones of mineralization nodules (after 3 days of culture) and mineral deposition (from 14 
days of culture further) are indicated with white arrows. Similarly, the presence of calcium, indicated 
with black arrows, can be observed as early as at 3 days of culture. The inserts images show a general 
view of the well 
 
Overall, the obtained results indicated the occurrence of osteogenesis in C2C12 cells as 
result of bioactive BMP-2 released from SPCL microparticles. Furthermore, DEX was found to 
be not suitable as an osteogenic agent for C2C12 cells, but could induce osteogenesis in ASCs. 
Both encapsulated drugs (DEX and BMP-2) remained bioactive upon encapsulation and after 
release in/from the SPCL microparticles. 
 
7.5 DISCUSSION 
Clinically, high doses of BMP-2 are needed to exert its effects in non-union tibial 
fractures or anterior fusion of the lumbar spine that can be detrimental by inducing 
hyperostosis or heterotopic ossification. Currently, BMP-2 is applied using a bovine collagen 
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sponge that can only be introduced to the defect using an open surgery and may elicit immune 
reactions. Hence, the presented study aimed to develop and characterize a novel injectable 
drug delivery system for BMP-2 by using SPCL microparticles. Therefore, three main aspects 
have been addressed during this study to provide answers to the initially formulated 
questions. Thus, whether biodegradable SPCL microparticles can serve as a carrier for 
controlled release of BMP-2 and DEX; whether the entrapped drugs, i.e., DEX and BMP-2, 
remain bioactive during encapsulation and upon release; and whether the released DEX and 
BMP-2 are equally active concerning osteogenesis in an osteo/myo-blast cell line (C2C12). 
BMP-2 was successfully encapsulated in the SPCL microparticles. However, the 
obtained encapsulation efficiency (EE) value was low ( ≅ 25%). Nevertheless, the released 
BMP-2 showed satisfactory levels of bioactivity. Therefore, it can be stated that this limitation 
of low EE does not jeopardize the functionality of the developed delivery system. Indeed, our 
value of EE for BMP-2 is lower than some other values reported in the literature for GFs [36, 
43, 44]. However, many of the reported encapsulation methods include the use of high 
temperatures and toxic organic solvents without using a carrier protein to protect the GFs. As 
a result, high values of EE are obtained, but the bioactivity of the GFs is in many cases 
compromised. Therefore, we used co-encapsulation method with BSA as carrier protein. 
Moreover, all the processing and encapsulation was performed at room temperature. 
Although this had resulted in lower encapsulation efficiency, the bioactivity of the GFs was 
preserved. Therefore, this method was shown to be more efficient, needing less GF for 
encapsulation purposes. In this study, a starch-poly-ε-caprolactone blend was chosen to 
encapsulate DEX and BMP-2 because of their known biocompatibility [37, 40, 45] and proven 
biodegradability [33, 46, 47]. Moreover, the combination of a hydrophilic natural material 
(starch) with a hydrophobic synthetic polymer (polycaprolactone), in a single material 
constitutes the major advantage of this system. Therefore, these loaded SPCL microparticles 
should result in an optimal biodegradable carrier to induce osteogenesis for bone TE. In a 
previous study [33], it was investigated the release of DEX from the SPCL microparticles in PBS 
and enzymatically controlled environments. The release mechanism was characterized by 
diffusion phenomena and at late stages by degradation of the microparticles. As a 
consequence, the biodegradation of the polymeric matrix controlled the overall DEX release 
process. The initial burst release observed for BMP-2 in the present work and previously for 
DEX [32, 33] can be explained as a result of drug entrapment in the proximity of the 
microparticles’ surface. Subsequently, the BMP-2 loaded SPCL microparticles start to take up 
water from the aqueous environment, with the consequent swelling of the polymeric matrix 
and diffusion of the BMP-2 through the polymer into the medium [48, 49]. As a result of poly-
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є-caprolactone (PCL) hydrophobicity, the release of BMP-2 from the SPCL microparticles is 
sustained from 2 up to 10 days. This is an evident advantage of this carrier system, being able 
to maintain bioactivity and newly BMP-2 being released up to 10 days. The pronounced burst 
release has been considered a drawback for several control delivery systems [50, 51]. 
However, for osteogenesis, at early stages high concentrations of BMP-2 are needed. 
Subsequently, more constant and sustained release is desired. The possibility of more 
sustained release of BMP-2 for longer time periods represent the most important benefit 
when compared with other delivery systems that have been proposed for BMP-2 [43, 52]. 
Thus, in this particular case, this system may be advantageous for bone TE. 
Indeed, BMP-2 loaded microparticles were able to induce osteogenesis in C2C12 cells 
and did not show any cytotoxicity. Moreover, the bioactivity of the released BMP-2 was 
confirmed since transfected C2C12 showed activation of the OCN promotor as measured by 
luminescence intensity. Activation of the OCN promotor is indicative of late-stage osteogenic 
differentiation [53]. This induction was maximal, as increasing concentration of BMP-2 loaded 
microparticles did not change activity, showing a plateau in luminescence intensity. This means 
that the BMP-2 induced a maximal cellular response. The BMP-2 receptor is maximally 
activated due to binding of the BMP-2 and thus no further increase in OCN activity can be 
found. BMP-2 receptor I and II activity is mainly regulated by downstream signal transduction 
molecules such as smad1, 5 and 8 all of them phosphorylate smad4. Interactions with RunX2 
are possible [54]. This indicates that the concentration of BMP-2 is enough to exert the 
maximal biological effect.  
The results were corroborated by ALP determinations, an early osteogenic marker. It is 
well known that BMP-2 can upregulate ALP activity [55]. Similar differentiation behavior was 
observed by the two different assays. Histology results confirmed highly bioactive BMP-2 was 
released from the SPCL microparticles, inducing mineralization including calcium deposition. As 
this activity is exerted via an ALP independent pathway, it can be concluded that the released 
BMP-2 exerts maximal effects as also mineralization is induced [56]. Thus, the BMP-2 loaded 
microparticles and the BMP-2 released from the microparticles were bioactive and able to 
induce osteogenesis and maturation. These are two distinct processes known from BMP-2 
action as has also been shown in primary myoblasts using BMP-2 gene therapy [57]. In 
contrast, DEX loaded microparticles were not able to induce osteogenesis, as indicated by 
absent ALP activity and OCN promotor activation. Interestingly, the same results were 
obtained with control solutions of plain DEX (without being encapsulated). Thus, the inactivity 
of the DEX samples was not a result of the encapsulation or inefficient in vitro release, but 
rather dependent on the cell type used (C2C12 cells). It has been shown that glucocorticoids, 
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among them DEX, inhibit proliferation and differentiation capacity in C2C12 cells [58, 59] but 
not in other cell types. This was confirmed by the ability of DEX loaded microparticles to 
induce osteogenesis in ASCs in contrast to C2C12, as observed by increased values of ALP.  
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Figure 7.7 Alkaline Phosphatase activity in human Adipose Derived Stem Cells (ASCs) incubated with DEX 
loaded microparticles as determined using pNP assay. Controls include unloaded SPCL microparticles 
(SPCL MP) and DEX (10
-8
 M) solution. Samples include DEX loaded microparticles incubated directly with 
the cells (1-10 mg/mL). Values are mean ± standard deviation (n=3). Pairs of values statistically 
compared are indicated (*) in the graph with the correspondent p value (p=0.4x10
-5
) 
 
This result indicated the DEX loaded SPCL microparticles were capable of stimulating 
the development of an osteogenic phenotype in human ASCs by releasing bioactive DEX. Thus, 
DEX may not be suitable to induce osteogenesis in the C2C12 cell line as it has been described 
previously [58, 59]. However, ASCs are more clinically relevant in the context of bone TE. 
Therefore, this line of investigation will be of continued interest in the future. Especially, as 
DEX is not a protein, it will elicit fewer immunologic reactions. Furthermore, the production of 
DEX is cheaper than that of BMP-2. However, DEX also contains the drawbacks of 
glucocorticoids. Therefore, careful investigations are necessary to evaluate its clinical 
suitability. 
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This study investigated the potential of a biodegradable microparticle system 
combined with bioactive molecules to induce osteogenesis. Although the encapsulation 
efficiency was low for BMP-2, the bioactivity was well preserved upon its release using the 
encapsulation method proposed in this study (co-encapsulation). DEX was encapsulated with 
high encapsulation efficiency values and was bioactive in ASCs while inducing osteogenesis. 
Our data suggest the biodegradability and biocompatibility of starch-based materials, as well 
as defined release profiles of encapsulated drugs, may allow their successful use as devices for 
the controlled/sustained delivery of bioactive molecules in bone TE. Especially, our device 
bears the advantage of requiring lower concentrations of BMP-2 and allowing a sustained 
release over longer periods of time than the currently available commercial products. 
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Chapter 8 
Synthesis, surface functionalization and characterization of superparamagnetic 
poly-ɛ-caprolactone microparticles 
 
8.1 ABSTRACT 
Nowadays, there has been a growing interest on developing strategies for cell isolation using 
magnetic functionalized particles. The basic instrumentation only requires a set of magnets 
and it has been described by different authors as a very effective technique. The most 
important factors in this process are the type of magnetic particles and the used ligand. In this 
study, we have successfully fabricated amino and epoxy surface functionalized magnetic 
microparticles by using poly-ɛ-caprolactone as coating material. Particles with size in the range 
of 4-135 µm, spherical shape and about 13% (wt) of magnetite entrapped inside a 
poly-ɛ-caprolactone shell were synthesized. The obtained core-shell microparticles 
demonstrated a superparamagnetic behavior. The superparamagnetic microparticles were in 
addition surface functionalized with amino and epoxy groups allowing for the incorporation of 
target ligands. Activation by O2 plasma treatment followed by epichlorohydrin reaction was 
proposed in order to functionalize the particles surface with epoxy groups. To the best of our 
knowledge, this study constitutes the first report on the application of this process on 
polymeric particulated systems. Furthermore, we have demonstrated the efficiency of the 
developed particles for bovine serum albumin (BSA) covalent coupling (covalent efficiency 
higher than 47% for epoxy and 71% for amino funcionalized particles). A protein coupling 
protocol for the developed functionalized magnetic microparticles was optimized and it is 
presented in this work. pH range on the vicinity of the isolectric point of the used ligand and 
lower ion concentrations buffers have shown to be two very important parameters on the 
performance of the particles. Moreover, when carbodiimide was used for NH2-m-PCL 
microparticles surface activation, the most favorable pH was in the optimal range for this 
reaction to occur. Finally, a good cell response, in terms of both viability and proliferation, was 
observed by the use of osteoblastic cell line. Furthermore, characteristic cell morphology and 
good proliferation resulted from the contact of the amino functionalized particles with human 
derived adipose stem cells. The overall research described herein may lead to further studies 
on the synthesis, surface functionalization and characterization of highly biocompatible 
superparamagnetic microparticles and consequent innovative applications. Furthermore, it 
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may help to attain a better understanding of the intricate relationship between the material 
surface functionality and the protein adsorption phenomena. Thus, predicting their behavior 
and improving the efficiency in forming a highly stable functional particle-protein biocomplex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This chapter is based on the following publication: 
Balmayor, E. R.; Pashkuleva, I.; Rada, T.; Gomes, M. E.; Azevedo, H. S.; Reis, R. L. Synthesis, 
surface functionalization and characterization of superparamagnetic poly-ɛ-caprolactone 
microparticles. 2009. Submitted. 
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8.2 INTRODUCTION 
Superparamagnetic nano- and microparticles have attracted much attention in the last 
decades due to their extensive applications in the biotechnology and medicine fields. The 
combination of their properties, such as size, shape, morphology, superparamagnetic behavior 
and ability for surface functionalization, provides a unique potential for further development 
in biomedical applications. Immunomagnetic separation of enzymes [1-5], proteins [5-7], and 
cells [8-10] or detection of specific targets in clinical diagnosis [10-13] by magnetic particles are 
only a few of the examples of their broad application. In addition, they are key components in 
medical diagnostics [14-16]. However, remaining challenges in particles development is the 
design and processing of highly specific materials tailored for a certain applications. 
Magnetite nanoparticles are defined as iron (II, III) oxide (Fe3O4) particles with average 
size in the nano-scale and presenting superparamagnetic features. Thus, the particles exhibit 
magnetic behavior only when placed within a magnetic field, showing no residual magnetism 
when the field is removed [15]. Usually, the particles are handled as a suspension or fluid. The 
magnetite suspension can be used as it is or the particles can be further coated with organic or 
inorganic compounds. Lately, polymeric materials have been used for this purpose [9, 17-21]. 
They present several advantages as coating material: like processing versatility allowing for 
controlled hydrophilicity/hydrophobicity, reactive surfaces, tailored degradation and low 
toxicity, among others. In this paper we have chosen poly-ɛ-caprolactone (PCL) as an example 
of an aliphatic polyester widely used in biomedical applications. It has been demonstrated that 
it is biodegradable [22-24] and biocompatible [23-25]. Moreover, this semicrystalline polymer 
can be easily processed by a variety of techniques [26] and its surface is easily functionalized 
[27, 28]. Core-shell polymeric particles containing a magnetic core (magnetite) entrapped 
inside a polymeric shell (PCL) were successfully developed and the procedure is described in 
this article. Functionalization of the surface targeting specific binding of antigens or antibodies, 
enzymes, proteins and cells can be further performed. Amino, epoxy and carboxy functional 
groups are some of the well known surface functionalities that favor covalent binding 
capabilities of the target ligands [5, 9]. Covalent binding is highly desired because it provides 
more stable material-biomolecule complexes. Furthermore, it avoids nonspecific reactions 
between the material surface and the target biomolecule and hence it directs the coupling 
reaction [29, 30]. 
The experimental procedure employing functionalized magnetic particles is quite 
simple (Figure 8.1). When added to a heterogeneous cell suspension, the particles will bind the 
targeted entities based on the specific interactions, such as covalent coupling [31, 32] or 
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electrostatic interactions between the material surface and the cell or biomolecule [33, 34]. 
The resulting complex can be removed from the suspension by placing the system within a 
magnetic field gradient because of the particles superparamagnetic behavior. 
 
 
Figure 8.1 Schematic representation of surface functionalized magnetic particles (A) and the principle of 
cell isolation using these particles (B) 
 
When developing magnetic particles intended to be used for cell isolation, several 
features needed to be carefully addressed: For instance, the size of the beads should be in the 
range of 5-50 µm with narrow size distribution, adequate hydrophobicity and surface 
functionalization [8]. This work presents the development of superparamagnetic poly-ɛ-
caprolactone microparticles with tailored characteristics for isolation of cells. 
Superparamagnetic m-PCL microparticles with different size, surface area, iron contents and 
surface chemistry (-NH2 and epoxy) were obtained and their capacity to covalent bind protein-
like ligands was analyzed. It was found that the protein adsorption can be significantly 
improved by the alternate surface functionalization. To the best of our knowledge this is the 
first research work that reports development of a set of different poly-ɛ-caprolactone core-
shell superparamagnetic microparticles with tailored surface functionalities for protein-like 
covalent binding. Moreover, we were also able to enhance both cell viability and proliferation 
to the developed microparticles. 
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8.3 EXPERIMENTAL 
8.3.1 Materials 
For the magnetite nanoparticles preparation, ferrous chloride tetrahydrate 
(FeCl2.4H2O; ≥ 98%) was purchased from Fluka (Switzerland). Ferric chloride hexahydrate 
(FeCl3.6H2O; 99%) and ammonium hydroxide solution (30-33% in water) were obtained from 
Riedel-de Haën (Germany). Oleic acid (99%) was purchased from Sigma-Aldrich (USA).  
Poly-ε-caprolactone (ToneTM PCL-787, average molecular weight 125 KDa, reported by 
the manufacturer) was obtained from Union Carbide Chemicals and Plastics Division (USA) and 
was used for the core-shell microparticles preparation. Dichloromethane (99.5%, stabilized 
with amylene) was purchased from Panreac (Spain) and polyvinyl alcohol (PVA, 87-90% 
hydrolyzed, average molecular weight 30 000-70 000) from Sigma-Aldrich (USA). For surface 
functionalization, 1,6-hexanediamine (98%) and epichlorohydrin (ECH, ≥ 99%) both purchased 
from Sigma-Aldrich (USA), were used. 
Bovine serum albumin (BSA, ≥96%) and N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (commercial grade), both purchased from Sigma-Aldrich 
(USA), were used for the binding experiments. Fluorescein 5-(6)-isothiocyanate (≥ 90%) 
obtained from Fluka (Switzerland) was used to label BSA protein. All the reagents were used as 
received. 
 
8.3.2 Magnetite nanoparticles synthesis 
The superparamagnetic magnetite nanoparticles were prepared by a co-precipitation 
method using iron chloride salts (Fe2+/Fe3+) as iron source [17-19, 35]. FeCl3.6H2O (1.80 M) and 
FeCl2.4H2O (1.20 M) were dissolved in distilled water previously degassed by bubbling N2 for 30 
minutes. Under a N2 atmosphere and vigorous mechanical stirring, the mixture was heated to 
80 oC. Subsequently, 40 mL of ammonium hydroxide solution (25% in water) were rapidly 
added, maintaining the reaction conditions for the following 30 minutes. In order to minimize 
the oxidation of the formed magnetite (Fe3O4) to ferromagnetic oxides (Fe2O3), the oxygen 
content of the precipitation medium was stabilized at the lowest level by continuous N2 
bubbling. After precipitation of magnetite particles, 15 mL of oleic acid was added dropwise 
(within a 10 minutes period). The mixture was heated for 30 minutes. At this time, the color of 
the mixture changed to a deep black lump indicating the formation of the magnetite particles. 
The precipitate was separated and then extensively washed using a mixture of distilled water 
and acetone (1:1, v:v). As a result of the external magnetic field, the particles were attracted 
Chapter 8 –Superparamagnetic poly-ɛ-caprolactone microparticles 
158 
towards the magnet within a few minutes allowing to discard the supernatants after each 
washing step. A homogeneous and fine black precipitate was obtained that was further dried 
in a vacuum desiccator at room temperature for 24 hours. 
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Figure 8.2 Synthesis of magnetite nanoparticles A). Magnetite stabilized by the interaction of the polar 
ends of the oleic acid molecules with the magnetite nanoparticles B) 
 
8.3.3 m-PCL core-shell microparticles preparation 
Core-shell magnetic poly-ε-caprolactone microparticles (m-PCL) were prepared by an 
emulsion solvent extraction/evaporation method [36], in which magnetite nanoparticles were 
included inside the polymeric shell. Briefly, PCL was dissolved in 5 mL of dichloromethane 
under vigorous stirring. After complete dissolution of the polymer, the magnetite 
nanoparticles were added. The mixture was sonicated for 10 minutes at 100 W using an 
ultrasonic bath “Ultrasons 3001208” (J.P.Selecta, Spain), to ensure a good dispersion of the 
magnetite nanoparticles in the polymeric solution. Subsequently, the suspension was dropped 
into a continuously stirred PVA medium (100 mL), and emulsified for 4 hours at different 
stirring rates using the dispersing device “Ultra-Turrax Yellow line DI 18 basic”, (IKA Werke 
GmbH & Co. KG, Germany). Different experimental conditions, such as magnetite to polymer 
ratio, PVA concentration and stirring rate were used (Table 8.1). The m-PCL microparticles 
were then collected by magnetic decantation, washed with distilled water and lyophilized to 
obtain a fine brownish powder. 
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Figure 8.3 Core-shell m-PCL microparticles formation 
 
8.3.4 Surface functionalization of the m-PCL core-shell microparticles 
8.3.4.1 Amino groups: aminolysis of m-PCL microparticles [37] 
Dried m-PCL microparticles were immersed in a 1,6-hexanediamine/2-propanol 
solution. The microparticles were chemically functionalized at two different temperatures (25 
and 37 oC) for a time period varying from 30 to 90 minutes, maintaining the reaction vessel 
under constant agitation (100 rpm). The effect of several reaction conditions on the 
microparticles functionalization was investigated and the obtained results are presented in 
Table 8.2. At the end of each treatment period, the amino functionalized m-PCL (NH2-m-PCL) 
microparticles were collected by magnetic decantation, and extensively dialyzed using 
deionized distilled water to remove the free 1,6-hexanediamine. Finally, NH2-m-PCL 
microparticles were dried in a vacuum desiccator at room temperature until constant weight. 
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Table 8.1 Experimental conditions used for the production of m-PCL microparticles and their effect on 
the particle size, magnetite content and magnetic properties for the obtained samples 
Samples 
Magnetite 
/polymer ratio 
PVA 
(%) 
Stirring rate 
(rpm) 
Particle Size 
(µm) ± S.D. 
Magnetite 
content
a
 (%) 
Ms/300K 
(emu/g) 
mr 
/300K 
m-PCL 1 0.005 
1 
11 000 
 
93.7 ± 8.3 0.59 3.8 0.2849 
m-PCL 2 0.05 97.4 ± 10.3 4.19 4.2 0.2530 
m-PCL 3 0.10 107.0 ± 9.2 10.34 4 0.3103 
m-PCL 4 0.15 134.1 ± 7.5 13.13 4.6 0.3007 
m-PCL 5 
0.10 
0.5 112.0 ± 4.8 
n.a. n.a. 
m-PCL 6 1 97.2 ± 11.0 
m-PCL 7 2 82.6 ± 8.3 
m-PCL 8 
1 
11 000 104.0 ± 5.2 
m-PCL 9 20 000 52.1 ± 6.9 
m-PCL 10 24 000 4.2 ± 2.1 
aDetermined by Thermogravimetric analysis (TGA) 
Ms: Saturation magnetization 
mr: Magnetic remanence 
 
 
Table 8.2 NH2 density (ninhydrin assay) as a function of the conditions employed for surface 
functionalization of m-PCL microparticles 
Samples 
Aminolysis time 
(min) 
1,6-hexanediamine 
(%) 
Aminolysis temperature 
(
o
C) 
NH2 density 
(X10
-7
 mol/mg) 
m-PCL - - - 0.007 ± 0.19 
NH2-m-PCL 1 30 10 37 5.59 ± 0.43 
NH2-m-PCL 2
a
 60 10 37 6.27 ± 0.33 
NH2-m-PCL 3 90 10 37 5.54 ± 0.56 
NH2-m-PCL 4 60 2 37 3.69 ± 0.40 
NH2-m-PCL 5 60 5 37 4.06 ± 0.27 
NH2-m-PCL 6 60 20 37 4.08 ± 0.59 
NH2-m-PCL 7 60 10 25 5.84 ± 0.83 
aNH2-m-PCL microparticles with the highest amount of NH2 surface groups, thus selected for BSA adsorption 
experiments 
 
8.3.4.2 Epoxide groups: cold plasma and epichlorohydrin reaction 
Epoxide groups were introduced on the surface of the m-PCL microparticles by using 
an adapted methodology, earlier proposed by Larson et al. [38] for oxide surfaces of films. The 
procedure is based on the use of a plasma activation step followed by chemical reaction. Both 
plasma activation and chemical functionalization were carried out in a radio frequency plasma 
reactor “PlasmaPrep5” (Gala Instruments, Germany). 
Before the experiments, the plasma chamber was thoroughly purged with a 
continuous flow of the gas (O2) used during the treatment to reduce trace amounts of air and 
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moisture. The m-PCL microparticles were exposed to oxygen plasma to activate the surface by 
peroxy and hydroxyl functional groups. The gas flow (O2) was adjusted in order to keep a 
constant pressure of 0.18 mbar inside the chamber. A power of 90 W was applied. The 
duration of the surface activation was 2 min. Subsequently, vapors of epichlorohydrin (ECH) 
were introduced inside the chamber (vapor pressure 21.1 oC at 13.8 mmHg) and allowed to 
react with the particles for 30 minutes (Figure 8.4). 
The epoxy functionalized m-PCL (epoxy-m-PCL) microparticles were then stored under 
dry controlled conditions, using a vacuum desiccator to preserve their full surface activity. 
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Figure 8.4 Reaction mechanism for epoxy surface functionalization of the core-shell m-PCL 
microparticles 
 
8.3.5 Physicochemical characterization of magnetite nanoparticles and m-PCL core-shell 
microparticles 
8.3.5.1 Morphological analysis: optical light transmission (OLT) and scanning electron 
microscopy (SEM) 
To investigate the morphology, shape and stability of the magnetite nanoparticles and 
m-PCL microparticles, a sample suspension (5 mg/mL in distilled water) was mounted onto a 
glass slide and observed in an optical microscope with polarized light source (Olympus BH2, 
Japan). The analyzed sample was photographed using a high-resolution Leica camera for image 
acquisition (Leica Microsystems GmbH, Germany). 
m-PCL microparticles were also analyzed by scanning electron microscopy (SEM), in 
order to characterize the surface morphology, shape and size. Dry m-PCL microparticles were 
mounted onto metal stubs with a carbon tape and then gold sputter-coated (Sputter Coater 
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SC502, Fisons Instruments, UK). Images were taken using a scanning electron microscope 
(Leica Cambridge S-360, UK). 
 
8.3.5.2 Size distribution: standard sieves meshes and dynamic light scattering (DLS) 
Particle size and size distribution for the magnetite were analyzed by dynamic light 
scattering (DLS) (Nano ZS ZEN3600, Malvern Instruments, UK). For the sample preparation, 
1-mg of dried magnetite nanoparticles was resuspended in a mixture of glycerol and ultrapure 
distilled water (1:1, v:v). 
The size distribution of the m-PCL microparticles obtained at different experimental 
conditions was determined through a separation process using series of standard sieves (20, 
60, 100, 125, 150, 250 μm: Linker Industrie-Technik GmbH, Germany). Each fraction was 
weighed out and correlated with the total mass of the analyzed microparticle sample. 
 
8.3.5.3 Fourier transformed infrared spectroscopy (FTIR) 
The chemical structure of the obtained particles was analyzed by fourier transformed 
infrared spectroscopy (FTIR) (IRPrestige-21, Shimadzu, Japan) in the transmission mode. Equal 
amounts of each sample (magnetite nanoparticles, PCL microparticles, and m-PCL 
microparticles) were mixed with KBr and then pressed into pellets. Transmission spectra were 
recorded using 32 scans with 4 cm-1 resolution, in the spectral range 4000-600 cm-1. 
 
8.3.5.4 X-ray diffraction analysis (XRD) 
The identification of the magnetite into the m-PCL microparticles, as well as the 
analysis of the obtained magnetite chemical structure was investigated by X-ray diffraction 
(XRD). X-ray diffraction patterns of magnetite nanoparticles, PCL microparticles (control 
sample without magnetite content) and m-PCL core-shell microparticles were determined in 
an X-ray diffractometer (Philips Analytical X’Pert MPD, The Netherlands). The data collection 
was performed using Cu2+ as anode material and monochromator used at a voltage of 40 kV. 
The samples were analyzed at an angle range (2θ) of 2-60o. Magnetite phases were identified 
by matching the diffraction peaks to the Joint Committee on Powder Diffraction Standars 
(JCPDS) files.  
 
8.3.5.5 Thermogravimetric analysis (TGA) 
The magnetite content entrapped inside the polymeric shell was determined using a 
thermogravimetric analyzer (TGA) (Q500, TA Instruments, USA). Dried samples (magnetite 
nanoparticles, PCL microparticles (without magnetite content) and m-PCL core-shell 
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microparticles) were analyzed in closed alumina cups in a temperature range 30-700oC. The 
used heating rate was 10oC/minute. All the experiments were carried out in a nitrogen 
atmosphere.  
 
8.3.5.6 Superparamagnetic properties: vibrational magnetometry (VSM) 
A vibrating sample magnetometer (VSM, LakeShore, USA) was used to study the 
magnetic properties of the obtained particles. Two different temperatures were used for 
sample analysis (5 and 300 oK). The applied magnetic field was varied from 60 000 to 
−60-000-Oe. Values of saturation magnetization (Ms) and remanence magnetization (Mr) as 
well as coercive field (Hc) and saturation field (Hs) are reported. 
 
8.3.6 Surface Characterization 
8.3.6.1 Detection of amino groups: ninhydrin assay 
To confirm and quantify the presence of amine groups on the surface of the 
functionalized m-PCL microparticles, ninhydrin colorimetric assay was used [27, 39, 40]. Briefly, 
10-mg of sample was immersed in 5 mL of 1.0 M solution of ninhydrin in ethanol for 1 minute. 
The container was then heated at 80 oC for 5 minutes to accelerate the reaction of the 
ninhydrin with the amino groups present on the surface of the microparticles. After discarding 
the suppernatant and allowing the complete evaporation of the ethanol, 5 mL of 1,4-dioxane 
was added to dissolve the microparticles. After complete dissolution of the sample, 5 mL of 
isopropanol were added to stabilize the formed blue compound. The sample was filtered to 
remove the insoluble magnetite material, and the absorbance of the final solution was 
measured at 570 nm. For quantification purposes, a calibration curve was prepared using 
solutions of known concentration of 1,6-hexanediamine in a mixture of 1,4-dioxane/ 
isopropanol (1:1, v:v). 
 
8.3.6.2 X-ray photoelectron spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) analysis was performed (ESCALAB 250iXL” 
spectroscope, VG Scientific, UK) with PISCES software for data acquisition and analysis. XPS 
measurements were carried out using a monochromatic Al (Kα) radiation (1486.92 eV). 
Photoelectrons were collected from a take-off angle of 90o relative to the sample surface. The 
measurement was performed in constant analyzer energy mode (CAE) with 100 eV for survey 
spectra and 20 eV for high-resolution spectra. Charge referencing was carried out by setting 
the lower binding energy C 1s photopeak at 285.0 eV. The chemical functional groups identity 
was obtained from the high-resolution peak analysis of carbon-1s (C1s) and oxygen-1s (O1s). 
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Overlapping peaks were resolved into their individual components using XPSPEAK 4.1 
software. For sample preparation, a suspension of dried microparticles was prepared in 
ethanol and dripped onto a silicon wafer surface. After the complete ethanol evaporation, the 
sample was introduced in the XPS pre-chamber for the measurements.  
 
8.3.7 BSA binding experiments 
Bovine serum albumin (BSA) was selected as a model protein to study the binding 
ability of the functionalized m-PCL microparticles. For the NH2-m-PCL microparticles, a typical 
carbodiimide (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, EDC) 
activation-coupling experiment was carried out [41]. Briefly, 10 mg of dried NH2-m-PCL 
microparticles were resuspended in 0.05 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer 
followed by the addition of a freshly prepared EDC solution (40 mg/mL in 0.05 M MES). The 
suspension was carefully mixed for 15 minutes at room temperature. Subsequently, BSA 
dissolved in MES buffer was added. The suspension was mixed on an orbital shaker for two 
different time periods (5 hours and overnight) and at two different temperatures (25 and 
37-oC). After this time, the supernatants were collected to determine protein concentrations. 
The microparticles were washed and resuspended in MES buffer and stored at 4 oC for further 
analysis. When epoxy-m-PCL microparticles were used, the particles were washed in MES 
buffer and subsequently mixed with BSA solutions, without previous activation of the surface 
of the microparticles. The experimental procedure was identical to the previously described 
for NH2-m-PCL microparticles.  
The effect of several experimental parameters on the covalent binding of BSA to the 
surface functionalized microparticles was studied. The pH was varied in the range of 3.5-7 
(MES buffer, 0.05 M). The influence of the ionic strength was investigated by adding different 
concentrations of NaCl (0.1, 0.5 and 1.5 M) to the buffer solution. In all experiments, BSA 
concentration in the supernatant was measured at 280 nm in UV spectrophotometer. 
To investigate the efficiency of protein covalent binding to the surface groups of the 
m-PCL functionalized microparticles, the protein-microparticles complexes were immersed in 
buffer medium containing 1% Tween 20, which removes only the physically coupled 
(adsorbed) protein [42, 43]. After elution, the released BSA was measured at 280 nm.  
 
8.3.7.1 Confocal laser scanning microscopy (CLSM) 
In order to visualize the BSA covalently bound to the surface of functionalized 
microparticles, confocal laser scanning microscopy (CLSM) (Olympus IX81, Japan) was 
performed. BSA was labeled with fluorescein isothiocyanate (FITC) prior the binding 
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experiments [44]. Briefly, FITC solution in DMSO (10 mg/mL) was slowly added to a 10 mg/mL 
BSA solution in 0.1 M carbonate buffer (pH 9), under moderate and continuous agitation at 
room temperature. The mixture was allowed to react overnight at 4 oC in a light protected 
vessel. The labelled protein solution was then extensively dialysed against PBS buffer (0.01 M, 
pH 7.4) at 4 oC and stored as lyophilized powder in a light protected container for further use.  
The subsequent binding experiments were carried out following the procedure 
described above (please see section 8.3.7) using FITC-BSA. After elution of the physically 
adsorbed FITC-BSA, the labeled protein-microparticles were washed with distilled water, 
mounted using “Vectashield” mounting medium (Vector Laboratories, USA) and visualized by 
CLSM. 
 
8.3.8 Cell culture studies in presence of functionalized m-PCL microparticles  
Both, a human Osteoblast-like cell line (SaOs-2) obtained from ECACC (UK) and human 
adipose derived stem cells (ASCs) obtained from the Blood Bank of the upper Austrian Red 
Cross (Austria) were used in this study. Cells were placed in direct contact with the developed 
microparticles in order to evaluate their effect on cell viability and cell proliferation. Thus, both 
cells, SaOs-2 and ASCs, were cultured in 12-well tissue culture plates, at a density of 1 X 105 
cells/mL having 1.5 mL/well, using Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich, USA) supplemented with 10% of heat-inactivated fetal bovine serum (FBS; Biochrom 
AG, Germany) and 1% of antibiotic/antimycotic solution (Sigma-Aldrich, USA) in a humidified 
atmosphere with 5% CO2, at 37 
oC. Twenty-four hours after cell seeding, the cells were 
approximately 80% confluent. At that time point, the culture medium was replaced by a 
suspension of the m-PCL microparticles samples to test in DMEM (1 mg/mL). The culture 
medium was changed every 2 days. In all cases, m-PCL microparticles were sterilized by 
ethylene oxide (EtO) [45]. After different incubation time (1, 3 and 7 days), the particles were 
removed by aspiration to perform the further assays. 
Cell viability was determined by means of a standard MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay [46, 47]. The MTS test 
was performed according to the manufacturer’s instructions (CellTiter 96 One Solution 
Proliferation Assay Kit, Promega, USA) as well as to previously described protocols [47, 48]. 
Briefly, the cell monolayer was treated with 200 µL/well of MTS reagent solution (5:1 ratio in 
serum-free DMEM culture medium without phenol red) and incubated for 3 hours at 37 oC in a 
humidified environment containing 5% of CO2. 100 µL medium from each well were 
transferred to a 96-well plate and the absorbance at 490 nm was determined (EL 312e 
Biokinetics microplate reader, BioTek Instruments, USA). The results are normalized to the 
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positive control (complete DMEM culture medium) for which 100% viability was attributed. 
The samples were tested in triplicate in three independent assays. 
Cell proliferation, after cell contact with the microparticles, was evaluated by 
quantifying the DNA content using PicoGreen (“dsDNA” quantification kit, Molecular Probes, 
USA) according to the manufacturer instructions. Before performing the assay, the cell 
monolayer was carefully washed with PBS buffer (0.01 M, pH 7.4), and then lysed by osmotic 
and thermal shock. The obtained supernatant was used for DNA analysis. Fluorescence was 
measured (485 nm excitation and 528 nm emission) in a microplate reader and the DNA 
amounts calculated according to a standard curve. The samples were tested in triplicate in 
three independent assays. 
Cell morphology was observed by optical microscopy after incubation of ASCs with the 
microparticles for 3 and 7 days. Each well containing the cell monolayer and the samples was 
washed with 0.1 M phosphate buffered saline solution and then fixed with 2.5% 
glutaraldehyde solution in PBS for 30 min at room temperature. This procedure was performed 
without removing the microparticles from the wells, thus being carefully to avoid the 
microparticles aspiration. The cells were then stained with 0.4% methylene blue solution in 
water and examined for microscopic visualization (Axioplan imager Z1, Carl Zeiss, Germany). 
The analyzed sample was photographed using a high-resolution camera for image acquisition 
(Leica Microsystems GmbH, Germany). 
 
8.4 RESULTS AND DISCUSSION 
Immunomagnetic separation of cells using superparamagnetic particles or beads 
coated with antibodies against surface antigens has been extensively investigated [8-10, 49]. It 
has been shown that this procedure is highly efficient for the isolation of several cell types, 
because the cells immunologically bound to the magnetic particles remain viable and 
thereafter they can be grown by placing the isolated fraction in suitable culture media.  
Particle properties such as size, shape, superparamagnetic behavior and surface 
functionality determine if they are suitable for immunomagnetic separation. 
 
8.4.1 Preparation of the superparamagnetic m-PCL microparticles 
Magnetite (Fe3O4) nanoparticles suspension was obtained by adapting a classical 
co-precipitation method patented by Reimers G. W. et. al [17-19, 35]. Oleic acid was added 
during the synthesis to provide hydrophobicity and adequate stability to the resulted 
nanoparticles suspension. The light microscopy images of the obtained magnetite 
Chapter 8 –Superparamagnetic poly-ɛ-caprolactone microparticles 
167 
nanoparticles suspension in water are shown in Figure 8.5 (a) and (b). As can be seen (Figure 
8.5 (b)), good suspension stability, defined spherical shapes and narrow size distribution 
(Figure 8.5 (c)) were achieved for the resulted system. Dynamic light scattering (DLS) 
measurements showed a mean diameter of 50 nm and a value of polydispersion index (PDI) of 
0.210, indicating low polydispersitivity of the obtained nanoparticles.  
The obtained magnetite nanoparticles were further entrapped within a 
poly-ɛ-caprolactone (PCL) shell to form core-shell microparticles. Particles with spherical 
shape, smooth surface morphology and particle size in the range 4-135 µm were obtained. 
Figure 8.6 shows scanning electron microscope (SEM) images of obtained m-PCL microparticles 
with size 4.2±2.1 µm (Figure 8.6 (c) and (d)) and 52.1±6.9 µm (Figure 8.6 (a) and (b)). 
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Figure 8.5 Optical micrographs of the synthesized magnetite nanoparticles at different magnifications 
(a) and (b), and their size distribution measured by DLS (c) in a mixture water-glycerine (1:1, v:v) 
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Chapter 8 –Superparamagnetic poly-ɛ-caprolactone microparticles 
168 
In contrast to the magnetite nanoparticles, the obtained m-PCL microparticles are 
rather polydisperse with higher value for both, particle size and polydispersion index (PDI) 
(Figure 8.7). This result was expected because of the different amount of magnetite entrapped 
inside the microparticles during the encapsulation process. It must be noticed that this process 
can be controlled by adjusting the experimental conditions and smaller size m-PCL 
microparticles with narrow size distribution can be obtained (Figure 8.6 (c)). 
 
 
 
  
Figure 8.6 SEM micrographs of the magnetic poly-ɛ-caprolactone (m-PCL) microparticles obtained at 
different stirring rates. 20 000 rpm (a) and (b); 24 000 rpm (c) and (d) 
 
It is well documented that for applications such as cell isolation, immunomagnetic 
beads should present adequate particle size [8, 15, 50]. On one hand, particles cannot be 
excessively small because they can penetrate inside the cells. On the other hand, they cannot 
be very large because of neglected function. It is reported that the optimal size for cell 
isolation is about 4 µm [15, 50]. The effect of the experimental conditions on the particle size 
of the m-PCL microparticles is summarized in Table 8.1. We found that the m-PCL 
microparticles size and distribution could be controlled by adjusting magnetite to polymer 
ratio, polyvinyl alcohol (PVA) concentration and stirring rate during their preparation.  
5 μm 20 μm 
50 μm 20 μm 
(a) (b) 
(c) (d) 
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Figure 8.7 Size distribution of the m-PCL microparticles 
 
The magnetite to polymer ratio was varied in the range 0.005-0.15. The increase of the 
magnetite content resulted in formation of larger and polydispersive particles, but no 
influence on the surface morphology and spherical shape of the particles was detected. 
Polyvinyl alcohol (PVA) was used as emulsifier and stabilizer agent during the particle 
formation. It has been previously reported that for concentrations of PVA higher than 2% the 
particle morphology is modified and can result in the lost of spherical shape [51]. Therefore, 
the effect of PVA concentration was also studied by varying its content in the emulsification 
medium from 0.5 up to 2%. It can be observed (Table 8.1) that the size of the microparticles 
slightly decreases as the PVA concentration increases, but its effect was not notorious on the 
particles shape or surface morphology. Hence, PVA concentration up to 2% is suitable for 
particle preparation by the emulsification method used herein. The stirring rate is the 
parameter with the more influence on the size of the m-PCL microparticles. The stirring rate of 
24 000 rpm resulted in highly monodiserse m-PCL microparticles with a diameter/size of 
4.2±2.1 µm (Figure 8.6 (c) and (d)). Once again, it was observed that the stirring rate influences 
the size and size distribution but not the morphology of the obtained microparticles. 
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8.4.2 Characterization of the obtained m-PCL microparticles 
Fourier transformed infrared (FTIR) spectrum of m-PCL microparticles confirmed the 
presence of the magnetite entrapped within the PCL shell. The characteristic broad band at 
580 cm-1 was observed in the spectrum of the synthesized magnetite as well as in the m-PCL 
microparticles spectrum (Figure 8.8). Characteristic bands of PCL around 1750, 1238, and 
1172-cm-1, which corresponds to C=O, asymmetric COC, OC-C and symmetric COC stretchings 
respectively, are present in both PCL microparticles with and without magnetite. 
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Figure 8.8 FTIR spectra of the obtained magnetic m-PCL microparticles and the respective controls. The 
characteristic band of magnetite is marked with a circle 
 
To confirm the crystalline structure of the obtained magnetite nanoparticles X-ray 
diffraction (XRD) was used. XRD patterns obtained for the magnetite nanoparticles and m-PCL 
microparticles are presented in Figure 8.9. XRD pattern confirmed the magnetite (Fe3O4) 
structure for the nanoparticles (Figure 8.9 (a)) with the detected peaks at 29.94, 35.4, 43.01, 
53.4 and 56.96 2theta degree (consistent with the standard data for magnetite JCPDS card 19-
0629). The XRD pattern of m-PCL microparticles (Figure 8.9 (b)) shows identical peaks 
confirming the quite successful entrapment of the magnetite in the PCL shell. Moreover, this 
result indicates no changes in the magnetite structure during the entrapment process. The 
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broadening of the peaks observed in the pattern of the m-PCL microparticles is consistent with 
the composite nature of the microparticles.  
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Figure 8.9 X-ray diffractograms for magnetite nanoparticles (a), m-PCL microparticles (b) and PCL 
microparticles (c). The insert graph shows the XRD pattern from 30-60 2theta degree. Characteristics 
peaks of magnetite phase (JCPDS card 19-0629) (*) 
 
The amount of the magnetite loaded in the m-PCL microparticles was studied by using 
thermogravimetric analysis (TGA). TGA analyzes were performed under N2 atmosphere to 
minimize the mass increase due to iron oxidation but allowing the polymer to decomposed 
thermally. TGA thermograms (Figure 8.10) obtained for the m-PCL microparticles show a 
continuous weight loss in the range of 300-400 oC, which correspond to the decomposition of 
PCL [52]. The remaining mass after this temperature corresponds to the iron content of the 
sample. As can be seen, the amount of entrapped magnetite coincides with the initial amount 
of magnetite (Table 8.1) and the highest magnetite content (13.13%) was obtained for the 
maximum initial amount of magnetite used for the m-PCL preparation.  
The magnetic properties of the obtained m-PCL microparticles are of key importance 
for their future applications. The magnetic properties, such as saturation magnetization (Ms), 
relative saturation remanence (mr=Mr/Ms) and coercivity of remanence (Hc) of the synthesized 
magnetite nanoparticles and m-PCL microparticles are presented in Table 8.1 and Figure 8.11.  
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Figure 8.10 TGA thermograms of m-PCL microparticles prepared with different amounts of magnetite 
 
The measurements were performed at room (300 oK) and at low temperatures (5 oK) 
where magnetite presents characteristic magnetic behavior. The obtained magnetite 
nanoparticles demonstrated superparamagnetic behavior at room temperature with 
saturation magnetization, Ms=15.7 emu/g (Figure 8.11 (a)). This value of Ms is lower than the 
reported value for magnetite [53]. This phenomenon has been observed and explained earlier 
by others authors [17] and can be related with the use of oleic acid (40% related with the 
amount of produced magnetite) to coat the nanoparticles during their preparation. Lower 
values were also obtained for mr (0.0637) indicating a typical superparamagnetic behavior, i.e. 
absence of magnetic memory of the sample once the applied field is removed. When the 
temperature was decreased to 5 oK, the saturation of magnetization increased to values of 
51.5 emu/g and the presence of broader hysteresis loop was observed (Figure 8.11 (b): 
Hc=250-Oe, mr=0.2544). The increment of the magnetization at low temperature can be related 
with the correspondent decline of the magnetocrystalline anisotropy. The fact that an 
incomplete saturation of the magnetization was observed at 5 oK, can be related with the 
presence of small grains (due to the nature of the sample), which explain also the gradual 
increment of Ms value after saturation. Moreover, at lower temperature there are a 
rearrangement of the Fe2+ and Fe3+ ions in the unit cell (magnetite crystallizes with spinel 
structure) with the consequent variation of the configuration of the magnetic moments in the 
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unit cell. Figure 8.11 (c) presents the magnetization curves of the resulting m-PCL 
microparticles. A typical superparamagnetic behavior without any hysteresis loop was 
observed with low values of magnetic remanence, mr=0.0637. However, the entrapment of the 
magnetite nanoparticles into the PCL shell resulted in a decrease of the saturation 
magnetization value to 4 emu/g. The loss of magnetization is due to the fact that the polymer 
(PCL) has not magnetic properties. Despite the decrease in the magnetization, an excellent 
isolation of the m-PCL microparticles from the working solution by placing a magnet (external 
magnetic field) near to the containing vessel was achieved (Figure 8.12). Superparamagnetism 
was identically observed after removing the external magnetic field. 
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Figure 8.11 Magnetization curves of synthesized magnetite nanoparticles at 300 
o
K (a), 5 
o
K (b) and for 
the resulting m-PCL microparticles measured at both, 300 and 5 
o
K (c) 
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(a) (b) 
Figure 8.12 Photographs showing the stability of m-PCL microparticles dispersed in water ((a)-right vial) 
and their response to an external magnetic field ((a)-left vial and (b)) 
 
8.4.3 Surface functionalization of the m-PCL microparticles 
The surface of the microparticles were successfully functionalized with amino (through 
carbodiimide activation) and epoxy groups aiming the covalent binding of protein-like ligands.  
Amino functionalized m-PCL microparticles were obtained by an aminolysis reaction. Different 
density of amino groups on the surface (Table 8.2) was achieved by controlling the 
1,6-hexanediamine concentration, reaction temperature and time. The quantification of –NH2 
groups on the modified m-PCL microparticles (NH2-m-PCL) was confirmed by a ninhydrin 
colorimetric assay. The absorbance, determined after functionalization, is significantly higher 
in comparison with untreated microparticles, clearly confirming the presence of amino groups 
on the surface. Table 8.2 shows –NH2 density as a function of aminolysis conditions. The 
amount of –NH2 groups on the m-PCL microparticle surface increases with the aminolysis time 
and 1,6-hexanediamine concentration. However, for aminolysis time greater than 60 minutes 
and 1,6-hexanediamine concentration higher than 10%, the density of the –NH2 groups 
decrease slightly. It was found that the temperature used during the aminolysis reaction does 
not influence the density of amino groups. The highest density, 5.0±0.2 X 10-7 mol/mg, was 
obtained for reaction time of 60 minutes with 10% of 1,6-hexanediamine. 
Epoxy functionalized microparticles were analyzed by X-ray photoelectron 
spectroscopy (XPS). The results from XPS are summarized in Table 8.3. We have observed the 
presence of Fe in the survey spectra for all the studied materials, evidence of the magnetite 
entrapped in the m-PCL microparticles and due to the used procedures for the preparation of 
the microparticles. The detected percentage of Si is due to the silicon wafers which were used 
as support for the sample preparation. As can be seen from the results, the best coating of the 
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silicon wafer surface was achieved with the plasma treated sample (only 0.4% Si). Nitrogen 
was detected only for the –NH2 functionalized m-PCL microparticles, confirming the success of 
the functionalization. However, XPS results did not show any significant difference between 
epoxy-modified and unmodified m-PCL microparticles. Previous studies also demonstrated 
that this technique does not provide clear evidence of the presence of amino and epoxy 
chemical groups on particles and films surfaces [37, 54]. Hence, additional techniques such as 
ninhydrin assay, protein adsorption experiments and confocal laser scanning microscopy, were 
employed in this work for confirmation of both, amino and epoxy functionalization of the 
m-PCL microparticles.  
 
Table 8.3 Surface chemical composition of functionalized m-PCL microparticles determined by XPS 
Sample %C %O %Fe %N %Si %Na 
m-PCL 57.4 28.4 0.7 n.d. 12.9 0.7 
m-PCL plasma treated 69.1 28.2 0.5 n.d. 1.4 0.7 
m-PCL epoxy functionalized 57.8 29.0 0.5 n.d. 10.7 2.1 
m-PCL amino functionalized 57.3 27.4 0.7 0.8 13 0.8 
 
8.4.4 Protein coupling experiments onto surface functionalized m-PCL microparticles 
Immunomagnetic cell isolation usually involves a series of specific reactions between 
antigens or antibodies bound onto the surface of the particles, and its correspondent match 
present in the cells [8]. Hence, antigens (Ag) and antibodies (Ab) can be consider as 
“intermediate biomolecules” that will define the efficacy of the isolation. Ag or Ab can be 
covalently bound to the particles surface if there are active sites. Using this approach, a highly 
stable bioconjugate can be formed, avoiding non-specific attachments and guarantying the 
proper orientation of the biomolecules on the particles surface. We have performed protein 
coupling experiments using BSA as a model protein to demonstrate the potential of the 
developed magnetic microparticles for binding other proteins of interest. 
To achieve covalent binding of BSA to the surface functionalized m-PCL microparticles, 
a carbodiimide coupling procedure was followed in the case of –NH2 functional particles, while 
direct protein coupling protocol was performed for epoxide activate surface particles. 
Different conditions in terms of BSA initial concentration, pH, ionic strength and incubation 
time were studied during the protein adsorption experiments (Figure 8.13).  
It must be highlighted that the binding curves in Figure 8.13 correspond to the total 
amount of BSA coupled onto the surface of different m-PCL microparticles, thus considering 
both, chemically coupled (covalent bound) BSA and physically coupled (adsorbed) protein. 
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Figure 8.13 BSA binding onto the m-PCL microparticles as a function of surface functionalization (a), 
pH-(b), ionic strength (c) and incubation time (d) 
 
The introduction of amino or epoxy groups on the surface of the microparticles 
provide the necessary active sites for immobilization of protein-like molecules via a covalent 
bond between these groups and the amino/carboxy groups available on protein molecules.  
Analysis of the results presented in Figure 8.13 (a) indicates that higher amount of BSA 
are bound to the surface of both functionalized m-PCL microparticles in comparison with 
untreated and plasma treated controls. However, highest amount of bound BSA was found 
when NH2-m-PCL microparticles (EDC-mediated reaction) were used. This result can be related 
to a variety of factors. The density of –NH2 and epoxy groups on the surface of the 
microparticles cannot be compared since a very different chemical processes were used to 
functionalize and characterize the microparticles surface. For both surface activated 
microparticles, BSA coupling experiments were carried out at pH 5.5, at which EDC reaction is 
highly favored. On the contrary, epoxide chemistry is favoured at neutral to alkaline pH. 
Consequently, BSA bound to NH2-m-PCL microparticles via EDC is preferential. 
Additionally, it can be observed a tendency to achieve a maximum binding plateau by 
increasing BSA initial amount. Saturation of the surface functional groups by protein molecules 
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is most probably the reason for this result. Above a certain value of initial protein 
concentration; there are no more available groups for covalent coupling of additional protein 
molecules. Consequently, the amount of bound protein remains constant. The observed 
saturation is directly conditioned by the efficiency of the surface modification and the surface 
area, thus determining the density of active groups and therefore the amount of coupled 
protein molecules.  
NH2-m-PCL microparticles were selected to further study the effect of the 
experimental conditions on the protein coupling. 
Figure 8.13 (b) shows the influence of pH on protein binding on NH2-m-PCL 
microparticles. The maximum protein binding was obtained at pH 5.5. As previously discussed, 
pH 5.5 is the optimal one for EDC activity. Consequently, the covalent coupling is highly 
favored and will control largely the protein binding process. On the other hand, this value is in 
the range of the isoelectric point (IEP) of BSA (pH 4.7) where the protein carries no net electric 
charge [41]. Thus at this pH, electrostatic repulsions are minimized since the protein in not 
charged due to the vicinity to its IEP. By either increasing or decreasing the pH from 5.5, the 
coupling of BSA to the microparticles surface was drastically diminished.  
At lower pH, the amino surface groups are highly protonated (NH3
+) and therefore not 
involved in the EDC reaction. Furthermore, at this pH (below BSA IEP) the protein net charge is 
positive and greater intermolecular repulsion and larger BSA conformational changes occur 
[55, 56]. The overall result is a decrease on protein binding on the microparticles surface at pH 
3.5. 
At pH 7 a similar result was observed. The coupling between the microparticles surface 
and protein molecules drastically diminish. Although it is reported that the EDC-mediated 
reaction can still take place at pH 7 [41], approaching basic pH this reaction is not favored. 
Consequently, above pH 7 the covalent coupling of BSA to the microparticles surface via EDC-
mediated reaction does not take place. 
The effect of ionic strength on protein binding was studied by increasing salt (NaCl) 
concentration. Figure 8.13 (c) shows the binding isotherms of BSA on NH2-m-PCL 
microparticles in MES buffer at pH 5.5 and ionic strength in the range 0.05-1.5 M. A drastic 
decrease in the bound protein was obtained at higher NaCl concentrations. The interaction 
between the protein molecules and the ions present in the solutions are most probably the 
reason for the observed decrease as chloride anions prefer to bind on the surface of the BSA 
molecules, resulting in changes in the conformation and local charge of the protein 
macromolecules [57]. These interactions compromise the availability of the protein molecules 
for the coupling with the microparticle surfaces.  
Chapter 8 –Superparamagnetic poly-ɛ-caprolactone microparticles 
178 
Increasing the incubation time from 5 hours to overnight did not show any significant 
influence over the amount of bound protein (Figure 8.13 (d)). Therefore, we can state that 5 
hours of incubation are enough to allow saturation of the microparticles surface with protein 
molecules. Similarly, changes of incubation temperature from 25 to 37 oC resulted in the same 
amount of bound BSA. This result was expected because temperatures in the studied range do 
not affect either the EDC chemistry or BSA stability and conformation. 
 
8.4.5 Desorption of the physically adsorbed BSA 
Physical adsorption occurs because of the material hydrophobicity and electrostatic 
interactions between the protein and the material surface [58, 59]. A major problem when 
working with functionalized surfaces is then to elucidate the amount of chemically (covalent) 
or physically bound protein. To ensure the separation of these two ways of protein binding, 
two key methodologies can be followed. Either the protein-particle complex can be treated 
with buffer solutions containing surfactants or, the surface functional groups that remain free 
after the protein binding can be quantified.  
We have used Tween 20 surfactant to remove the physically adsorbed protein and 
hence to distinct the covalently bound protein. Table 8.4 summarizes the values of covalent 
bound protein to both, amino and epoxy functionalized surface. As can be seen, about 70% of 
the BSA on the amino activated surface was covalently bound. Epoxy superparamagnetic 
microparticles also show high amount of covalent coupled protein (47%). 
 
Table 8.4 Efficiency of BSA coupling as a result of the surface functionalization 
Samples 
BSA Totally bound 
(mg/g)
a
 
BSA Covalent coupled 
(mg/g) 
Covalent coupling 
yield (%) 
m-PCL 3.42 ± 2.5 - - 
m-PCL plasma treated 5.00 ± 2.7 - - 
m-PCL epoxy functionalized 40.79 ± 2.6 19.37 ± 3.2 47.49 
m-PCL amino functionalized 68.04 ± 3.0 48.92 ± 1.9 71.90 
aBSA totally bound includes protein physically adsorbed plus covalently coupled 
 
Confocal laser scanning microscopy (CLSM) was used to visualize the covalently 
coupled BSA (Figure 8.14). Fluorescein isothiocyanate (FITC) labeled BSA was employed during 
the binding experiments. CLSM results confirmed both: i) successful surface functionalization 
by the surface treatments proposed in this work (amino and epoxide) and consequently ii) 
efficient covalent binding of the FITC-BSA onto the microparticles surface. Most intense 
fluorescence was observed when NH2-m-PCL microparticles were used. This result again 
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confirmed a more efficient covalent binding for these microparticles in comparison with the 
epoxy functionalized ones.  
 
100 µm 100 µm
100 µm 20 µm
(a) (b)
(c) (d)
 
 
Figure 8.14 Confocal microscopy images of the magnetic microparticles after FITC-BSA covalent coupled 
at the surface. m-PCL microparticles without binded protein (a), FITC-BSA covalently coupled onto 
epoxy-m-PCL microparticles (b), NH2-m-PCL microparticles (C) and (d) 
 
8.4.6 Cell viability and proliferation as result of the contact with m-PCL microparticles 
The effect of the superparamagnetic microparticles on cell viability and proliferation 
was followed up to 7 days by using MTS and DNA assays respectively. Human Osteoblast-like 
cells (SaOs-2) were placed in contact with epoxy and amino magnetic microparticles (1 X 105 
cells/mL). m-PCL and plasma treated m-PCL microparticles were used as controls for 
evaluation of the effect of functionalization, while DMEM culture medium was used as control 
for 100% cell viability. Figure 8.15 (a) and (b) represent MTS and DNA results, respectively. 
Increasing values of O.D. were found with increasing culture time, indicating that none of the 
tested samples is toxic. The cell viability was found to be above 80% when compared to 
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positive control (100%) after 7 days of culture. Analysis of DNA results, presented on Figure 
8.15 (b), showed no detrimental effect on cell proliferation in the presence of the 
microparticles. Surface functionalization treatments did no influence the cell viability and 
proliferation. All the tested samples resulted in very similar values of O.D. and quantified DNA 
amounts.  
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Figure 8.15 Cell viability (MTS) and proliferation (DNA) for osteoblast-like cells (SaOs-2) in direct contact 
with the studied m-PCL micropaticles after different incubation time 
 
One of the common application of the superparamagnetic microparticles is in the 
isolation of adipose-derived stem cells (ASCs) [60]. Adipose tissue is very suitable and 
abundant source of adult stem cells with multipotent properties suitable for tissue engineering 
and regenerative medicine [60, 61]. Hence, we studied the ASCs response to the presence of 
Incubation time 
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the amino functionalized m-PCL microparticles (Figures 8.16 and 8.17). BSA coupled 
NH2-m-PCL microparticles (via EDC activation) was also used for comparison.  
 
(a)
(b)
 
Figure 8.16 Optical micrographs of adipose-derived stem cells (ASCs) in contact with NH2-m-PCL 
microparticles (methylene blue staining, 7 days of culture): in DMEM culture medium (a) and in direct 
contact with the NH2-m-PCL microparticles (b) 
 
Characteristic morphology of ASCs was observed when they were cultured in contact 
with the microparticles (Figure 8.16 (b)) and no morphological changes were identified in 
comparison with the control (Figure 8.16 (a)). After 7 days of culture, the cells were able to 
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adhere onto the bottom of the well, spread and proliferate in contact with the magnetic 
microparticles. The quantification of the DNA indicates good cell proliferation (Figure 8.17). As 
can be seen, the microparticles did not influence the growth and proliferation of the used cells. 
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Figure 8.17 DNA assay of ASCs in the presence of the microparticles in comparison with the control 
 
8.5 CONCLUSIONS 
Superparamagnetic poly-ɛ-caprolactone (m-PCL) microparticles were prepared by 
mixing a magnetite nanoparticle suspension, obtained by co-precipitation from an Fe3+/Fe2+ 
solution, with a poly-ɛ-caprolactone solution followed by an emulsion solvent 
extraction/evaporation technique to form core-shell microparticles. m-PCL microparticles 
presented spherical shape, smooth surface and particle size in the range 4-135 µm. 
Superparamagnetic behavior was observed for both, magnetite nanoparticles (core-) and m-
PCL microparticles (core-shell). Amino groups were successfully introduced onto their surface 
by aminolysis, whereas epoxy groups were introduced by plasma activation and a vacuum 
vapor-phase reaction. To ensure the particles’ capability for covalent binding of protein-like 
ligands, bovine serum albumin (BSA) was used as model protein. The high covalent binding 
capacity for BSA and low physical protein adsorption indicates their capability for covalent 
binding of protein-like targets. Indeed, that suggests their potential application for isolating 
cells since this process is mostly based on specific antibody-antigen reactions. From the several 
experimental parameters investigated on the binding capacity, pH showed the most 
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pronounced influence. Cell viability, proliferation and morphology were investigated by 
combining microparticles with osteoblast-like cells (SaOs-2) and human adipose-derived stem 
cells (ASCs). The developed microparticles presented excellent biocompatibility against both 
SaOs-2 and ASCs. 
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Chapter 9 
Summary, final remarks and future work 
The overall goal of the work presented in this thesis was to develop novel 
microparticulate materials for the controlled release of bioactive agents for bone repair and 
regeneration. The materials were characterized and evaluated for their biological response in 
vitro. The preceding chapters described the work that was performed to achieve this goal and 
this chapter summarizes the significant findings in the experiments presented and describes 
how the conclusions address the aforementioned hypotheses. 
 
9.1 Summary and final remarks 
Nano- and microparticles have been extensively used in biomedical applications mainly 
as drug delivery systems. These microparticle systems can also be of utility in tissue 
engineering applications, where they can serve as carriers for the encapsulation and release of 
growth factors or they can be used to isolate cells from heterogeneous populations [1-4]. 
Moreover, particles can be combined with hydrogels or scaffolds to modify and improve their 
mechanical properties [5-9].  
It was objective of this dissertation research to develop and characterize new 
microparticulate systems with potential application in bone tissue engineering. To accomplish 
this aim, a group of materials was selected with starch being the base material used in the 
formulation of developed particulate systems. In order to produce the particles, several 
preparation methods, mainly based on emulsion technology, were used. All the tested 
procedures generated very stable emulsions, allowing control the drop size and homogeneity 
by varying reaction conditions (polymeric concentration, composition of emulsification 
medium, stirring rate, reaction time, type of crosslinker). Several analytical and microscopic 
techniques were used to characterize the physicochemical properties of the developed 
microparticles in terms of particle size and size distribution, shape and morphology, porosity, 
and chemical structure. By changing the reaction parameters, microparticles with different 
surface morphologies (from smooth to porous), well defined spherical shapes and particle size 
in the micron-scale (4-900 µm) were obtained. Stirring rate was found to be the most 
important parameter affecting the particle size, whereas the polymer concentration and 
emulsification medium showed the largest influence on surface morphology. Thus, the first 
objective proposed in this thesis was accomplished since particulate systems based on 
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different materials (starch-poly-ε-caprolactone, SPCL; chitosan-starch, CHT-ST; 
poly-ε-caprolactone, PCL) and exhibiting diverse properties were successfully prepared. 
In order to apply these particulate systems in vivo, biodegradability is a desired 
property. Medical devices with the ability to degrade inside the body have a major advantage 
since they are designed to perform their function and subsequently degrade without need for 
surgical removal. Therefore, a subsequent objective of this work was to investigate the 
biodegradation properties of the developed CHT-ST and SPCL microparticles (Chapter 4 and 6). 
The PCL microparticles were not considered for degradation studies since they are proposed 
for cell isolation where material degradation is unlikely to happen. Physiological conditions 
were mimicked by incubating the materials in phosphate buffered saline (PBS) solution serving 
as an isotonic solution. To understand the effect of enzymes present in the human blood 
plasma on the materials degradation, PBS solutions supplemented with α-amylase and/or 
lipase at physiological concentrations were also used. As a result of incubating the 
microparticles with these enzymatic solutions, the particle size decreased, the spherical shape 
was lost and their structure became more porous. Increasing percentages of weight loss and 
concentration of sugars in solution indicated the progress of the degradation process. The 
degradation rate was found to be more rapid in the initial 15 days. At the end of the 
degradation period, about 83% of original weight was lost for SPCL and 67% for CHT-ST. The 
concentration of reducing sugars released into the solution as result of starch hydrolysis 
catalyzed by amylase ranged from 10-20 mg/mL for SPCL and CHT-ST. For the SPCL 
microparticles incubated with lipase, a decrease in pH over time was observed due to the 
release of carboxylic acids as a consequence of PCL hydrolysis present in the SPCL blend. 
Although the biodegradability of the proposed polymeric systems was demonstrated in 
vitro, a major concern related with the in vivo use of biodegradable polymers is the possible 
toxicity of their degradation products. During the course of their degradation, polymeric 
materials may release toxic products which may compromise their biocompatibility. Hence, 
the developed microparticles described in this thesis were screened in vitro for their possible 
cytotoxicity using either mouse skeletal myoblast cell line (C2C12) or human osteoblast-like 
cell line (SaOs-2). In general, the microparticles were found to be non-cytotoxic but in some 
cases some toxicity was observed when SaOs-2 cells were incubated with extracts from SPCL 
microparticles. It was postulated that the observed toxicity could be caused by the presence of 
residual methylene chloride (organic solvent used for the polymer dissolution) which was 
leached out during the incubation of the microparticles with the cells. To test this hypothesis, 
the SPCL microparticles were subjected to extensive dialysis to ensure the removal of possible 
leachable compounds used in their processing. In a subsequent cytotoxicity assay, cell viability 
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values higher than 80% were obtained for both SaOs-2 (results not shown) and C2C12 cells 
(Chapter 7). Furthermore, for CHT-ST microparticles comparable results were found. In this 
case, the crosslinking chemicals used during the particle preparation were found to influence 
their cytotoxicity. When glutaraldehyde (GA) was used as a crosslinking agent, no more than 
55% of cell viability was obtained. This result confirmed the known toxic character of GA and 
its influence impairing the biocompatibility of its crosslinked products. Different modifications 
in the microparticle processing, such as reduced concentrations of GA, alternative crosslinking 
agents (e.g. sodium tripolyphosphate (TPP) and oxidized starch), increased amount of starch 
and repeatedly washing steps, were investigated to overcome this problem.  
In the situations in which toxicity was observed, an extensive washing step is required to 
reduce toxicity from residual solvents or other chemicals used during the microparticles 
processing. 
Once biodegradability and non-toxicity was demonstrated for the developed 
particulate systems, the next step in the thesis included testing their potential as carrier of 
important factors in bone repair strategies. Gentamicin (GTM) a heat-stable antibiotic 
particularly useful in orthopaedics, was encapsulated in CHT-ST microparticles to be used as an 
injectable formulation. Dexamethasone (DEX) and bone morphogenetic protein 2 (BMP-2), two 
known osteogenic agents, were encapsulated into SPCL microparticles. DEX and BMP-2 were 
individually loaded into the microparticles by direct incorporation in the SPCL matrix.  
Subsequently, the capability of the microparticles to act as carriers for those molecules 
was evaluated by analyzing the loading efficiencies and the release behavior from each carrier 
system. In addition, the loaded systems were also tested in vitro to investigate the activity of 
released molecules. The activity of released antibiotic was analyzed against bacteria and the 
osteogenic potential of DEX and BMP-2 encapsulated into SPCL micropartices was assessed 
using in vitro cell differentiation assays. 
Encapsulation of GTM into CHT-ST microparticles was achieved with an EE in the range 
of 55-67%. A burst release was observed followed by a sustained release. Due the hydrophilic 
nature of CHT-ST matrix and consequent matrix swelling, a significant amount of GTM was 
released. The drug release mechanism was found to be influenced by a close contribution of 
both polymer relaxation and drug diffusion, indicating that degradation of the matrix also 
contributes for controlling the release kinetics. Antibacterial activity of encapsulated GTM was 
confirmed, since the released antibiotic (up to 30 days) was able to inhibit the growth of 
Staphylococcus aureus. This result indicated that GTM stability and bactericidal properties 
were clearly not affected by the encapsulation process and release. 
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Encapsulation efficiencies (EE) of about 93% were obtained for DEX, whereas for BMP-
2 only 24% of the protein was encapsulated. This low efficiency obtained for BMP-2 
incorporation is related directly with the encapsulation methodology. BMP-2 was co-
encapsulated with bovine serum albumin (BSA) as a carrier protein in a ratio 1:20 000, causing 
a reduced amount of BMP-2 incorporated. However, BSA as carrier protein was indispensable 
for the preservation of the stability and bioactivity of the growth factor during loading and in 
vitro release. In vitro release studies indicated the presence of a burst release for both DEX and 
BMP-2, mainly during the first 24 hours. This was followed by a slow and steady release, which 
is typically observed for biodegradable polymers. Released BMP-2 was able to maintain its 
bioactivity during encapsulation and upon release, as shown by the osteogenic effect in C2C12 
cells. Interestingly, the same effect was not observed in the case of DEX. Tested DEX standard 
solutions and DEX loaded SPCL microparticles were not able to induce osteogenesis in C2C12 
cells, as indicated by absence of ALP activity and OCN-promotor activation. On the contrary, 
DEX loaded SPCL microparticles were capable of inducing osteogenesis in human ASCs, which 
are primary cells and therefore with more clinical relevance.  
This set of experiments and data show that several aims proposed in this thesis were 
satisfactorily achieved. Starch, in combination with other materials, was processed to obtain 
non-toxic and biodegradable microparticles with adequate properties for the incorporation 
and release of a wide group of bioactive agents, including antibiotics, steroids and growth 
factors. 
Besides soluble factors, the use of isolated cells is an essential aspect in tissue 
regeneration strategies. Therefore, much attention has been given to cell sorting for 
applications in cell research and therapy. Magnetic cell separation methods are among some 
of the most efficient methods for bulk cell separation. Although much is now commercially 
available, the development of new types of magnetic particles and their surface modification 
are still an area of ongoing research. Magnetic PCL (m-PCL) microparticles were, therefore, 
developed for cell separation and isolation purposes. Superparamagnetism, uniform and 
adequate size distribution and functionalized surface are considered the most important 
characteristics in the design and formulation of microparticles for cell isolation. An optimal 
superparamagnetic behavior was obtained by the creation of a magnetite nanoparticulate core 
and a PCL shell. A suitable magnetic response, able to perform particle separation from a 
solution, was observed by the application of an external magnetic field. Moreover, no 
significant residual magnetism could be measured when removing the field. Protein binding 
studies on functionalized m-PCL microparticles using BSA showed high coupling yields with low 
levels of non-specific adsorption, thus suggesting the successful attachment of antibodies to 
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microparticle surfaces in isolation experiments. Additionally, the developed magnetic PCL 
microparticles showed excellent biocompatibility in cell-based assays (cell morphology, 
viability, and proliferation) using both SaOs-2 and ASCs.  
Materials in particulate form have gained increased importance in tissue engineering 
strategies having into account their enormous potential to deliver within the cellular 
microenvironment bioactive molecules that are able to regulate cell activities. All of the carrier 
systems presented in this thesis represent novel forays into the fields of biomaterials, drug 
delivery and tissue engineering. In the process of developing these systems, an attempt was 
made to better understand the fundamental aspects of their formulation on their resulting 
functionality and biocompatibility. The obtained results are promising, since the benefits of 
delivering bioactive molecules within a carrier material to mediate cellular processes were 
clearly shown, and can enhance the applicability of delivery systems in tissue engineering 
applications  
 
9.2 Future work 
A number of valuable results were obtained in this research project which will hopefully be of 
utility in future investigations. The development of an efficient and controlled system for the 
delivery of BMP-2 and new methods for the surface functionalization of magnetic 
microparticles used in cell isolation are the most significant contributions of this thesis. Much 
work remains, however, to be done. The next logical steps may include the following studies: 
- To develop bioactive osteoconductive systems by combining the microparticulate 
systems with bioactive glasses or incorporating functional groups (e.g. silanol groups) 
to induce the formation of apatite on the surface of the microparticles.  
- To optimize the developed starch-based microparticles to be used in dynamic cell 
culture conditions, using for example the High Aspect Ratio Vessel bioreactor or other 
appropriate bioreactors.  
- To undertake in vivo studies to assess the potential of BMP-2 loaded SPCL 
microparticles to induce new bone formation in critical size defects in animal models. 
- To explore the developed systems as carriers in gene delivery therapies using non-viral 
vectors for bone and cartilage regeneration.  
Chapter 9 – Summary and final remarks 
192 
- To finalize the work related with the development of magnetic PCL microparticles, 
including experiments to prove the efficient isolation of specific cells and hopefully to 
apply the system as a cell separation method.  
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